Processing of TOP2-DNA covalent complexes by the ubiquitin-proteasome system by Swan, Rebecca Louise
Processing of TOP2-DNA covalent complexes 
by the ubiquitin-proteasome system 
Rebecca Louise Swan 
Thesis submitted for the degree of  
Doctor of Philosophy 
Institute for Cell and Molecular Biosciences 
Faculty of Medical Sciences 
Newcastle University 
July 2018 
  
Abstract 
DNA topoisomerase II (TOP2) poisons are widely used anticancer drugs which 
induce cytotoxic protein-DNA crosslinks termed TOP2-DNA covalent complexes. 
The TOP2-DNA covalent complex is a normally transient intermediate of the TOP2 
reaction mechanism, whereby an intact DNA duplex is passed through an enzyme-
mediated double strand break (DSB) in another DNA molecule. A covalent linkage 
between the TOP2 active site tyrosine and each DNA end conceals the break and 
prevents its recognition by DNA damage response proteins. However, in the 
presence of a TOP2 poison the TOP2-DNA complex is stabilised, leading to the 
accumulation of enzyme-linked DSBs which ultimately lead to cell death. Repair of 
the TOP2-DNA covalent complex first requires the removal of TOP2 from DNA ends, 
leading to the liberation of a protein-free DSB. While a number of pathways are 
available for the removal of the TOP2 adduct, one mechanism involves the 
proteasomal degradation of TOP2. The proteasomal degradation of proteins is 
largely regulated through the conjugation of ubiquitin to target proteins 
(ubiquitination). However, the requirement for ubiquitination in the processing of 
TOP2-DNA covalent complexes is unclear, with conflicting studies reporting both 
ubiquitin-dependent and -independent mechanisms. In the current study, inhibition of 
ubiquitination slowed the removal of TOP2 adducts from DNA and reduced the 
appearance of protein-free DSBs following etoposide treatment. Inhibition of the 
ubiquitin-dependent AAA ATPase VCP/p97 also prevented the processing of TOP2-
DNA complexes to protein-free DSBs, indicating a previously unreported role for 
VCP/p97 in the repair of TOP2 poison-induced DNA damage. Inhibition of the 
ubiquitin-proteasome system increased the growth-inhibitory effects of four clinically 
relevant TOP2 poisons, and may be a viable strategy for the improvement of therapy 
with TOP2 poisons. This work confirms a ubiquitin-dependent mechanism of TOP2-
DNA complex processing by the proteasome, which may be facilitated by the 
unfolding and extraction of TOP2-DNA complexes by VCP/p97. 
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Chapter 1 Introduction 
Topoisomerase II (TOP2) poisons are widely used and effective anticancer drugs 
which disrupt the normal TOP2 reaction mechanism. In the absence of TOP2 poison, 
TOP2 induces an enzyme-bridged double strand DNA break (DSB) in one DNA 
molecule so that another DNA duplex can be passed through, thereby alleviating 
topological constraints in DNA such as knots and supercoils. However, TOP2 
poisons inhibit religation of the TOP2-mediated DSB, leading to the persistence of 
TOP2-DNA covalent complexes in which TOP2 remains covalently attached to each 
5’ end of the DSB. Misrepair of the TOP2-DNA covalent complex is associated with 
the development of therapy-related leukaemias, and therefore a better 
understanding of how this damage is repaired may inform improvements in therapy 
with TOP2 poisons. A key step in TOP2-DNA complex repair is the removal of TOP2 
from the break, which is required for recognition of the DSB by DNA damage 
response proteins. Among other pathways, this is largely achieved through the 
proteasomal degradation of the TOP2 protein adduct, yet little is known about how 
the proteasomal processing pathway is regulated. In particular, the ubiquitin-
dependence of TOP2-DNA complex degradation by the proteasome is both 
suggested and disputed in the literature. This work clarifies a ubiquitin-dependent 
mechanism of TOP2-DNA complex repair which is required for the processing of 
TOP2-DNA complexes to protein-free DSBs, and also reveals a potential and 
previously unreported role of the ubiquitin-dependent protein segregase VCP/p97. 
With the ongoing development of proteasome and ubiquitination inhibitors, this 
suggests that targeting the ubiquitin-proteasome system would be a viable strategy 
to improve TOP2 poison therapy. The purpose of the current chapter is to first outline 
the cellular roles of TOP2 enzymes, the TOP2 reaction mechanism and how it is 
targeted by anticancer drugs. Known mechanisms of TOP2-DNA complex repair are 
then discussed, including existing evidence for the role of the ubiquitin-proteasome 
system. 
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1.1 DNA topoisomerases and DNA topology 
The double-helical structure of DNA ensures the high fidelity transmission of genetic 
information, but is also prone to various topological problems. For example, 
separation of DNA strands during replication or transcription leads to compensatory 
over-winding (positive supercoiling) which restricts access to affected genes (Gilbert 
and Allan, 2014). Consequently, DNA-dependent processes such as replication and 
transcription are inhibited in regions of supercoiled DNA. As a large biological 
polymer, DNA can also form knots in which a single DNA molecule becomes self-
entangled, while entanglement of more than one DNA molecule leads to the 
formation of catenanes (Lim and Jackson, 2015). Supercoils, knots and catenanes 
are resolved by an important group of enzymes called DNA topoisomerases. 
Type I and type II topoisomerases induce single- and double- stranded DNA breaks 
(SSBs and DSBs), respectively (Pommier et al., 2010). Topoisomerase I (TOP1 and 
TOP1mt) and Topoisomerase III (TOP3α and TOP3β) are type I topoisomerases 
which relieve positive supercoiling by introducing a nick in one strand and rotating 
the opposite intact strand around the SSB, or by passage of the intact strand through 
the break, respectively. This strand passage mechanism is also common to 
Topoisomerase II (TOP2), a type II topoisomerase which instead passes an intact 
double-stranded DNA duplex through a DSB in another DNA molecule (Figure 1.1). 
While type I topoisomerases alleviate positive supercoils during replication and 
transcription, TOP2 can also unknot and untangle complex DNA structures such as 
the catenanes formed between sister chromatids following DNA replication (DiNardo 
et al., 1984; Uemura et al., 1987; Clarke et al., 1993; Sumner, 1995; Bower et al., 
2010). While both TOP1 and TOP2 are important anticancer drug targets, TOP2-
targeting agents are also associated with the development of therapy-related 
leukaemias, and are the focus of this study. 
  
3 
 
 
Figure 1.1. Strand passage by TOP2 enzymes. TOP2 unwinds and decatenates DNA by 
inducing a double strand break (DSB) in one DNA molecule, so that another DNA duplex 
can be passed through. 1) TOP2 binds G segment DNA (green). 2) T segment DNA (red) is 
captured within the N gate upon ATP binding. 3) Nucleophilic attack of the G segment leads 
to the induction of an enzyme-bridged DSB termed the TOP2-DNA covalent complex. T 
segment DNA is passed through the break. 4) G segment DNA is religated and T segment is 
released. TOP2 dissociates from DNA, ready for another round of catalysis. Figure 
reproduced from (Bates et al., 2011), licenced under a CC BY NC licence 
(https://creativecommons.org/licenses/by-nc/4.0/legalcode). 
1.1.1 The TOP2-DNA covalent complex 
DSBs are potentially lethal events, leading to cell death or mutagenesis. To avoid 
unnecessary DNA damage responses or illegitimate recombination events during 
strand passage, each monomer of the dimeric TOP2 enzyme remains covalently 
linked to each DNA end during induction of the TOP2-mediated DSB. This enzyme-
linked DSB is a transient intermediate of the normal TOP2 reaction mechanism, 
termed the TOP2-DNA covalent complex. The TOP2-DNA complex is formed 
following a transesterification reaction between the TOP2 active site tyrosine and the 
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phosphate backbone of DNA. Specifically, the nucleophilic tyrosine residue donates 
an electron pair to the electrophilic 5’ phosphate of DNA, forming a 5’-phosphotyrosyl 
bond with a 4 base overhang (Deweese and Osheroff, 2009). Meanwhile, the 3’OH 
end of each broken DNA strand interacts non-covalently with TOP2. Subsequently, 
an intact DNA duplex is passed through the TOP2-concealed DSB, and the DSB is 
religated following nucleophilic attack of the 5’-phosphotyrosyl bond by the free 3’OH 
end of DNA. TOP2 poisons inhibit this final religation step, leading to the stabilisation 
of TOP2-DNA complexes and the persistence of TOP2-mediated DSBs. 
1.1.2 Structure of TOP2 isoforms 
There are two TOP2 isoforms in human cells sharing 68% overall amino acid 
sequence identity and the same reaction mechanism (Austin et al., 1995). TOP2A 
and TOP2B are encoded by separate genes on chromosome 17 and chromosome 3 
respectively, thought to have arisen through a gene duplication event (Lang et al., 
1998). Both contain three structural domains, including an N-terminal domain, a 
catalytic centre (known as the breakage-reunion core or DNA binding and cleavage 
core) and a C terminal domain (Austin et al., 1995). The N-terminal domain contains 
one ATPase domain per protomer of the dimeric enzyme, which together form the N 
gate upon ATP binding and dimerization (Wu et al., 2011) (Figure 1.2). The DNA 
binding and cleavage core includes the TOPRIM domain and WHD domain, which 
contain Mg2+ chelating residues and an active site tyrosine, respectively. Together 
with the Tower domain, this forms the DNA gate, which is primarily responsible for 
DNA binding (Wendorff et al., 2012). The catalytic centre also contains the C gate, 
which mediates DNA exit after strand passage. Finally, the C terminal domain (CTD) 
displays the least sequence identity (34%) between TOP2 isoforms (Austin et al., 
1993), and has been used to generate isoform-specific antibodies. While not directly 
involved in catalysis, the CTD is implicated in the regulation of catalytic activity and 
nuclear localisation (Cowell et al., 1998; Meczes et al., 2008; Gilroy and Austin, 
2011; Clarke and Azuma, 2017). The C terminus is subject to various post-
translational modifications such as phosphorylation and SUMOylation (Cardenas et 
al., 1992; Wells et al., 1994; Ishida et al., 1996). In particular, SUMOylation of the 
TOP2A CTD leads to recruitment of Claspin to the centromere during mitosis, and is 
essential for successful chromosome segregation (Ryu et al., 2015; Clarke and 
Azuma, 2017). Modifications can also occur elsewhere in the TOP2 protein which 
5 
 
modulate TOP2 activity (Chikamori et al., 2003; Grozav et al., 2009; Ryu et al., 
2010). For example, SUMOylation of Lys662 in the DNA gate leads to inhibition of 
decatenation activity (Ryu et al., 2010; Higgins, 2012; Wendorff et al., 2012), and this 
is thought to be important for the regulation of centromeric decatenation during 
mitosis. 
 
Figure 1.2. TOP2 domain structure. Upon dimerization, TOP2 forms three interfaces (the 
N gate, DNA gate and C gate) which control strand passage. The N gate is formed by the 
ATPase domain, while the DNA gate is formed between the TOPRIM, WHD and Tower 
domains. Figure adapted from (Wendorff et al., 2012) and (Schoeffler and Berger, 2008).  
1.1.3 The TOP2 catalytic cycle 
Dimerisation of TOP2 protomers leads to the formation of three inter-protomer 
interfaces termed “gates” through which an intact or “transport” DNA segment (T 
segment) is passed during strand passage. This includes the N gate (formed by 
adjacent ATPase domains), the DNA gate (formed by TOPRIM and WHD domains 
together with DNA) and the C gate. Firstly, the “gate” DNA segment (G segment) is 
passed through the N gate and positioned near the catalytic tyrosine and Mg2+ ions 
for cleavage. ATP binding facilitates capture of the T segment within the N gate, 
followed by cleavage of the G segment (Wendorff et al., 2012). Nucleophilic attack of 
the DNA backbone by the active site tyrosine leads to formation of the TOP2-DNA 
covalent complex, characterised by the 5’-phosphotyrosyl bond between TOP2 and 
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DNA. The T segment is then passed through the enzyme-linked DSB, and the G 
segment is religated. ATP hydrolysis of a second ATP molecule then leads to 
dissociation of the TOP2 protein from DNA, ready for another round of catalysis. 
1.1.4 Cellular roles of TOP2 isoforms 
Despite their structural similarity, TOP2A and TOP2B are differentially expressed 
and are responsible for different roles in the cell. For example, levels of TOP2A peak 
during G2/M phase (Heck et al., 1988; Woessner et al., 1991), where it mediates the 
recruitment of Claspin to mitotic centromeres (Ryu et al., 2015; Clarke and Azuma, 
2017) and the decatenation of sister chromatids (DiNardo et al., 1984; Uemura et al., 
1987; Clarke et al., 1993; Sumner, 1995; Bower et al., 2010). Consequently, TOP2A 
is essential for successful segregation of chromosomes during anaphase, and is 
almost absent in non-proliferating cells (Woessner et al., 1991). In contrast, levels of 
TOP2B remain relatively constant throughout the cell cycle, and is present in non-
cycling quiescent cells (Woessner et al., 1991; Austin and Marsh, 1998).  
TOP2B-specific functions are mostly associated with transcription, and the 
expression of specific genes are up or downregulated in TOP2B knockout cells (Lyu 
et al., 2006; Tiwari et al., 2012; Madabhushi et al., 2015). This includes many genes 
which are involved in neuronal functions, such as neurotrophin factor p75, and early 
response genes Fos and Npl4 (Tiwari et al., 2012; Madabhushi et al., 2015). 
Consistently, TOP2B is directly implicated in the differentiation of neural cells, as 
knockout mice are non-viable due to defective neural development (Yang et al., 
2000), and cultured neurons lacking TOP2B display reduced neurite outgrowth (Nur 
et al., 2007). TOP2B is also recruited to promoters in response to hormones 
including oestrogen, androgens and retinoic acid (Ju et al., 2006; McNamara et al., 
2008; Perillo et al., 2008; Haffner et al., 2010; Manville et al., 2015), thereby further 
implicating TOP2B in the regulation of transcription. Other studies have since shown 
that TOP2B binding is not restricted to promoters but is detected throughout the 
genome at sites of open chromatin (Manville et al., 2015; Uuskula-Reimand et al., 
2016; Canela et al., 2017). Specifically, TOP2B directly binds CTCF and loop anchor 
sites, where it is thought that DNA unwinding facilitates the formation of loop 
extrusions (Manville et al., 2015; Uuskula-Reimand et al., 2016; Canela et al., 2017). 
Loop extrusions are formed by cohesin and CTCF, mediating long range interactions 
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between enhancer and promoter elements which facilitates transcription initiation. 
Therefore, TOP2B is involved in the initiation of transcription both through binding of 
promoters and through regulation of higher order chromatin structure. Interestingly, 
TOP2A has also been detected at specific promoters (Thakurela et al., 2013) and is 
shown to interact with both RNA polymerase I and RNA polymerase II (Mondal and 
Parvin, 2001; Ray et al., 2013). In a recent study, TOP2A cleavage sites were not 
detected within promoters but were detected in genes associated with high levels of 
transcription elongation (Yu et al., 2017). Therefore, both TOP2 isoforms have 
specific and distinct roles in transcription. 
1.1.5 TOP2 poisons 
The ability of TOP2 enzymes to induce DSBs is exploited in cytotoxic anticancer 
therapy through the use of TOP2 poisons, which prevent religation of TOP2-induced 
DSBs (Nitiss, 2009; Pommier et al., 2010; Pommier, 2013). This leads to the 
accumulation of DNA damage in the form of DSBs and stabilised TOP2-DNA 
complexes. In contrast, catalytic TOP2 inhibitors like dexrazoxane inhibit TOP2 
activity without stabilising TOP2-DNA covalent complexes and DSBs. TOP2 poisons 
are widely used and effective drugs in the treatment of both solid and haematological 
tumours, often prescribed in combination with other cytotoxic drugs such as 
alkylating agents and microtubule inhibitors. Therefore, TOP2 poisons remain highly 
clinically relevant in the landscape of increasingly targeted anticancer therapies. 
Clinically used TOP2 poisons include the non-intercalating epipodophyllotoxins 
(etoposide and teniposide), and intercalating poisons like mitoxantrone (an 
anthracenedione), doxorubicin and epirubicin (anthracyclines) and mAMSA (an 
acridine) (Figure 1.3). While TOP2 is the only known target of etoposide and 
teniposide, the intercalation of other poisons into DNA produces other DNA 
damaging effects which may also contribute to their cytotoxicity. For example, high 
concentrations of doxorubicin lead to alterations in DNA structure which prevents 
TOP2 binding (Pommier et al., 2010). Cardiotoxicity is an important dose-limiting 
effect of doxorubicin therapy, which is thought to involve redox cycling of doxorubicin 
and the production of reactive oxygen species (Tsang et al., 2003; Kim et al., 2006; 
Pommier et al., 2010). Although TOP2 is undoubtedly an important target for 
mitoxantrone cytotoxicity (Errington et al., 1999; Toyoda et al., 2008; Lee et al., 
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2016), DNA binding by mitoxantrone also induces the compaction of chromatin and 
the inhibition of transcription and replication (Kapuscinski and Darzynkiewicz, 1986; 
Chiang et al., 1998). In addition, mitoxantrone inhibits the polymerisation of 
microtubules (Ho et al., 1991). Because of the potential TOP2-independent effects of 
intercalating poisons, etoposide and teniposide were used in the current project to 
study the repair of TOP2-mediated DNA damage. 
Etoposide, teniposide, mitoxantrone, mAMSA and the anthracyclines are all 
interfacial poisons which prevent religation of the TOP2-mediated DSB. Interfacial 
inhibitors are those which bind and inhibit transient reaction intermediates of 
macromolecular complexes (Pommier et al., 2015). This is in contrast to covalent 
poisons, which bind TOP2 away from the active site and form covalent adducts with 
TOP2 (Lindsey et al., 2014). Specifically, interfacial TOP2 poisons bind within the 
DNA binding and cleavage core, increasing the distance between the active site 
tyrosine residue and the Mg2+-chelating residues of the TOPRIM domain (Wu et al., 
2011; Wu et al., 2013). Furthermore, drug binding physically blocks nucleophilic 
attack of the 5’-phosphotyrosyl bond by the 3’OH of DNA, which is required for 
religation.  
The chemical biology of TOP2 poisons has been partly elucidated through studies of 
drug-resistant or hypersensitive TOP2A and TOP2B mutants. Many of these 
mutations are located within the core catalytic domain, where resistance may occur 
due to alterations in drug binding or steps in catalysis. For example, the E522K 
TOP2B mutant was identified in a number of independent studies following selection 
with mAMSA and other acridines (Leontiou et al., 2004; Leontiou et al., 2007). While 
the E522K mutation confers increased resistance to mAMSA, resistance to 
etoposide is decreased, as previously shown following mutation of the homologous 
residue in the bacteriophage T4 TOP2 enzyme (Leontiou et al., 2004). Other 
mutations in this region of human TOP2A (R486K and E571K) have also been 
shown to increase resistance to TOP2 poisons including both mAMSA and etoposide 
(Patel et al., 2000), and are proposed to disrupt a drug binding pocket. Q778 of 
human TOP2B was recently identified as an important residue for etoposide binding, 
while the equivalent methionine residue in TOP2A (M762) did not affect etoposide 
binding (Zdraljevic et al., 2017). This indicates the existence of isoform-specific 
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differences in drug binding, which may influence the differential targeting of TOP2 
isoforms by different TOP2 poisons (discussed below in section 1.1.7). 
Other mutations have been identified which specifically interfere with enzyme 
catalysis. For example, the TOP2B P732L mutation inhibits DNA cleavage in the 
presence of calcium ions, and increases resistance to mAMSA, etoposide and 
doxorubicin (Leontiou et al., 2006; Leontiou et al., 2007). A mutation in the ATPase 
domain has also been described which reduces the affinity of TOP2 for ATP and 
ATP hydrolysis activity (Gilroy et al., 2006). 
 
Figure 1.3. Chemical structures of clinically used TOP2 poisons. 
1.1.6 Etoposide 
Etoposide (VP-16) is used in combination with other chemotherapeutic drugs in the 
treatment of a range of cancers including testicular cancer, small cell lung cancer, 
non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, acute myeloid leukaemia and 
ovarian cancer. A two-drug model was proposed for TOP2 poisoning by etoposide 
whereby two etoposide molecules are required to poison both monomers of the 
dimeric TOP2 protein (Bromberg et al., 2003). As such, poisoning of a single TOP2 
monomer (for example at lower doses of etoposide) prevents the religation of one 
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DNA break but not the other, leading to the induction of SSBs. TOP2 poison-induced 
SSBs themselves are cytotoxic (Rogojina and Nitiss, 2008) and can be converted to 
DSBs upon collision with the replication machinery (Avemann et al., 1988; D'Arpa et 
al., 1990; Lin et al., 2009). It was initially estimated that for each etoposide-induced 
DSB there are 7-20 SSBs (Pommier et al., 2010), while more recent studies suggest 
that only 2-3% of etoposide-induced breaks are DSBs (Muslimovic et al., 2009; Yu et 
al., 2017). 
1.1.7 Targeting of TOP2 isoforms by TOP2 poisons 
TOP2 poisons target both TOP2A and TOP2B (Willmore et al., 1998; Errington et al., 
1999; Willmore et al., 2002; Errington et al., 2004). This has been demonstrated 
using the TARDIS assay to visualise and quantify levels of TOP2A- and TOP2B- 
DNA complexes following treatment with etoposide, mitoxantrone, mAMSA and 
idarubicin (Willmore et al., 1998; Errington et al., 1999; Willmore et al., 2002; 
Errington et al., 2004). TOP2-DNA complexes are reversed upon drug removal from 
cells, and TOP2-DNA complex reversal has also been studied using the TARDIS 
assay. These studies have shown that TOP2-DNA complexes induced by 
intercalating TOP2 poisons like mitoxantrone and idarubicin are significantly more 
stable than those induced by non-intercalating TOP2 poisons such as etoposide 
(Willmore et al., 2002; Errington et al., 2004; Lee et al., 2016). Strikingly, while 50% 
of etoposide-induced TOP2A-DNA complexes are reversed within 40 minutes of 
drug removal, the half-life of mitoxantrone-induced TOP2A-DNA complexes is 
significantly greater, with 50% TOP2A-DNA complexes remaining after 10 hours 
(Errington et al., 2004; Lee et al., 2016). This suggests that the stability of TOP2-
DNA complexes may be increased through additional contacts between intercalating 
TOP2 poisons and DNA. 
Various studies have demonstrated the importance of TOP2A in TOP2 poison 
cytotoxicity. For example, Nalm-6 cells heterozygous for TOP2A (Nalm-6TOP2A+/-) are 
significantly more resistant to etoposide than wild type cells or Nalm-6 TOP2B 
knockout cells (Toyoda et al., 2008; Lee et al., 2016). This may be related to the 
stability of etoposide-induced TOP2A-DNA complexes compared to etoposide-
induced TOP2B-DNA complexes, which have half-lives of 40 minutes and 20 
minutes, respectively (Errington et al., 2004). Similarly, doxorubicin resistance is also 
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highest in Nalm-6TOP2A+/- cells compared to wild type or TOP2B knockout cells 
(Toyoda et al., 2008; Lee et al., 2016). However, TOP2B knockout cells are also 
significantly more resistant to etoposide than wild-type cells, albeit to a lesser extent 
than Nalm-6TOP2A+/- cells (Errington et al., 1999; Toyoda et al., 2008; Lee et al., 
2016). TOP2B knockout cells are also less sensitive to mAMSA and mitoxantrone 
(Errington et al., 1999; Toyoda et al., 2008; Lee et al., 2016) and therefore, TOP2B is 
also an important mediator of TOP2 poison cytotoxicity. 
1.1.8 TOP2 poison genotoxicity and the development of therapy-related 
leukaemia 
While both isoforms are involved in TOP2 poison cytotoxicity, TOP2B is most 
associated with TOP2 poison genotoxicity (Azarova et al., 2007; Azarova et al., 
2010; Cowell et al., 2012; Smith et al., 2013). For example, skin-specific knockout of 
TOP2B in a mouse carcinogenesis model showed that etoposide-induced melanoma 
is largely TOP2B-dependent (Azarova et al., 2007), although the role of TOP2A was 
not investigated in the same study. Evidence for TOP2B-dependent genotoxicity is 
also extended to lymphoblastic cell lines whereby TOP2B knockout in Nalm-6 cells 
significantly reduces the appearance of etoposide-induced micronuclei, and 
specifically reduces the appearance of etoposide-induced chromosomal breaks in 
translocation-prone loci such as MLL and RUNXI (Cowell et al., 2012; Smith et al., 
2013). TOP2 poison genotoxicity is associated with the development of therapy-
related acute myeloid leukaemia (t-AML), which accounts for approximately 5-10% of 
all AML cases, and is associated with a poor prognosis (Cowell and Austin, 2012; 
Pendleton et al., 2014). Therefore, the development of t-AML after TOP2 poison 
therapy is an important clinical problem.  
Although t-AML is also associated with alkylating agents, TOP2 poison-associated t-
AML is specifically characterised by a short latency period (<2 years) and balanced 
chromosome translocations, frequently involving the MLL (KMT2A) gene (11q23) 
(Allan and Travis, 2005; Cowell and Austin, 2012). Other common gene 
translocations following TOP2 poison therapy include the RUNXI:RUNXITI t(8;21) 
translocation and the PML:RARA t(15;17) translocation (Allan and Travis, 2005; 
Chen et al., 2010; Cowell et al., 2012; Smith et al., 2013). Intriguingly, etoposide-
induced translocation sites in the MLL locus are concentrated in a 1 Kb region at the 
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telomeric end of the 8 Kb breakpoint cluster region (BCR), the latter of which is 
associated with de novo AML (Cowell and Austin, 2012; Pendleton et al., 2014). 
Leukaemogenic chromosomal translocations occur upon the aberrant repair of DSBs 
at translocation-prone loci. Like radiation-induced damage, TOP2 poison-induced 
DNA damage can be repaired by non-homologous end joining (NHEJ) or by 
homologous recombination (HR) repair, depending on the cell cycle phase. 
However, most TOP2 poison-induced damage is repaired by NHEJ which operates 
throughout the cell cycle (Jin et al., 1998; Adachi et al., 2003; Willmore et al., 2004; 
Ayene et al., 2005; Malik et al., 2006; de Campos-Nebel et al., 2010; Maede et al., 
2014). While HR repair utilises a homologous sister chromatid as a template for high 
fidelity repair, NHEJ involves the potentially error-prone ligation of DNA ends 
(Hoeijmakers, 2001). Misrepair by NHEJ or a parallel alternative end joining (alt-EJ) 
pathway is thought to be associated with chromosome translocations (Ghezraoui et 
al., 2014), and binding of NHEJ proteins such as Ku80 and DNA-PKcs occurs within 
a known AML breakpoint cluster region following etoposide treatment (Kantidze et 
al., 2006). It is therefore thought that TOP2 poison-induced chromosome 
translocations occur at susceptible TOP2 cleavage sites due to aberrant end joining 
repair. It is unclear why TOP2 poison genotoxicity appears to show isoform 
preference, but is thought to involve the role of TOP2B in transcription (Cowell et al., 
2012). It is proposed that transcription factories provide the close proximity required 
for interaction between translocation partners at susceptible TOP2B cleavage sites 
(Cowell et al., 2012). In contrast, Canela et al. suggest that TOP2B-mediated DSBs 
within breakpoint cluster regions are not transcription-dependent but are instead 
related to the role of TOP2B at loop anchor sites, which are vulnerable to DNA 
breaks (Uuskula-Reimand et al., 2016; Canela et al., 2017). Importantly, recent 
evidence also implicates TOP2A in the induction of etoposide-induced 
translocations, as TOP2A cleavage cluster regions were also detected within known 
cancer fusion genes including MLL, PML, RARA and RUNXI (Yu et al., 2017). 
Therefore, targeting of TOP2A may also contribute to the genotoxicity of TOP2 
poisons. 
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1.2 Repair of TOP2 poison-induced DNA damage 
TOP2 poison-induced DSBs are concealed by the covalently bound TOP2 protein, 
and cannot be repaired until TOP2 is removed from the trapped TOP2-DNA 
complex. As mentioned in section 1.1.1, the 5’-phosphotyrosyl linkage between 
TOP2 and the TOP2-mediated DSB conceals DNA ends from DNA damage 
detection systems during the normal TOP2 reaction mechanism. Consistently, 
processing of drug-stabilised TOP2-DNA complexes to protein-free DSBs is required 
for the activation of DNA damage-dependent kinase DNA-PK (Martensson et al., 
2003). It was therefore hypothesised that preventing the processing of TOP2-DNA 
complexes to DSBs could reduce the likelihood of aberrant NHEJ, and hence the 
occurrence of leukaemogenic chromosomal translocations. Inhibition of TOP2-DNA 
complex processing with small molecule inhibitors is proposed in the current study 
as a viable approach to reduce the overall genotoxicity of TOP2 poisons. To achieve 
this, more must be understood about the various mechanisms of TOP2 removal from 
TOP2-DNA complexes. There are at least two types of processing pathways to 
convert TOP2-DNA complexes to ligatable DNA ends, including a nucleolytic and a 
proteolytic mechanism. These pathways are described in more detail below. 
1.2.1 Nucleolytic processing 
In the nucleolytic processing pathway, TOP2 adducts are removed by targeting the 
DNA. Nucleases such as Mre11 (of the MRN complex) can cleave the DNA end 
bearing the TOP2 protein (Neale et al., 2005; Hartsuiker et al., 2009; Lee et al., 
2012). Mre11 is a nuclease with both endonuclease and exonuclease activities 
which are utilised during HR repair for the processing of DNA ends to 3’ single 
stranded DNA (DNA end resection) (Cannavo and Cejka, 2014; Liu and Huang, 
2016). Importantly, Mre11 nuclease activity is also specifically involved in the 
resection and removal of 5’-adducts from DNA ends (Moreau et al., 1999; Stohr and 
Kreuzer, 2001; Connelly et al., 2003; Neale et al., 2005), including TOP2-DNA 
complexes (Hartsuiker et al., 2009; Hamilton and Maizels, 2010; Aparicio et al., 
2016; Hoa et al., 2016; Wang et al., 2017). Interestingly, basal levels of TOP2-DNA 
complexes (in the absence of TOP2 poison) are increased upon Mre11 inhibition, or 
in cells lacking full length Mre11 (Nakamura et al., 2010; Lee et al., 2012; Hoa et al., 
2016). This suggests that Mre11 is involved in the repair of endogenously trapped 
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TOP2-DNA complexes, which are thought to arise in the presence of abasic sites or 
other DNA-distorting lesions (Wilstermann and Osheroff, 2001; Stingele and Jentsch, 
2015). The Mre11-dependent removal of TOP2 adducts also involves the nuclease 
CtIP (Sae2 in yeast). Like Mre11, depletion of CtIP significantly increases etoposide 
sensitivity and increases levels of etoposide-induced TOP2-DNA complexes in yeast 
and vertebrate cells (Hartsuiker et al., 2009; Rothenberg et al., 2009; Nakamura et 
al., 2010; Quennet et al., 2011; Aparicio et al., 2016; Liao et al., 2016). This may 
involve the nuclease activity of CtIP itself, or the CtIP-dependent stimulation of 
Mre11 nuclease activity (Anand et al., 2016; Liao et al., 2016). Furthermore, the 
interaction of CtIP with BRCA1 is required for the removal of TOP2 adducts from 
DNA, and depletion of BRCA1 also increases levels of etoposide-induced TOP2-
DNA complexes (Nakamura et al., 2010; Aparicio et al., 2016). Alternatively, 
etoposide-induced DSBs can be resected by the exonuclease DNA2, although this 
occurs after the removal of TOP2 from the TOP2-DNA complex (Tammaro et al., 
2016).  
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1.2.2 Proteasomal processing 
TOP2-DNA complexes can also be removed by targeting the TOP2 protein to the 
proteasome. In the proteasomal processing pathway, the bulk of the TOP2 protein is 
degraded by the proteasome, leaving behind short peptides linked to DNA via a 
phosphotyrosyl linkage which can be removed by TDP2 (Figure 1.4). TDP2 is a 5’-
phosphodiesterase which specifically cleaves the 5’-phosphotyrosyl bond between 
degraded or denatured TOP2 and DNA (Cortes Ledesma et al., 2009; Gao et al., 
2014). Alternatively, intact TOP2-DNA complexes can be removed directly by TDP2 
in co-operation with the ZATT SUMO ligase in a proteasome-independent manner 
(Schellenberg et al., 2017). However, this TDP2-dependent processing pathway 
appears to contribute significantly only upon proteasome inhibition, suggesting that 
the proteasomal pathway is a major mechanism of TOP2 complex removal. 
The proteasomal degradation of TOP2-DNA complexes has been demonstrated in a 
number of cell lines, including mouse embryonic fibroblasts (MEFs) (Mao et al., 
2001; Zhang et al., 2006; Ban et al., 2013), HeLa cells (Alchanati et al., 2009), K562 
cells (Lee et al., 2016), U2OS cells (Tammaro et al., 2013) and a panel of colorectal 
cancer cell lines (Fan et al., 2008). Specifically, proteasomal inhibition prevents the 
TOP2 poison-induced degradation of TOP2A and TOP2B (Mao et al., 2001; Zhang 
et al., 2006; Alchanati et al., 2009; Ban et al., 2013) and prolongs the half-life of 
etoposide- and mitoxantrone- induced TOP2-DNA complexes (Fan et al., 2008; Lee 
et al., 2016). Subsequently, proteasome inhibition also suppresses the etoposide-
induced phosphorylation and activation of various DNA damage response proteins, 
including histone H2AX, RPA, and p53 (Zhang et al., 2006; Fan et al., 2008). 
Interestingly, the retinoblastoma tumour suppressor protein pRb has been implicated 
in the proteasomal degradation of TOP2B-DNA complexes, as the etoposide-
induced degradation of TOP2B and phosphorylation of histone H2AX is also 
impaired in pRb null MEFs (Xiao and Goodrich, 2005). pRb also mediates the 
interaction between TOP2B and BRCA1, which may contribute to the repair of 
etoposide-mediated damage through its role in DNA repair, or as a function of its E3 
ubiquitin ligase activity. 
The proteasomal degradation of TOP2B in response to TOP2 poisons is reported to 
be transcription-dependent (Mao et al., 2001; Fan et al., 2008; Tammaro et al., 
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2013). Proteasomal degradation also occurs in the absence of DNA damage with the 
TOP2 catalytic inhibitor, ICRF-193 (Isik et al., 2003; Xiao et al., 2003). Consequently, 
it has been proposed that TOP2B degradation is induced upon the collision of the 
transcription machinery with the trapped TOP2 cleavable complex, rather than by 
DNA damage per se (Mao et al., 2001; Xiao et al., 2003). In contrast, the 
proteasomal degradation of TOP2 is not replication-dependent (Mao et al., 2001; 
Fan et al., 2008), although replication may be involved in the activation of a distinct 
etoposide-induced DNA damage response which is important for etoposide 
cytotoxicity (Fan et al., 2008). Fan et al. show that both transcription-dependent and 
replication-dependent mechanisms were required for NHEJ repair, demonstrating 
the importance of TOP2 processing in the repair of TOP2-mediated DNA damage 
(Fan et al., 2008). 
 
Figure 1.4. Processing of TOP2-DNA complexes to protein-free DSBs. For DSB repair 
to occur, TOP2 protein adducts must first be removed from the drug-stabilised TOP2-DNA 
complex. This is partly achieved through the proteasomal degradation of TOP2, leaving 
behind small tyrosyl peptides which are directly removed by TDP2. TDP2 generates ligatable 
ends for non-homologous end joining (NHEJ), which is predominantly required for the repair 
of TOP2 poison-induced DSBs. Alternatively, TOP2-DNA complexes can be removed by 
proteasome-independent mechanisms such as direct removal by TDP2 in co-operation with 
ZATT, or by cleavage of DNA ends by nucleases such as Mre11/CtIP.  
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1.2.3 Other mechanisms of TOP2-DNA complex removal 
The nucleolytic and proteolytic pathways of TOP2-DNA complex processing are 
considered the two major pathways of TOP2 removal from DNA. However, in 
addition to the TDP2/ZATT-dependent pathway mentioned above, other 
mechanisms have also been described. For example, the half-life of mitoxantrone-
induced TOP2-DNA complexes is increased in cells deficient for CSB (Rocha et al., 
2016). CSB is an essential component of transcription coupled nucleotide excision 
repair (TCR-NER), which is initiated upon transcription stalling. This suggests that 
collision of drug-stabilised TOP2-DNA complexes with elongating RNA polymerase II 
may lead to the removal of TOP2 by NER, which would presumably depend on the 
NER nucleases XPF and XPG. Roche et al. also show that mitoxantrone (and 
etoposide) sensitivity is increased in CSB-deficient and other NER-deficient cell 
lines. Interestingly, siRNA knockdown of Ku70 increases sensitivity to etoposide in a 
manner that is independent of its role in NHEJ repair (Ayene et al., 2005), indicating 
a potential Ku-dependent mechanism of repair which may involve the AP lyase 
activity of Ku (Roberts et al., 2010). It is therefore plausible that multiple pathways 
exist for the removal of TOP2-DNA complexes and the subsequent repair of TOP2 
poison-induced DNA damage. 
While many pathways contribute to the repair of TOP2 poison-induced DNA 
damage, the proteasomal degradation of TOP2-DNA complexes appears to be a 
major removal mechanism. Although it was initially thought that only TOP2B-DNA 
complexes are proteasomally degraded (Mao et al., 2001; Isik et al., 2003), 
subsequent studies showed that TOP2A-DNA complexes are also degraded via 
proteasomal activity, but at a slower rate (Zhang et al., 2006; Fan et al., 2008; 
Alchanati et al., 2009; Lee et al., 2016). Timely proteasomal degradation is largely 
regulated through ubiquitination, yet little attention has been given to the potential 
role of ubiquitin in the processing of TOP2-DNA complexes. The proteasomal 
degradation of TOP2A-DNA complexes appears to be ubiquitin-dependent 
(Alchanati et al., 2009), but conflicting studies report both ubiquitin dependent and 
independent mechanisms of TOP2B degradation after etoposide or teniposide 
treatment (Mao et al., 2001; Ban et al., 2013). Clarification of the ubiquitin-dependent 
pathway would provide valuable mechanistic insights into the repair of TOP2 poison-
induced DNA damage, which could be used to improve therapy with TOP2 poisons. 
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Indeed, this was a primary aim of the current project. The remainder of this chapter 
will therefore outline what is known about the ubiquitin-proteasome system, and the 
ubiquitin-dependent degradation of TOP2. 
1.3 The ubiquitin-proteasome system 
1.3.1 Cellular roles of the proteasome 
The principal function of the proteasome is to degrade intracellular proteins. Protein 
degradation must be a tightly regulated process, and this is largely achieved through 
the conjugation of ubiquitin to target proteins (ubiquitination). While initially 
considered a route for the destruction of damaged or potentially toxic misfolded 
proteins, the cellular roles of the proteasome are much more widespread than 
originally anticipated (Adams, 2003). The proteasome regulates the turnover of many 
proteins, thereby maintaining appropriate concentrations of proteins in cells. This 
affects many cellular processes, including DNA damage repair, cell survival and 
proliferation (Jacquemont and Taniguchi, 2007; Murakawa et al., 2007). For 
example, proteasomal degradation of the inhibitor protein IκB is required for the 
translocation of NFκB into the nucleus, where it mediates the transcription of genes 
encoding anti-apoptosis proteins and pro-inflammatory cytokines (Adams, 2003). 
The proteasome also regulates cell cycle progression, and is overexpressed in 
various cancers (Rastogi and Mishra, 2012). Due to its apparent role in 
tumorigenesis, the ubiquitin-proteasome system became a viable drug target for 
cancer therapy, which was achieved following FDA and EMA approval of the 
proteasome inhibitor bortezomib. Bortezomib (as well as the approved second 
generation proteasome inhibitor carfilzomib) is now used in the treatment of multiple 
myeloma alone or in combination with other chemotherapeutic drugs (Merin and 
Kelly, 2014). 
1.3.2 Structure of the 26S proteasome 
The 26S proteasome is a multi-subunit complex comprising the 20S core particle 
and the 19S regulatory particle (Figure 1.5). The 20S core adopts a barrel-like 
conformation, formed by four stacked heptameric rings (α7β7β7α7). The two outer α-
rings (α1-7) form a narrow pore which restricts access to the proteolytic active sites 
situated within the internal chamber of the inner β-rings (β1-7) (Navon and 
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Ciechanover, 2009; da Fonseca et al., 2012; Budenholzer et al., 2017). In each β-
ring there are three active sites containing a catalytic threonine residue at the N 
terminus of the β1, β2 and β5 subunits. These sites differ in their precise proteolytic 
activity, cleaving after preferred amino acid residues (where B1 is caspase-like, B2 is 
trypsin-like and B5 is chymotrypsin like) (Navon and Ciechanover, 2009; Tomko and 
Hochstrasser, 2013).  
 
Figure 1.5. Structure of the 26S proteasome. The 26S proteasome consists of the 20S 
core particle and the 19S regulatory particle. The 20S is made up of four heptameric rings 
(two α rings and two β rings), while the 19S contains a hexameric ATPase ring (Rpt 1-6) 
which mediates protein unfolding. The 19S is also associated with ubiquitin receptors and 
deubiquitinase enzymes, which facilitate the proteasomal degradation of ubiquitinated 
proteins. Figure adapted from (Murata et al., 2009).  
Substrate entry into the 20S core is controlled in part by the opening and closing of 
the 20S narrow pore. Opening of the pore requires additional proteasome activators, 
which bind each end of the 20S core. For example, the proteasome activators PA28 
and PA200 facilitate pore opening and degradation in an ATP- and ubiquitin- 
independent manner, although this is restricted to a small subset of unstructured 
proteins (Inobe and Matouschek, 2014). Most proteasomal degradation requires the 
19S regulatory particle which, as well as pore opening, mediates the degradation of 
ubiquitinated proteins by unfolding and deubiquitinating substrates prior to their 
translocation into the 20S proteasome. 
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The 19S consists of two structural elements termed the lid and the base. However, 
the lid does not cap the base but interacts with both the base and the 20S core, 
seemingly holding the two together (Tomko and Hochstrasser, 2013). The interaction 
between the lid and the base is stabilised through binding to Rpn10, which also 
functions as a ubiquitin receptor (Budenholzer et al., 2017). The base contains six 
AAA ATPases (Rpt1-6), which are arranged in pairs to form a ring structure. Like 
PA28 and PA200, Rpt2, Rpt 3 and Rpt5 contain HbYX motifs which are inserted into 
the outer α-ring of the 20S core. This induces a conformational change in the outer 
α-ring which facilitates pore opening, and subsequent translocation of proteins into 
the 20S core for proteolysis. In addition to pore opening, the 19S AAA ATPases 
regulate the translocation of ubiquitinated substrates through the 20S core by protein 
unfolding. The proteasome-associated deubiquitinases (DUBs) Rpn11, Usp14 and 
Uch37 remove ubiquitin chains from proteins prior to degradation, which are recycled 
into free ubiquitin. 
1.3.3 Ubiquitin and ubiquitin-dependent proteasomal degradation 
Ubiquitin is a small protein (8.5 kDa, 76 amino acids) which is coupled to target 
lysine residues through the successive action of three enzymes; an E1 activating 
enzyme, E2 conjugating enzyme and E3 ubiquitin ligase (Figure 1.6). Firstly, 
ubiquitin is processed by DUBs to reveal a C terminal double glycine motif. Ubiquitin 
is then activated by one of two E1 activating enzymes which involves the formation 
of a high-energy thioester bond between ubiquitin and the E1 active site cysteine in 
an ATP-dependent manner (Komander, 2009). The activated ubiquitin moiety is then 
transferred to the catalytic cysteine residue of an E2 conjugating enzyme through the 
formation of another thioester bond. Subsequently, ubiquitin is transferred to the 
target protein by an E3 ligase enzyme, which binds the substrate together with the 
E2 conjugating enzyme. The precise mechanism by which ubiquitin is transferred to 
the target differs according to the type of E3 ligase enzyme (Komander and Rape, 
2012). For example, while RING ubiquitin ligases simply facilitate the transfer of 
ubiquitin from the E2 to the substrate lysine, ubiquitin is first transferred to the 
catalytic cysteine residue of HECT ubiquitin ligases before conjugation to the target 
protein. The human genome encodes two E1 enzymes, 37 E2s and >600 E3s. 
Therefore, ubiquitin enzymes represent a large group of potential drug targets for the 
modulation of ubiquitin-dependent proteasomal degradation.  
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Figure 1.6. Ubiquitin conjugation by E1, E2 and E3 enzymes. Ubiquitin is first activated 
upon the formation of a high energy thioester bond with the E1 ubiquitin activating enzyme. 
Ubiquitin is then transferred to an E2 conjugating enzyme, which is bound by an E3 ubiquitin 
ligase. Ubiquitin may then be transferred to the target protein directly (RING E3 ligases) or 
indirectly following transfer to the E3 ligase (HECT E3 ligases). The formation of 
polyubiquitin chains may or may not lead to proteasomal degradation, where the target is 
destroyed and ubiquitin chains are recycled.  
Ubiquitin can be conjugated singly to target proteins (monoubiquitination) or to 
multiple sites on the target protein (multimonoubiquitination). However, ubiquitin also 
contains 7 lysine residues (K6, K11, K27, K29, K33, K48, K63) which themselves 
can be ubiquitinated leading to the formation of polyubiquitin chains 
(polyubiquitination). The consequence of polyubiquitination is related to the distinct 
topology of alternative polyubiquitin chains. While K48-, K11- or K29- linked ubiquitin 
chains are most commonly associated with ubiquitin-dependent proteolysis, all chain 
types (with the exception of K63-linked chains) have been implicated in proteasomal 
degradation (Xu et al., 2009; Bedford et al., 2011). It is important to note that 
ubiquitination serves many functions which are unrelated to proteasomal 
degradation. For example, K63-linked chains are associated with the regulation of 
protein-protein interactions and signalling (including during the DNA damage 
response) (Komander, 2009).  
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1.3.4 TOP2 ubiquitination 
Multiple ubiquitination sites have been detected in TOP2A and TOP2B, including 
many which reside in the DNA binding and cleavage core (Kim et al., 2011) (Figure 
1.7). However, little is known about their function. Ubiquitination of TOP2A is 
associated with proteasomal degradation in response to various stimuli, including 
glucose starvation, HDAC inhibition, and teniposide treatment (Alchanati et al., 2009; 
Yun et al., 2009; Chen et al., 2011). Specifically, ubiquitination of TOP2A is 
implicated in the proteasomal processing of drug-stabilised TOP2A-DNA complexes, 
as inhibition of the BMI1/RING1A ubiquitin ligase prevents the proteasomal 
degradation of TOP2A after teniposide exposure (Alchanati et al., 2009). Similarly, 
Mao et al. demonstrated a requirement for ubiquitination in the proteasomal 
degradation of TOP2B following teniposide treatment. Mao et al. showed that 
inactivation of a temperature-sensitive ubiquitin E1 enzyme in ts85 murine cells 
prevented the teniposide-induced degradation of TOP2B (Mao et al., 2001). 
However, an equivalent study showed that etoposide-induced TOP2B degradation 
was unaffected in ts85 cells at the non-permissive temperature, implicating a 
ubiquitin-independent mechanism of proteasomal degradation (Ban et al., 2013). 
Therefore, the requirement for ubiquitin in the proteasomal processing of TOP2B-
DNA complexes remains unclear. A major aim of the current project is thus to 
determine the requirement for ubiquitin in the proteasomal processing of TOP2A- 
and TOP2B- DNA complexes. 
Given that there are over 600 human E3 ubiquitin ligases, identification of the E3 
ubiquitin ligases involved in the ubiquitination of TOP2-DNA complexes may enable 
more specific inhibition of TOP2-DNA complex processing by the proteasome. 
Importantly, the E3 ubiquitin ligases involved in TOP2 degradation varies by type of 
stress. For example, the ECV ubiquitin ligase complex is involved in TOP2A 
degradation in response to glucose starvation (Yun et al., 2009), while Fbw7 is a 
Csn5-associated ubiquitin ligase involved in HDAC inhibitor-induced TOP2A 
downregulation (Chen et al., 2011). Interestingly, HDAC inhibitor induced TOP2A 
degradation involves the upregulation of casein kinase II, which phosphorylates 
TOP2A and primes it for a second phosphorylation by GSK3β. In this instance, 
TOP2A phosphorylation was required for the recruitment of Fbw7 and its subsequent 
proteasomal degradation. Furthermore, BRCA1-mediated TOP2A ubiquitination first 
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requires the phosphorylation of TOP2A (Lou et al., 2005). This emphasises the 
importance of other post-translational modifications in the regulation of TOP2 
ubiquitination. 
 
Figure 1.7. TOP2 ubiquitination sites. Schematic of known ubiquitination sites in TOP2A 
and TOP2B as identified and reported by (Kim et al., 2011). Metabolically labelled HCT116 
cells were treated with 1 µM bortezomib (proteasome inhibitor) for 8 hours and lysed. 
Digestion of ubiquitinated peptides with trypsin produces a K-ε-GG (diglycine or “DiGly”) 
motif which were isolated by immunoprecipitation with a DiGly-specific antibody. Eluted 
peptides were then identified and analysed by LC-MS/MS. Data is accessible online at 
https://ggbase.hms.harvard.edu.  
1.3.5 TOP2 SUMOylation 
SUMOylation can also lead to the ubiquitin-dependent proteasomal degradation of 
proteins. SUMO is a ubiquitin-like (UBL) protein (of which there are four isoforms; 
SUMO-1, SUMO-2, SUMO-3 and SUMO-4) which can be conjugated to target 
lysines following activation, conjugation and ligation by a SUMO E1, E2 and E3 
enzyme, respectively. SUMO-targeted ubiquitin ligases (StUBLs) are E3 ubiquitin 
ligases containing a SUMO-interacting motif (SIM), which binds non-covalently to 
SUMOylated proteins (Geoffroy and Hay, 2009). Recruitment of a StUBL to a 
SUMOylated protein can lead to the formation of hybrid SUMO-ubiquitin chains 
following the conjugation of ubiquitin to the existing SUMO chain. RNF4 is a StUBL 
known to generate hybrid SUMO-ubiquitin chains at DSBs, which are bound by SIM- 
and UIM- (ubiquitin-interacting motif) containing proteins such as VCP/p97 and 
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Rap80 (Guzzo et al., 2012; Nie and Boddy, 2016). Binding of hybrid SUMO-ubiquitin 
chains by Rap80 mediates the recruitment of BRCA1, and is thus involved in the 
regulation of DSB repair (Guzzo et al., 2012). 
RNF4 mediates the ubiquitination of mitotic chromosomes in response to etoposide 
in a SUMO-dependent manner, although the SUMOylated target was not identified in 
the same study (Saito et al., 2014). This may be important as TOP2A and TOP2B 
are SUMOylated in response to etoposide and teniposide (Mao et al., 2000; 
Agostinho et al., 2008; Schellenberg et al., 2017), and previous studies using the 
TARDIS assay have demonstrated the presence of SUMO-1 and SUMO-2/3 chains 
on etoposide-induced TOP2-DNA complexes (Jobson, 2004). Indeed, a SUMO-
dependent pathway of TOP2-DNA complex processing was recently proposed 
whereby SUMOylation of TOP2-DNA complexes by the ZATT SUMO ligase 
facilitates the direct removal of TOP2 adducts by TDP2 (Schellenberg et al., 2017; 
Zagnoli-Vieira and Caldecott, 2017). TDP2 does not contain a canonical SIM, but 
contains five SUMO binding elements which are required for the interaction between 
TDP2 and TOP2. Intriguingly, TDP2 also contains a ubiquitin binding domain which 
is also required for the repair of TOP2-DNA complexes, although the precise function 
of this domain is unknown (Rao et al., 2016). While the SUMO- and TDP2- 
dependent pathway was independent of proteasomal degradation, other studies 
suggest a role for SUMO in the degradation of TOP2. For example, studies in yeast 
have shown that Rrp2 (a DNA translocase) competes with Slx8 (the yeast homolog 
of RNF4) for binding to SUMOylated TOP2 and thus prevents its ubiquitin-dependent 
proteasomal degradation (Wei et al., 2017). Furthermore, depletion of the SUMO E2 
enzyme (Ubc9) in a mutant chicken DT40 cell line prevented the ICRF-193 induced 
proteasomal degradation of TOP2B (Isik et al., 2003). This suggests that crosstalk 
between SUMO and ubiquitin is involved in the regulation of TOP2 degradation. 
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1.4 VCP/p97  
VCP/p97 is an evolutionarily conserved and highly abundant protein which is also 
involved in the regulation of the ubiquitin-proteasome system. As a AAA ATPase, 
VCP/p97 uses the energy from ATP hydrolysis to unfold ubiquitinated proteins. This 
facilitates the extraction of proteins from protein complexes or cellular components, 
often (but not always (Ramadan et al., 2007)) for proteasomal degradation. For 
example, VCP/p97 is well known for its role in endoplasmic reticulum associated 
degradation (ERAD), whereby the segregase activity of VCP/p97 enables the 
extraction of ubiquitinated p90 from the SPT23 transcription factor for nuclear 
targeting (Rape et al., 2001). This function is not limited to the ER, but has also been 
described for the removal of proteins from chromatin. This is discussed in detail in 
section 1.4.3. 
1.4.1 VCP/p97 is an important mediator of the ubiquitin-proteasome system 
Importantly, the function of VCP/p97 in the ubiquitin-proteasome system is much 
more extensive than initially thought. VCP/p97 is required for the proteasomal 
degradation of many ubiquitinated proteins (Dai and Li, 2001), which accumulate in 
response to VCP/p97 inhibition similarly to proteasomal inhibition (Heidelberger et 
al., 2018). Notably, VCP/p97 is not required for the degradation of all proteins 
targeted to the proteasome, as the abundance of accumulated ubiquitinated proteins 
upon complete VCP/p97 inhibition is less than that induced by proteasomal inhibition 
(Heidelberger et al., 2018). Beskow et al. used a series of Drosophila VCP/p97 
ATPase mutants to test the role of VCP/p97 enzymatic activity in the ubiquitin-
proteasome system. These studies revealed a widespread role for VCP/p97 in the 
pre-processing of many substrates, which was required for their proteasomal 
degradation (Beskow et al., 2009). In addition to the extraction of proteins from the 
ER and chromatin, Barthelme and Sauer propose that, like the 19S regulatory 
particle, VCP/p97 functions as an alternative proteasome activator (Barthelme and 
Sauer, 2013; Inobe and Matouschek, 2014). Therefore, VCP/p97 may act to facilitate 
the unfolding of proteins required for translocation into the 20S proteasome. In 
support of this, various studies have demonstrated an interaction between VCP/p97 
and the proteasome. Besche et al. were the first to detect VCP/p97 on purified 
proteasomes, occurring in very small quantities which suggests that the interaction is 
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transient under normal conditions (Besche et al., 2009). This interaction is stabilised 
in conditions of proteotoxic stress following treatment with arsenite or proteasome 
inhibitor, and leads to a 4-fold increase in proteasome activity (Isakov and Stanhill, 
2011). This suggests that VCP/p97 increases the efficiency of proteasomal 
degradation when the proteasome is compromised, likely by providing additional 
unfoldase activity. 
1.4.2 VCP/p97 structure 
AAA ATPases utilise energy from ATP hydrolysis to induce large conformational 
changes which are transduced to bound substrates for protein unfolding and 
remodelling. AAA ATPases are characterised by the presence of a 250 amino acid 
AAA domain, which is highly conserved in all domains of life from archaea to 
eukaryotes (Snider et al., 2008). The AAA domain binds and hydrolyses ATP, which 
is mediated by a Walker A and Walker B motif, respectively (Pye et al., 2006). AAA 
ATPases may contain one (type I) or two (type II) hexameric AAA domains. 
VCP/p97 is a hexameric type II AAA ATPase, with each protomer containing two 
ATPase domains, D1 and D2. The twelve resulting ATP binding sites form stacked 
rings arranged around a central pore (Figure 1.8). Hexamerisation and assembly of 
VCP/p97 requires the D1 domain, while a large proportion of ATPase activity is 
attributed to D2. It is thought that ATP induces large conformational changes in 
VCP/p97 which are transduced to the substrate protein, although these changes 
have been difficult to elucidate in structural studies due to limited resolution and the 
tight binding of ADP to the D1 domain (Pye et al., 2006). Nonetheless, studies 
describe a rotation of D1 and D2, and in particular the opening and closing of the D2 
central pore for the threading through of the unfolded protein substrate (van den 
Boom and Meyer, 2018).  
The VCP/p97 hexameric assembly also contains six N terminal domains which 
protrude from each protomer repeat of the D1 domain, where they mediate 
interactions with cofactors and adaptor proteins. Cofactors include a number of 
ubiquitin ligases and deubiquitinase enzymes, further implicating VCP/p97 as an 
important component of the ubiquitin-proteasome system. In addition, ubiquitin 
adaptor proteins such as p47 and Ufd1-Npl4 direct VCP/p97 to a multitude of cellular 
functions, interacting with VCP/p97 via UBX or UBXL domains (Meyer et al., 2000). 
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The interaction of all VCP/p97-interacting domains (including UBX, UBX-L, 
VIM/VBM, SHP and PUB/PUL domains) with VCP/p97 have now been resolved by 
X-ray crystallography (Stach and Freemont, 2017). UBX-containing proteins such as 
p47 and UBXD1 contain a C terminal UBX (ubiquitin regulatory X) domain, which 
binds the N terminal region of VCP/p97 (Dreveny et al., 2004). UBX-containing 
proteins typically interact with ubiquitin via an N terminal UBA domain. While p47 is 
most associated with membrane fusion events and UBXD1 is involved in lysosomal 
autophagy (Papadopoulos et al., 2017), other UBX-containing proteins such as FAF1 
have been implicated in chromatin-associated degradation. Specifically, FAF1 is 
required for the VCP/p97-dependent degradation of the replication licensing factor 
CDT1, which facilitates replication fork progression (Franz et al., 2016; Stach and 
Freemont, 2017). 
Similarly, UBX-L (UBX-like domain)-containing proteins (such as the VCP/p97-
associated DUB YOD1) also bind the VCP/p97 N terminus. Npl4 is a UBX-L-
containing protein which, together with Ufd1, is involved in various VCP/p97-
dependent functions including ERAD, ribosome-associated degradation (RAD) and 
chromatin-associated degradation (CAD) (Vaz et al., 2013; Stach and Freemont, 
2017) (Figure 1.8). The interaction between the Npl4 UBX-L domain and VCP/p97 is 
stabilised by Ufd1, which makes additional contacts with the VCP/p97 N terminus via 
a SHP motif (another VCP/p97-interacting sequence) (Le et al., 2016). Both Npl4 
and Ufd1 also bind ubiquitin via a zinc finger domain and UT3 domain respectively, 
with a preference for K48-linked ubiquitin chains (Ye et al., 2003).  
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Figure 1.8. Structure and functions of VCP/p97. A) Domain structure of a VCP/p97 
monomer, containing an N terminal domain, two ATPase domains (D1 and D2) and a C 
terminal domain. B) Structure of the VCP/p97 hexameric assembly and associated functions, 
mediated by specific ubiquitin adaptor proteins Npl4-Ufd1, UBXD1 and p47. Figure 
reproduced from (Vaz et al., 2013), licenced under a CC BY licence 
(https://creativecommons.org/licenses/by/4.0/legalcode).  
1.4.3 Role of VCP/p97 in the DNA damage response 
The role of VCP/p97 in the extraction and removal of chromatin-associated proteins 
is particularly evident during the DNA damage response. After the initial wave of 
DNA damage-induced phosphorylation by ATM, ATR and DNA-PK kinases, 
ubiquitination regulates both the recruitment and removal of repair proteins from the 
damage site. The ubiquitin-dependent recruitment of DNA repair proteins such as 
BRCA1 and 53BP1 to DSBs is mediated by the E3 ubiquitin ligases RNF8 and 
RNF168 (Huen et al., 2007; Mailand et al., 2007; Doil et al., 2009; Panier and 
Durocher, 2009; Bekker-Jensen and Mailand, 2011; Mattiroli et al., 2012). VCP/p97 
itself is recruited to DSBs in a ubiquitin- and Ufd1-Npl4- dependent manner, which 
seems to be mediated mostly through the binding of K48-linked ubiquitin chains 
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(Meerang et al., 2011). The ubiquitin-dependent removal of DNA repair proteins is 
then largely mediated by VCP/p97. For example, VCP/p97 is required for the 
removal of polycomb protein L3MBTL1 from the H4K20me2 histone mark, which 
otherwise antagonises the binding of 53BP1 (Acs et al., 2011). Thus, VCP/p97 
enables the recruitment of 53BP1 to DSBs. VCP/p97-dependent chromatin 
extraction is observed for a number of other repair proteins, including DNA-PKcs and 
Rad51-Rad52 (Bergink et al., 2013; Jiang et al., 2013). The removal of chromatin-
associated proteins by VCP/p97 is therefore important for the co-ordination of DNA 
repair. 
VCP/p97 is also required to restore DNA to its undamaged state by removing repair 
proteins once DSB repair has occurred. Ku70/80 adopts a ring structure, which loops 
onto DNA ends and mediates the recruitment of NHEJ proteins such as DNA-PKcs, 
XRCC4, DNA ligase IV, and Artemis (Postow, 2011). Once the break is repaired, 
Ku70/80 becomes sterically trapped on DNA, and is removed in a ubiquitin-
dependent manner (Brown et al., 2015). VCP/p97 was recently identified as an 
ATPase activity required for the unfolding and extraction of ubiquitinated Ku70/80 
from DNA following DNA repair (van den Boom et al., 2016). 
1.4.4 Role of VCP/p97 in the repair of UV-induced DNA damage 
UV irradiation induces bulky DNA adducts and interstrand crosslinks which are 
repaired by nucleotide excision repair (NER). As the name suggests, NER involves 
the excision of the damaged DNA strand, recognised by DDB2 and XRC. 
Importantly, siRNA knockdown of VCP/p97 leads to the accumulation of 
ubiquitinated DDB2 at UV damage sites (Puumalainen et al., 2014), suggesting the 
removal of DDB2 is VCP/p97-dependent. 
Another consequence of UV-induced DNA damage is the stalling of RNA 
polymerase II (RNAPII) on DNA. Transcription stalling can also occur due to 
topological constraints, dNTP depletion, and bulky DNA adducts (including TOP2-
DNA complexes). There are a number of available mechanisms to overcome these 
obstacles. However, irreversible transcription stalling leads to the induction of the 
“last resort” pathway of RNAPII proteasomal degradation on chromatin (Wilson et al., 
2013). Specifically, it is the large subunit of RNAPII (Rpb1) which is degraded, while 
other subunits of the elongation complex remain to be reused. 
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Being such a crucial enzyme, the proteolysis of RNAPII is highly regulated, and this 
is achieved by ubiquitination of Rpb1 (Harreman et al., 2009; Wilson et al., 2013). 
Firstly, Rpb1 is polyubiquitinated by Rsp5, which forms K63-linked ubiquitin chains. 
Secondly, these ubiquitin chains are trimmed back to monoubiquitin by the DUB, 
Usp2. Subsequently, Rpb1 is polyubiquitinated with K48-linked ubiquitin chains. At 
this point, RNAPII can be rescued by another DUB which removes K48-linked 
ubiquitin chains (Usp3). Otherwise, the proteasome is recruited to chromatin leading 
to degradation of Rpb1. Verma et al. showed that the interaction between Rpb1 and 
the proteasome is VCP/p97-dependent in yeast, and indeed the proteasomal 
degradation of Rpb1 requires the ATPase activity of VCP/p97 (Verma et al., 2011; 
Lafon et al., 2015). This was later demonstrated in human cells (He et al., 2017a). 
Therefore, VCP/p97 extracts protein complexes from chromatin which are otherwise 
trapped or tightly associated.  
Interestingly, it has been suggested that the proteasomal processing of TOP2-DNA 
complexes requires additional unfoldase activity, such as that of RNAPII-associated 
19S AAA ATPases (Ban et al., 2013). Given the ability of VCP/p97 to extract and 
unfold trapped protein complexes from DNA, it was hypothesised that VCP/p97 
could facilitate the proteasomal processing of TOP2-DNA complexes. Notably, 
inactivation of a temperature-sensitive Cdc48 (the yeast homolog of VCP/p97) leads 
to the accumulation of ubiquitinated TOP2 (Wei et al., 2017). In addition, Cdc48 is 
required for the degradation of TOP1-DNA complexes by the non-specific protease, 
Wss1 (Stingele et al., 2014; Balakirev et al., 2015). 
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1.5 Aims 
The major aims of the current project are as follows: 
 To determine the requirement for ubiquitin in the processing of etoposide-
induced TOP2A- and TOP2B- DNA complexes (Chapter 3). 
 To investigate the ubiquitination of TOP2 in the presence and absence of 
etoposide (Chapter 4). 
 To investigate the potential role of VCP/p97 in the processing of etoposide-
induced TOP2-DNA complexes (Chapter 5). 
 To test the effect of inhibitors of the ubiquitin-proteasome system on TOP2 
poison-induced growth inhibition and genotoxicity (Chapter 6). 
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Chapter 2 Materials and Methods 
2.1 Drugs and Chemicals 
All drugs and chemicals were purchased from Sigma-Aldrich (Dorset, UK) except for 
PYR-41, PRT4165 and HLI373 (purchased from Merck Millipore, Massachusetts, 
USA), MLN7243 (Active Biochem Ltd, Hong Kong), MLN4924 (R&D systems, 
Minneapolis, USA) and PR-619 (Tocris Bioscience, Bristol, UK). All drugs were 
dissolved in DMSO, unless otherwise stated. Sea-prep agarose (with ultra-low gelling 
temperature) used for TARDIS experiments was purchased from Fisher Scientific 
(New Hampshire, US). 
2.2 Cell culture 
Cells were grown in RPMI medium containing 10% FBS and 5% v/v penicillin-
streptomycin, and incubated at 37°C, 5% CO2 in a humidified atmosphere. Cell 
culture was performed under aseptic conditions. Cells were passaged every 2 or 3 
days and maintained between 1 x 105 – 1 x 106 cells/mL for K562, and between 2 x 
105 – 2 x 106 cells/mL for Nalm-6 cells. 
2.2.1 Cell lines 
The K562 leukemic cell line is derived from the bone marrow of a 53 year old female 
CML patient, characterised by the presence of the Philadelphia chromosome, t(9;22). 
Nalm-6 is a human pre-B ALL cell line derived from the peripheral blood of a 19 year 
old male patient. Nalm-6TOP2A+/- and Nalm-6TOP2B-/- cells were generated as previously 
described by Adachi et al. (Adachi et al., 2006). 
2.3 Trapped in Agarose DNA Immunostaining (TARDIS) assay 
2.3.1 Drug treatment 
K562 cells were seeded at a density of 2 x 105 cells/mL and incubated overnight. 
Exponentially growing cells were treated with etoposide alone or in combination with 
small molecule inhibitors as indicated in the text, and an additional 100 µM etoposide 
positive control was used for data normalisation. After drug treatment, etoposide-
containing media was removed by centrifugation (1000 rpm for 5 minutes) and cells 
were washed in ice cold Phosphate Buffered Saline (PBS). Alternatively, cells were 
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incubated for a further 2 hours in fresh media containing DMSO or relevant small 
molecule inhibitor, and cells were collected and washed at half-hour intervals (0, 0.5, 
1 and 2 hours). After removal of the supernatant, cells were stored on ice for no 
longer than 30 minutes to minimise the reversal and repair of TOP2-DNA complexes. 
2.3.2 Slide preparation and cell spreading 
Microscope slides were coated with 0.5% Sea-prep low melting point agarose (Fisher 
Scientific, US) prior to cell spreading. Cells were resuspended in 50 µL ice cold PBS 
and briefly heated in a 37°C water bath for approximately 20 seconds. An equivalent 
volume of 2% molten agarose was added to the cells and mixed thoroughly. 50 µL of 
cell suspension was added to duplicate slides (one for staining for TOP2A and one 
for TOP2B) and spread evenly using a clean microscope slide. Slides were 
subsequently placed on an ice-cooled glass plate in order to rapidly set the agarose 
and to minimise TOP2 complex reversal. 
2.3.3 Cell lysis 
Cells were lysed in buffer containing 1% w/v SDS, 20 mM NaPO4 (pH 6.5), 10 mM 
EDTA and 0.25% v/v protease inhibitor cocktail (AEBSF, Aprotinin, Bestatin, E-64, 
Leupeptin and Pepstatin A purchased from Sigma-Aldrich, Dorset, UK) for 30 
minutes. Cells were incubated for a further 30 minutes in 1 M NaCl prior to three 
successive washes in PBS. 
2.3.4 Antibody incubations 
All antibody incubations were carried out for 1.5 hours at room temperature. Primary 
antibodies specific for TOP2A or TOP2B (see Table 1 for antibody details) were 
diluted in PBS containing 1% w/v BSA and 0.1% v/v Tween 20. For the study of 
TOP2-DNA complex ubiquitination or SUMOylation by TARDIS, slides were 
incubated with anti-ubiquitin antibodies (APU2, APU3 or FK2) or an anti-SUMO-2/3 
antibody. Slides were then washed three times in PBS-T (1x 30 seconds, 2x 5 
minutes) and stored at 4°C overnight in PBS-T containing protease inhibitors. 
Secondary antibody was diluted in blocking buffer and added to slides in subdued 
light. Finally, slides were washed in PBS (2x 5 minutes, 1x 20 minutes) prior to 
staining with 2 µg/mL Hoechst 33258 DNA stain (Life Technologies, USA). Slides 
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were mounted using Vectashield mounting medium (Vector Laboratories, CA) and 
stored at 4°C until further analysis. 
2.3.5 Fluorescence microscopy 
Microscopy was performed using an Olympus IX-81 confocal microscope fitted with a 
Hamamatsu Orca-AG camera. Analysis was performed using Volocity software 
(Perkin-Elmer) and GraphPad Prism version 4 as previously described by Cowell et 
al. (Cowell et al., 2011). Optimal exposure time was determined by autoexposure of 
the brightest sample, which was set at the beginning of each experiment. 
2.4 Immunofluorescence 
Cells were washed and resuspended in ice-cold PBS then added to wells of poly-L-
lysine coated multi-well reaction slides. After 10 minutes, surplus cells were washed 
away in PBS and the remaining cells were fixed in 4% paraformaldehyde for 10 
minutes. Slides were washed twice in PBS then transferred to a coplin jar containing 
KCM-T [120 mM KCl, 20 mM NaCl, 10 mM Tris-HCl pH 8.0, 1 mM EDTA, 0.1% Triton 
X-100] for 15 minutes to permeabilise the cells. Cells were then incubated in blocking 
buffer [KCM-T + 10% dried milk powder + 2% BSA] for 1 hour at room temperature, 
or overnight at 4°C. Antibodies were used as described in Table 1. Primary 
antibodies (TOP2A, TOP2B, histone, RNAPII, Ku80, ɣH2AX), were diluted in 
blocking buffer and added to slides for 1 hour at room temperature. Slides were then 
washed three times in KCM-T (3x 10 minutes) before the addition of secondary 
antibody. Secondary antibodies (anti-mouse or anti-rabbit, Alexa Fluor 488 or 594) 
were also diluted in blocking buffer and added to slides for 1 hour at room 
temperature in the dark. Slides were washed as above, prior to mounting of cover 
slips using Vectashield mounting medium with DAPI. Slides were stored at 4°C until 
further analysis. 
2.5 siRNA knockdown 
K562 cells were suspended in culture medium to a density of 2 x 107 cells/mL. For 
each siRNA, 300 µL of cell suspension was transferred to an electroporation cuvette 
and the indicated siRNA was added to a final concentration of 500 nM. 
Electroporation was executed using the Fischer EPI2500 electroporator at 330 V and 
10 mS pulse length. Cells were allowed to recover for 15 minutes at room 
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temperature, then transferred to fresh media in a T25 or T75 cell culture flask. All 
siRNA was used at a concentration of 500 nM, and handled under DNase- and 
RNase- free conditions. 
2.6 SDS-PAGE 
2.6.1 Preparation of whole cell extracts 
Cells were first lysed in ice-cold extraction buffer [10 mM MgCl2, 50 mM Tris-HCl, pH 
7.4, 4 µM DTT and 50 µL/mL protease inhibitor cocktail (Sigma-Aldrich, UK)], then 
SDS was added to 0.25 % v/v to lyse the nuclear membrane. Chromatin-bound 
proteins were released by digestion of the DNA with 50 µg/mL DNase I, and 
incubated on ice for at least 10 minutes (until the viscosity of the lysate was 
reduced). The lysate was mixed 1:1 with solubilisation buffer [2% SDS, 20% glycerol, 
5% β-mercaptoethanol, 0.6 M Tris-HCl, pH 7.2], and heated at 68°C for 10 minutes. 
Whole cell extracts were stored at -80°C until required. 
2.6.2 Estimation of protein concentration 
The total protein concentration of whole cell extracts was determined by Bradford 
assay using a standard BSA curve of known concentration. Whole cell lysates 
contain SDS, which can interfere with the Bradford dye reagent. To account for this, 
a 2 mg/mL BSA stock was initially diluted 1:1 with solubilisation buffer to give a final 
SDS concentration of 1% as in whole cell lysates. The 1 mg/mL BSA standard and 
whole cell lysates were then serial diluted 1:2 across a 96 well plate in dH2O, 
together with a blank dH2O control for background subtraction. Quickstart Bradford 
dye reagent (BioRad, UK) was added to each well and incubated at room 
temperature for 10 minutes. The absorbance of each well was measured using a 
BioRad microplate reader 550 at 595nm, and the average absorbance of the blank 
control wells was subtracted from each reading. The linear region of the blank-
corrected BSA standard curve was used to generate a line equation to deduce x 
(protein concentration, mg/mL) from y (A595nm). The estimated protein concentration 
from at least 3 dilutions of each sample was multiplied by the dilution factor, then 
combined to produce an average.  
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2.6.3 Polyacrylamide gel electrophoresis 
Samples were mixed 1:1 with 2x SDS sample buffer and heated at 68°C for 10 
minutes. Unless otherwise stated, samples were run on 4-20% gradient gels 
(Generon, or BioRad, UK) at 120 V, 500 mA for up to 2 hours using Tris-HEPES 
running buffer [60% HEPES, 35% TRIS, 5% SDS] or Tris-Glycine running buffer 
[Tris, Glycine, 5% SDS].  
2.7 Western blotting 
After gel electrophoresis, proteins were transferred to nitrocellulose membrane 
(Hybond ECL, GE Healthcare, UK) by wet transfer [25 mM Tris, 192 mM glycine, 
20% v/v methanol, pH 8.3] at 100 V for 1 hour. The membrane was transferred to 
blocking buffer [5% milk in TBS-T; 20 mM Tris-HCl, pH 7.4, 150 mM NaCl and 0.1% 
Tween 20] for at least 1 hour, then incubated in primary antibody (diluted in blocking 
buffer as indicated in Table 1) for 1 hour at room temperature or 4°C overnight. The 
membrane was rinsed in TBS-T, followed by consecutive washes in TBS-T for 1x 15 
minutes, and 2x 5 minutes. An HRP-linked secondary antibody (diluted 1:10,000 in 
blocking buffer) was added to the blot for 1 hour, followed by washes in TBS-T as 
above. The blot was incubated for 5 minutes with ECL detection reagent (BioRad, 
UK), and developed on film or using the LiCor c-DiGit scanner, as indicated. 
2.7.1 Western blot quantification 
Blots processed on film were scanned and quantified using Image Lab version 5.2.1 
(BioRad), and blots processed using the LiCor c-Digit western blot scanner were 
quantified using Image Studio 5.0 (LiCor). The band density of each lane was 
normalised to the corresponding actin control, and protein levels were expressed as 
a percentage of the relevant control. 
2.8 5-ethynyl uridine (EU) assay 
EU is incorporated into newly synthesised mRNA transcripts and detected by a 
simple click chemistry reaction between an azide and an alkyne, followed by 
fluorescence microscopy. Cells were treated with the indicated concentration of α-
Amanitin or DRB, followed by 1 hour incubation with 1 mM EU. Cells were adhered 
onto poly-L-lysine slides and fixed in 4% PFA for 10 minutes, prior to 
permeabilisation with KCM-T buffer for 15 minutes [120 mM KCl, 20 mM NaCl, 10 
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mM Tris-HCl pH 8.0, 1 mM EDTA, 0.1% Triton X-100]. The Click-iT reaction cocktail 
was prepared as specified in the manufacturer’s instructions, and added to fixed cells 
for 30 minutes at room temperature, protected from light. Hoechst 33258 was used to 
stain DNA, and slides were mounted with coverslips and analysed by fluorescence 
microscopy. 
2.9 Ubiquitin pulldown assays 
The isolation of ubiquitinated proteins with TUBEs or MultiDsk2 was performed as 
described by Anindya et al. (Anindya et al., 2007). 8 x 105 cells were lysed in 200 µL 
TENT buffer [20 mM Tris-HCl (pH 8.0), 2 mM EDTA, 150 mM NaCl, and 1% Triton X-
100] containing 10 mM NEM and protease inhibitors. Where indicated, lysates were 
sonicated using the Bandelin Sonopuls HD 2070 for 5x 15 seconds (5 cycles at 20% 
power). Other lysis conditions tested during optimisation are outlined in Appendix 
Table 2. After centrifugation for 10 minutes at 14,000 g (15,300 rpm) and 4°C, the 
supernatant was collected and incubated in the presence of 1.8 µM GST-TUBE 1 or 
2, or 0.2 µM MultiDsk2 for at least 20 minutes on ice (longer incubations were also 
performed from 1 hour to overnight, see Appendix Table 2). Lysates were then 
incubated with 35 µL GST-beads for 90 minutes at 4°C on rotation. Beads were 
collected by brief centrifugation, and the unbound supernatant collected as flow-
through (FT). Beads were washed 1x in TENT buffer and 2x in PBS, then stored 
at -20°C overnight. Ubiquitinated proteins were eluted from the beads by boiling in 2x 
sample buffer at 95°C for 10 minutes. 
2.10 Immunoprecipitation 
2 x 106 cells were lysed in 200 µL RIPA buffer [50 mM Tris-HCl pH 7.4, 600 mM 
NaCl, 1% NP40, 0.4% sodium deoxycholate, 0.1% SDS, 1 mM MgCl2, 1 mM EGTA] 
containing 10 mM N-ethylmaleimide (NEM, Sigma-Aldrich) and protease inhibitor 
cocktail (20 µL/mL, Sigma-Aldrich). Lysates were treated with DNase I (at a final 
concentration of at least 50 µg/mL) for 30 minutes on ice. Where indicated, lysates 
were also sonicated using three 5 second bursts and 35% power, with 3 second 
pauses, or treated with 250 units of benzonase for 15 minutes. The concentration of 
NaCl was reduced from 600 mM to 150 mM by diluting the lysate 1:4 in ice-cold 
dilution buffer (RIPA buffer without NaCl). The lysate was cleared by centrifugation at 
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15,300 g at 4°C for 10 minutes, and the supernatant was transferred to a clean tube. 
Lysate was stored at -80°C in 100 µL aliquots for subsequent IPs. 
The indicated IP antibody was added to 100 µL cleared lysate and incubated at 4°C 
on rotation for 2 hours. 30 µL of protein A- or protein G- sepharose beads were 
washed 3x in dilution buffer and added to each lysate. Lysates were incubated with 
beads for 90 minutes at 4°C on rotation, and a small volume of supernatant was 
collected as flow-through (i.e. whole cell lysate after IP). The beads were washed 2x 
in dilution buffer and 1x in PBS, then used immediately or stored overnight at -20°C. 
Proteins were eluted from the beads by boiling at 95°C for 10 minutes in 40 µL 2x 
sample buffer, then analysed by SDS-PAGE and western blotting. Western blotting of 
IP samples was performed using the HRP-conjugated Veriblot detection reagent for 
IP (abcam, ab131366, used at 1:2000 in 5% milk-TBS-T) which detects non-reduced 
IgG, but not denatured IgG which is present as a result of the IP procedure. 
Therefore, the Veriblot reagent circumvents the detection of antibody heavy and light 
chains which can interfere with IP interpretation. 
2.11 XTT potentiation assay 
The XTT growth inhibition assay was performed using the XTT Cell Proliferation kit 
(Roche, Switzerland). Cells were seeded in 96 well plates at a density of 1 x 104 cells 
per well (Nalm-6) or 2 x 103 cells per well (K562) and incubated for 24 hours prior to 
drug treatment. Cells were treated with increasing concentrations of TOP2 poison 
alone or in combination with a fixed dose of various ubiquitination inhibitors 
(MLN7243, PYR-41, PRT4165 or HLI373) and incubated for 120 hours (>4 technical 
replicates). XTT reagent was mixed 50:1 with electron coupling reagent and added to 
each well, followed by a further 4 hours incubation at 37°C. Absorbance values 
(OD450nm) were obtained using the BioRad 550 Microplate Reader and analysed 
using GraphPad Prism version 4. 
A sub-lethal concentration (corresponding to 20% growth inhibition, IC20) of each 
inhibitor was determined by XTT assay for use in combination experiments. To 
account for this, all data were normalised to the inhibitor-only control (no TOP2 
poison) as 100% growth and a media-only control was used as 0% growth. 
Potentiation factors (Pf50) were calculated as a ratio of the IC50 (concentration at 50% 
growth inhibition with respect to untreated controls) of TOP2 poison alone and the 
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IC50 of TOP2 poison in combination with ubiquitination inhibitor. Pf50 values were 
calculated for each separate experiment, and are therefore presented as the mean 
Pf50 factors of at least 3 biological replicates. 
2.12 Micronucleus assay 
Cells were treated with the indicated concentration of etoposide alone or in 
combination with MLN7243 for 48 hours (or MMS as a clastogenic positive control). 
Cell growth and viability was determined by cell counting and trypan blue exclusion. 
Cells were washed in PBS then incubated with 2 µg/mL ethidium monoazide bromide 
(EMA) for the labelling of apoptotic or necrotic cells. Cells were adhered to poly-L-
lysine coated slides and fixed in 4% PFA for 10 minutes. After DNA staining with 
Hoechst 33258, micronuclei were visualised and counted manually by fluorescence 
microscopy. 
2.13 Statistical analyses 
Where multiple comparisons were required for two independent variables (drug 
treatment and time), two-way ANOVA followed by Bonferroni post-test was used to 
determine statistical significance. For comparison of two sample means, a one-tailed, 
unpaired t-test was used. All data are presented as the mean ± SEM, and p values 
>0.05 were considered statistically significant.
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Chapter 3 Investigating the role of the ubiquitin-proteasome 
system in the processing of etoposide-induced TOP2-DNA 
complexes 
3.1 Introduction 
The repair of drug-stabilised TOP2-DNA complexes is particularly challenging due to 
the covalent 5’-phosphotyrosyl linkage between the TOP2 active site tyrosine and 
DNA. The TOP2-mediated double strand break (DSB) is concealed by the TOP2 
protein, preventing its recognition by the DNA damage response machinery 
(Martensson et al., 2003). Consequently, TOP2 must be removed from the TOP2-
DNA complex before DSB repair can occur. Mechanisms of TOP2 removal include 
the nucleolytic cleavage of DNA ends by Mre11/CtIP (Hartsuiker et al., 2009; Lee et 
al., 2012; Aparicio et al., 2016), or the degradation of TOP2 by the proteasome (Mao 
et al., 2001; Zhang et al., 2006; Fan et al., 2008; Sunter et al., 2010; Lee et al., 
2016). In the proteasomal pathway, TOP2 is degraded and the remaining TOP2 
peptides can be removed from the 5’ end by the 5’-phosphodiesterase, TDP2 
(Cortes Ledesma et al., 2009; Zeng et al., 2011; Schellenberg et al., 2012; Gao et 
al., 2014). Alternatively, a proteasome-independent mechanism was recently 
described whereby TDP2 removes TOP2 adducts in co-operation with the ZATT 
SUMO ligase in a SUMO-dependent manner (Schellenberg et al., 2017). However, 
this pathway did not contribute significantly to the clearance of TOP2-DNA 
complexes in the presence of functional proteasomes, and therefore the proteolytic 
removal of TOP2 is a major repair pathway. 
Many studies have demonstrated a role for the proteasome in the degradation of 
TOP2 following exposure to TOP2 poisons. While earlier publications suggest that 
only TOP2B-DNA complexes are processed by the proteasome (Mao et al., 2001; 
Isik et al., 2003; Azarova et al., 2007), it has since been shown that TOP2A is also 
degraded in response to TOP2 poisons, including etoposide, teniposide and 
mitoxantrone (Fan et al., 2008; Alchanati et al., 2009; Sunter et al., 2010; Lee et al., 
2016). Inhibition of the proteasome also reduces the activation of etoposide-induced 
DNA damage signals including phosphorylation of histone H2AX, ATM, Chk1, Chk2 
and the induction of RPA foci (Zhang et al., 2006; Fan et al., 2008; Tammaro et al., 
2013), consistent with the notion that TOP2 must be removed from DNA before the 
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DSB can be repaired. Interestingly, the proteasomal pathway of TOP2-DNA complex 
removal seems to involve transcription, as inhibition of transcription also prevents the 
proteasome-dependent degradation of TOP2 and the liberation of TOP2 poison-
induced DSBs (Mao et al., 2001; Fan et al., 2008; Ban et al., 2013; Tammaro et al., 
2013). It has therefore been hypothesised that TOP2 degradation is initiated upon 
collision of TOP2-DNA complexes with elongating RNA polymerase II. 
Proteasomal degradation is often (but not always) preceded by the ubiquitination of 
the target protein. This is accomplished in a three-step cascade involving an E1 
ubiquitin activating enzyme (UAE), E2 conjugating enzyme and E3 ligating enzyme 
(see Chapter 1, Figure 1.6). Indeed, the ubiquitin-dependent proteasomal 
degradation of TOP2A has been demonstrated in response to various stimuli, 
including HDAC inhibition (Chen et al., 2011) and overexpression of the ECV 
ubiquitin ligase (Yun et al., 2009). Importantly, the BMI1/RING1A ubiquitin ligase was 
recently implicated in the teniposide-induced proteasomal degradation of TOP2A-
DNA complexes, which was inhibited upon siRNA knockdown or chemical inhibition 
of BMI1/RING1A (Alchanati et al., 2009). The ubiquitin-dependence of TOP2B-DNA 
complex processing has also been suggested in studies employing a temperature 
sensitive murine cell line (ts85), whereby inactivation of the major ubiquitin activating 
enzyme (UAE1) disrupted the teniposide-induced degradation of TOP2B (Mao et al., 
2001). While the ubiquitin-dependent degradation of teniposide-induced TOP2A- and 
TOP2B-DNA complexes has been demonstrated by two independent research 
groups (Mao et al., 2001; Alchanati et al., 2009), another study showed that the 
etoposide-induced degradation of TOP2B-DNA complexes did not require UAE1 
activity using the UAE1 temperature sensitive cell line previously used by Mao et al. 
(Ban et al., 2013). The degradation of etoposide-induced TOP2B-DNA complexes 
was also unaffected by expression of mutated ubiquitin, whereby one or all lysine 
residues in ubiquitin are mutated to arginine and are therefore unable to form 
ubiquitin chains (Ban et al., 2013), suggesting that ubiquitin is not required for the 
processing of etoposide-induced TOP2B-DNA complexes. While the only 
conceivable difference between the experiments performed by Mao et al. and Ban et 
al. was the use of teniposide or etoposide respectively, there are a number of 
caveats with these approaches which may lead to opposing results. Firstly, 15% of 
ubiquitin activating enzyme activity remains in ts85 cells at the non-permissive 
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temperature, which could be due to incomplete inactivation of UAE1 or due to the 
presence of a second ubiquitin activating enzyme, UBA6 (Finley et al., 1984; 
Groettrup et al., 2008). Therefore, some ubiquitination activity remains in ts85 cells 
which may account for the conflicting results between two separate studies (Mao et 
al., 2001; Ban et al., 2013). Secondly, cells overexpressing mutated ubiquitin also 
contain endogenous wild type ubiquitin, which may form polyubiquitin chains thereby 
leading to the degradation of TOP2B-DNA complexes. Thus, the requirement for 
ubiquitin in the proteasomal processing of TOP2-DNA complexes remains elusive. 
3.2 Aims 
The role of ubiquitin in the proteasomal processing of TOP2-DNA complexes was 
investigated in the current study by chemical inhibition and siRNA knockdown of the 
ubiquitin activating enzymes, UAE1 and UBA6. MLN7243 is a highly specific UAE 
inhibitor which inhibits UAE1 and UBA6 by forming a MLN7243-ubiquitin adduct 
(Misra et al., 2017; Hyer et al., 2018). The effect of UAE inhibition (as well as specific 
E3 ubiquitin ligase inhibition) on the processing of TOP2-DNA complexes was first 
investigated using the TARDIS assay to measure the removal of etoposide-induced 
TOP2 complexes from DNA. The ɣH2AX assay was then used to measure the 
appearance of etoposide-induced protein-free DSBs following UAE inhibition or 
siRNA knockdown. This approach was also used to investigate the role of 
transcription and the contribution of other known processing pathways, including the 
nucleolytic pathway and the proteasome-independent TDP2-mediated pathway. 
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3.3 Principles of the TARDIS assay 
The TARDIS assay is an immunofluorescence-based technique used for the 
visualisation and quantification TOP2-DNA covalent complexes (Willmore et al., 
1998; Cowell et al., 2011; Cowell and Austin, 2018). Unlike standard 
immunofluorescence where cells are fixed on microscope slides, drug-treated cells 
are first mixed with 1% low melting point agarose (Figure 3.1A). The agarose-
suspended cells are then spread onto microscope slides and allowed to set on an 
ice-cooled glass plate. The cells, now embedded in agarose, are subjected to 
stringent lysis: first in buffer containing 1% SDS, then in 1 M NaCl. These steps 
remove most cellular constituents including proteins which are not covalently bound 
to the genomic DNA, which itself is too large to escape the agarose and so remains 
on the slide as a number of “nuclear ghosts”. The remaining DNA can then be 
probed for TOP2A and TOP2B covalent complexes using isoform-specific 
antibodies, followed by staining with corresponding fluorescent secondary antibodies 
and Hoechst DNA stain. TOP2-DNA complexes are detected by fluorescence 
microscopy through the co-localisation of TOP2 with DNA, and quantified by 
integrated fluorescence per nucleus. Therefore, the TARDIS assay is a statistically 
powerful technique which gives a cell-by-cell measurement of TOP2-DNA complex 
levels. Individual values are presented by scatter diagram, or median values are 
displayed on histograms (Figure 3.1B). Where data from replicate experiments has 
been combined, error bars represent the mean of medians ± SEM.  
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Figure 3.1. Visualisation and quantification of TOP2-DNA complexes using the 
TARDIS assay. A) Schematic representation of the TARDIS assay. B) Etoposide (VP-16) 
dose-response in K562 cells. Cells were incubated with 0.5% DMSO or the indicated 
concentration of etoposide for 2 hours (each containing equivalent volumes of DMSO), and 
levels of TOP2A- and TOP2B- DNA complexes were measured using the TARDIS assay. 
Scatter diagrams show the raw integrated fluorescence of individual nuclei from a single 
experiment, with a red line to denote median values. The data are then normalised to an 
additional 100 µM etoposide control (set as 100%), and statistical significance is determined 
using an unpaired t-test to compare normalised median values of triplicate experiments. 
Histograms represent the mean of median values ± SEM (n=3).   
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3.3.1 Etoposide and teniposide dose-response 
Figure 3.1B shows the dose-dependent increase in levels of TOP2A- and TOP2B- 
DNA complexes in K562 cells following 2 hours treatment with etoposide, quantified 
using the TARDIS assay. In the absence of etoposide, non-covalently bound TOP2 
is washed away during lysis and is therefore not detected in a DMSO-treated 
negative control. However, TOP2A- and TOP2B- DNA complexes are readily 
detectable upon treatment with 10 µM etoposide, with signals increasing in a dose-
dependent manner up to 100 µM etoposide (Figure 3.1B). Levels of TOP2A- and 
TOP2B- DNA complexes become saturated at 100 µM, as no significant increase 
was detected between 100 µM and 250 µM etoposide (p=0.1666 and p=0.4908, 
respectively). 100 µM etoposide was therefore used in the TARDIS assay throughout 
this study, unless otherwise stated. 
Existing studies investigating the role of the ubiquitin-proteasome system in the 
proteasomal processing of TOP2-DNA complexes generally involve the treatment of 
cells with high doses of etoposide (VP-16) at 250 µM, or the closely related TOP2 
poison teniposide (VM-26) at 100 µM (Mao et al., 2001; Zhang et al., 2006; Fan et 
al., 2008; Alchanati et al., 2009; Ban et al., 2013). Like etoposide, teniposide is an 
epipodophyllotoxin which differs only by the presence of an aromatic thiophene 
group at the C4 glycosidic ring (Figure 3.2A). To directly compare the efficacy of 
etoposide and teniposide, K562 cells were treated with increasing concentrations of 
etoposide or teniposide for 2 hours, and levels of TOP2-DNA complexes were 
determined by TARDIS assay. Levels of TOP2A- and TOP2B- DNA complexes 
became saturated at 10 µM teniposide, reflecting a ten-fold higher potency 
compared to etoposide (Figure 3.2B). Indeed, there were no significant differences 
between levels of TOP2A- and TOP2B- DNA complexes induced by 100 µM 
etoposide and 10 µM teniposide (p=0.4591 and p=0.3298, respectively). Consistent 
with this, the IC50 (concentration at 50% growth inhibition) of etoposide is 
approximately 7-fold higher than that of teniposide in K562 cells, as determined by 
XTT assay (Lee, 2016). 
47 
 
 
Figure 3.2. Induction of TOP2-DNA complexes by etoposide and teniposide, measured 
by TARDIS assay. A) Chemical structure of the epipodophyllotoxins etoposide and 
teniposide. B) K562 cells were treated with increasing concentrations of etoposide (VP-16) 
or teniposide (VM-26) for 2 hours, and levels of TOP2A- and TOP2B- DNA complexes were 
measured by TARDIS assay. All data are normalised to 10 µM etoposide as 100%, and error 
bars represent the mean of medians ± SEM of three replicate experiments (n=3).   
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3.3.2 TARDIS removes non-covalently bound proteins from DNA 
It is expected that the rigorous lysis conditions used during the TARDIS procedure 
will remove all non-covalently bound proteins from DNA, including those that are 
tightly-associated with chromatin such as RNA polymerase II and Ku70/80. While the 
tight association of RNA polymerase II with DNA is essential for genome stability 
during gene transcription (Wilson et al., 2013), Ku70/80 becomes sterically trapped 
on DNA following DNA damage and repair (Postow, 2011; van den Boom et al., 
2016). 
To test whether all non-covalently bound chromatin proteins are removed during 
TARDIS lysis, slides were probed for all histones, Rpb1 (the RNA polymerase II 
large subunit) and Ku80. K562 cells were treated with 100 µM etoposide (VP-16) or 
0.2 % v/v DMSO for 2 hours prior to the quantification of the indicated proteins by 
standard immunofluorescence (Figure 3.3, left panel) or TARDIS (Figure 3.3, right 
panel). As anticipated, TOP2A was detected on TARDIS slides following exposure to 
etoposide. Histones, Rpb1 and Ku80 were readily detectable by standard 
immunofluorescence, but were not detectable on TARDIS slides. Therefore, lysis in 
buffer containing SDS followed by incubation in buffer containing high salt is 
sufficient to remove non-covalently bound chromatin proteins from DNA, but does 
not disrupt the covalent 5’-phosphotyrosyl linkage between drug-stabilised TOP2 and 
DNA. 
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Figure 3.3. Removal of non-covalently bound chromatin-associated proteins 
(histones, RNA polymerase II and Ku80) from TARDIS slides. K562 cells were treated 
with 100 µM etoposide (VP-16) for 2 hours, prior to fixation in paraformaldehyde and 
standard immunofluorescence (left panel) or processing via the TARDIS assay (right panel). 
Slides were probed for TOP2A and other chromatin-associated proteins including all 
histones, RNA polymerase II large subunit (Rpb1), and Ku80.   
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3.4 Using the TARDIS assay to investigate the role of the ubiquitin-
proteasome system in TOP2-DNA complex removal 
The TARDIS assay can be used to measure the repair of drug-stabilised TOP2-DNA 
complexes by quantifying levels of TOP2-DNA complexes remaining following drug 
removal. With the exception of irreversible TOP2 poisons like clerocidin (Binaschi et 
al., 1997) (see also Appendix Figure 1), drug-stabilised TOP2-DNA complexes are 
reversible upon drug washout. In this way, TARDIS has been used to measure the 
half-lives of TOP2A- and TOP2B- DNA complexes following treatment with various 
TOP2 poisons. For example, the half-lives of etoposide-induced TOP2A- and 
TOP2B- DNA complexes after etoposide washout are 40 minutes and 20 minutes, 
respectively (Willmore et al., 2002; Errington et al., 2004; Lee et al., 2016). This 
approach can also be used to study the contribution of the proteasome to the active 
removal of TOP2 complexes from DNA, as treatment of cells with a proteasome 
inhibitor significantly slowed, though did not completely prevent, the reversal of 
TOP2A- and TOP2B- DNA complexes after etoposide removal (Lee et al., 2016). 
In the current study, the TARDIS assay was used to address the potential role of 
ubiquitination in the removal of TOP2 complexes from DNA. The role of the 
proteasome was confirmed using the proteasome inhibitor MG132, while the role of 
ubiquitination was examined using the ubiquitin activating enzyme (UAE) inhibitor 
MLN7243 (Figure 3.4A). Inhibition of the proteasome can be assessed through the 
accumulation of ubiquitinated proteins which would otherwise be degraded. In 
contrast, targeting of ubiquitin activating enzymes inhibits the very first step in the 
ubiquitination cascade, leading to the absence of ubiquitin conjugates. To test the 
efficacy of MG132 and MLN7243 in K562 cells, cells were treated with the indicated 
concentration of MG132 or MLN7243 for 2 hours, and levels of ubiquitin conjugates 
were measured by western blot. Treatment of cells with 1, 5, 10 and 20 µM MG132 
induced the accumulation of ubiquitinated proteins compared to untreated control, 
while treatment with MLN7243 completely abolished levels of ubiquitin conjugates at 
all doses tested (Figure 3.4B). 
To examine the effect of MG132 and MLN7243 on the removal of etoposide-induced 
TOP2 complexes from DNA, K562 cells were treated with 100 µM etoposide alone or 
in combination with 10 µM MG132 or 10 µM MLN7243 for 2 hours. Etoposide was 
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removed from the culture medium and cells were incubated for a further 2 hours in 
etoposide-free medium containing MG132 or MLN7243 (or DMSO) to maintain 
inhibition of the proteasome or ubiquitination, respectively. Levels of TOP2-DNA 
complexes were measured at 0, 0.5, 1 and 2 hours after etoposide removal using the 
TARDIS assay (Figure 3.4C). 
As previously shown, co-treatment of cells with MG132 did not affect levels of 
TOP2A- or TOP2B- DNA complexes immediately following 2 hours continuous 
exposure to etoposide (0 hours after VP-16 removal) (Lee et al., 2016). Similarly, 
inhibition of ubiquitination with the UAE inhibitor MLN7243 did not affect the 
induction of TOP2A- or TOP2B- DNA complexes by etoposide, suggesting that 
ubiquitination does not influence the formation of TOP2-DNA complexes. Neither 
MG132 nor MLN7243 treatment alone affected basal levels of TOP2-DNA 
complexes at any of the time points tested. 
The effect of proteasome or UAE inhibition on the processing of TOP2-DNA 
complexes was determined by comparing levels of TOP2-DNA complexes at 
individual time points after etoposide removal, rather than by rate. Given that levels 
of TOP2-DNA complexes were not significantly different at the time of etoposide 
removal (0 hours), it was assumed that any differences in the level of TOP2-DNA 
complexes at subsequent time points was due to changes in the processing of 
TOP2-DNA complexes. While rate of TOP2 complex removal could theoretically be 
measured by comparing the gradient of each curve, more data points (within 2 hours 
of etoposide removal) are required to accurately determine the rate of TOP2-DNA 
complex removal. Instead, a two-way ANOVA was used to statistically compare each 
curve, which accounts for both variables affecting TOP2-DNA complex levels (i.e. 
drug treatment and time). 
As expected, levels of TOP2-DNA complexes reduced with time following the 
removal of etoposide from the culture medium (Errington et al., 2004; Lee et al., 
2016), likely reflecting the combined effect of the spontaneous reversal of complexes 
(i.e. completion of the TOP2 reaction mechanism upon dissociation of etoposide) 
and the active removal of TOP2 from DNA by various processing mechanisms 
including proteasomal degradation. Consistently, levels of remaining TOP2A-DNA 
complexes were significantly increased in the presence of MG132 at 0.5, 1 and 2 
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hours following etoposide removal (p<0.05), while remaining TOP2B-DNA 
complexes were significantly increased after 0.5 hours (p<0.001). Notably, the 
reversal of TOP2B-DNA complexes is faster than that of TOP2A-DNA complexes 
both in the presence and absence of MG132, consistent with the half-lives of 
etoposide-induced TOP2A- and TOP2B-DNA complexes reported by others 
(Errington et al., 2004; Lee et al., 2016). Although slowed, the removal of etoposide-
induced TOP2 complexes from DNA still occurred in the presence of MG132. 
Indeed, levels of TOP2B-DNA complexes return to background levels within 1 to 2 
hours of etoposide removal even in the presence of MG132, representing 
proteasome-independent mechanisms of TOP2-DNA complex removal or 
spontaneous complex reversal following completion of the TOP2 reaction cycle. 
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Figure 3.4. Inhibition of the ubiquitin-proteasome system and the effect on etoposide-
induced TOP2-DNA complex levels. A) Chemical structure of MLN7243, an inhibitor of 
ubiquitin activating enzymes (UAE). B) Dose-response of the proteasome inhibitor MG132 
and UAE inhibitor MLN7243. K562 cells were treated with the indicated concentration of 
MG132 or MLN7243 for 2 hours. Whole cell extracts were electrophoresed and total levels of 
ubiquitination were detected by western blot. Blots were probed with the anti-ubiquitin 
antibody clone FK2, which recognises all conjugated ubiquitin (mono- and poly-ubiquitinated 
proteins). C) The effect of MG132 and MLN7243 on levels of TOP2-DNA complexes was 
measured by TARDIS assay. K562 cells were treated for 2 hours with 100 µM etoposide 
(VP-16) alone or in combination with 10 µM MG132 and/or 10 µM MLN7243. Etoposide was 
removed from the culture medium, and cells were incubated for up to 2 hours in etoposide-
free medium but in the continued presence of 0.1% v/v DMSO, 10 µM MG132 and/or 10 µM 
MLN7243. Levels of TOP2A- and TOP2B- DNA complexes were measured following 2 hours 
continuous drug exposure (0 hours after VP-16 removal) or 0.5, 1 or 2 hours incubation in 
etoposide-free medium. Statistical significance was determined by two-way ANOVA with 
Bonferroni post-test to compare replicate means (n=3 for TOP2A, n=6 for TOP2B). Averages 
represent mean of medians ± SEM.  
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Interestingly, levels of remaining etoposide-induced TOP2A- and TOP2B- DNA 
complexes were also significantly increased in the presence of MLN7243 following 
etoposide removal, indicating reduced TOP2 complex processing. Similarly to 
proteasome inhibition, levels of remaining TOP2A-DNA complexes were significantly 
increased at 0.5, 1 and 2 hours after etoposide removal (p<0.01), and levels of 
remaining TOP2B-DNA complexes were increased after 0.5 hours (p<0.001). To 
determine whether each inhibitor exerts its effects via the same pathway, etoposide-
treated cells were also co-incubated with both 10 µM MG132 and 10 µM MLN7243. 
Levels of remaining TOP2A- and TOP2B- DNA complexes were not significantly 
increased by both inhibitors compared to each inhibitor alone, suggesting that the 
roles of the proteasome and ubiquitin activating enzymes are epistatic. Although 
levels of TOP2-DNA complexes were not affected after etoposide removal, 
administration of both inhibitors together did significantly increase the initial levels of 
TOP2A- and TOP2B- DNA complexes induced by etoposide immediately following 2 
hours continuous exposure (0 hours after VP-16 removal, p<0.01 and p<0.001, 
respectively). 
To further investigate the role of ubiquitin in the removal of TOP2-DNA complexes, 
the TARDIS assay was repeated following co-incubation of cells with etoposide and 
one of two additional UAE inhibitors, PYR-41 or PYZD-4409. K562 cells were treated 
with etoposide alone or in combination with 10 µM PYR-41, followed by the removal 
of etoposide and incubation in the continued presence of DMSO or PYR-41 for up to 
2 hours. Levels of TOP2A- and TOP2B- DNA complexes were measured following 0, 
0.5, 1 and 2 hours after etoposide removal. Consistently, levels of remaining TOP2A-
DNA complexes were significantly higher in the presence of PYR-41 after 1 or 2 
hours incubation in etoposide-free medium (p<0.01), and levels of TOP2B-DNA 
complexes were significantly higher after 1 hour (p<0.05) (Figure 3.5A). Similarly, 
treatment of cells with 10 µM PYZD-4409 also increased levels of remaining TOP2A-
DNA complexes following 1 or 2 hours incubation in etoposide-free medium 
(p<0.001), and increased levels of remaining TOP2B-DNA complexes after 1 hour 
(p<0.001) (Figure 3.5B). 
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Figure 3.5. Effect of UAE inhibitors PYR-41 and PYZD-4409 on levels of etoposide-
induced TOP2-DNA complexes. A) K562 cells were treated for 2 hours with 100 µM 
etoposide (VP-16) alone or in combination with 10 µM PYR-41. Cells were collected (0 hours 
after VP-16 removal) or incubated for 0.5, 1 or 2 hours in etoposide-free medium containing 
0.1% v/v DMSO or 10 µM PYR-41 to maintain UAE inhibition. B) K562 cells were treated 
with 100 µM etoposide alone or in combination with 10 µM PYZD-4409 for 2 hours followed 
by up to 2 hours incubation in etoposide-free medium containing 0.1% v/v DMSO or 10 µM 
PYZD-4409. Levels of TOP2A- and TOP2B- DNA complexes were measured using the 
TARDIS assay, and statistical significance was determined by two-way ANOVA with 
Bonferroni post-test (n=3). Values represent the mean of median ± SEM, normalised to the 
average TOP2-DNA complex levels at 2 hours continuous exposure to 100 µM etoposide (0 
hours after VP-16 removal). C) Chemical structures of UAE inhibitors, PYR-41 and PYZD-
4409. D) Western blot to compare total levels of K48-linked ubiquitin conjugates (APU2 
antibody) following treatment with PYR-41, PYZD-4409 or MLN7243. K562 cells were 
treated for 2 hours with 10 µM of PYR-41, PYZD-4409 or MLN7243 alone or in combination 
with 10 µM MG132, as indicated.  
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PYR-41 and PYZD-4409 are structurally distinct from MLN7243 (Figure 3.5C), and 
therefore the slowed removal of TOP2-DNA complexes by all three UAE inhibitors is 
unlikely to be due to the same off-target effect. To compare the efficacy of PYR-41 
and PYZD-4409 with MLN7243, levels of K48-linked ubiquitin conjugates were 
measured by western blot as an indication of UAE inhibition. K562 cells were treated 
for 2 hours with 10 µM PYR-41, 10 µM PYZD-4409 or 10 µM MLN7243 alone or in 
combination with 10 µM MG132 (for enrichment of ubiquitinated proteins). As 
expected, levels of K48-linked ubiquitin were increased following MG132 treatment 
(Figure 3.5D). PYR-41 alone reduced levels of K48-linked ubiquitin compared to 
untreated control, though did not prevent the MG132-induced accumulation of 
ubiquitinated proteins. Ubiquitination was not noticeably affected by 10 µM PYZD-
4409 alone, and PYZD-4409 did not affect the accumulation of ubiquitinated proteins 
upon MG132 treatment. Strikingly, K48-linked ubiquitination of proteins was not 
detectable following MLN7243 treatment alone or in combination with MG132. 
Therefore, MLN7243 is a highly effective UAE inhibitor which was used for the 
duration of this study. 
3.4.1 siRNA knockdown of ubiquitin activating enzymes 
The role of ubiquitin in the removal of TOP2-DNA complexes was also investigated 
following siRNA knockdown of the major UAE, UAE1. K562 cells were transfected 
with 500 nM non-coding (CON) siRNA or 500 nM UAE1 siRNA by electroporation, 
and levels of UAE1 protein were measured by western blot (Figure 3.6A). UAE1 
levels were reduced to 1% in UAE1 siRNA knockdown cells after 72 hours compared 
to control siRNA-treated cells. Thus, all subsequent experiments were performed in 
UAE1 knockdown cells 72 hours after electroporation. 
CON siRNA or UAE1 siRNA knockdown cells were treated with 100 µM etoposide 
for 2 hours, followed by etoposide washout and 2 hours further incubation in drug-
free medium. Levels of TOP2A- and TOP2B- DNA complexes were measured by 
TARDIS assay at 0, 0.5, 1 and 2 hours after etoposide removal. Unlike chemical 
inhibition of UAE, levels of etoposide-induced TOP2A-DNA complexes were not 
significantly affected by UAE1 knockdown at any of the time points tested (Figure 
3.6B). Initial levels of TOP2B-DNA complexes were significantly increased in UAE1 
knockdown cells following 2 hours continuous exposure to etoposide (p<0.001, 0 
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hours after VP-16 removal), but returned to control levels at 0.5, 1 and 2 hours after 
etoposide removal. Figure 3.6C shows the level of UAE1 protein and K48-linked 
ubiquitin conjugates in control versus UAE1 knockdown cells from a single TARDIS 
experiment, measured by western blot. As in previous experiments (Figure 3.6A) 
siRNA knockdown was highly efficient, as UAE1 was not detectable in UAE1 
knockdown cells (0%, Figure 3.6C). However, 39% of K48-linked ubiquitination still 
occurred suggesting the presence of remaining UAE activity. 
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Figure 3.6. siRNA knockdown of ubiquitin activating enzyme 1 (UAE1) and the effect 
on TOP2-DNA complex levels measured by TARDIS assay. A) K562 cells were 
transfected with 500 nM non-coding siRNA (CON siRNA) or 500 nM UAE1 siRNA by 
electroporation. Cells were collected following 24, 48, 72 and 96 hours after electroporation 
and levels of UAE1 protein were tested by western blot. UAE1 levels were quantified and 
expressed as the percentage remaining compared to the corresponding CON siRNA control. 
B) CON siRNA or UAE1 siRNA knockdown cells were treated with 100 µM etoposide (VP-
16) for 2 hours, followed by 2 hours incubation in etoposide-free medium. TOP2A- and 
TOP2B- DNA complex levels were measured by TARDIS assay at 0, 0.5, 1 and 2 hours after 
etoposide removal, and statistical comparisons were made by two-way ANOVA followed by 
Bonferroni post-test (n=3). C) Levels of UAE1 protein and K48-linked ubiquitin in CON 
siRNA and UAE1 siRNA knockdown cells from a single experiment in B were measured by 
western blot. Protein levels were quantified and expressed as the percentage remaining 
compared to a non-electroporated control, as described in Chapter 2, section 2.7.1.  
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UBA6 is a second and more recently discovered UAE enzyme which is also inhibited 
by MLN7243 (Hyer et al., 2018). Like UAE1, UBA6 is essential in mice, suggesting 
that UAE1 and UBA6 are required for separate functions and are not simply 
redundant enzymes (Groettrup et al., 2008). Interestingly, the E2 conjugating 
enzyme Use1 is charged by UBA6 but not UAE1, implying the existence of distinct 
ubiquitin activation pathways (Jin et al., 2007). Furthermore, UBA6 is required for the 
ubiquitination of a defined set of substrates, indicating a level of specificity which 
exists at the level of ubiquitin activation (Liu et al., 2017). Therefore, the effect of 
MLN7243, but not UAE1 siRNA, on the removal of TOP2-DNA complexes could be 
attributed to inhibition of UBA6-dependent ubiquitination. To test this, K562 cells 
were transfected with 500 nM UBA6 siRNA by electroporation. Figure 3.7A shows 
the levels of UBA6 in CON siRNA-treated versus UBA6 siRNA-treated cells at 24, 
48, 72 and 96 hours after electroporation. UBA6 levels were reduced to 28% after 24 
hours compared to CON-siRNA treated cells, and were undetectable after 72 hours 
(0%). Therefore, all experiments with UBA6 siRNA knockdown cells were performed 
72 hours after electroporation. 
CON siRNA or UBA6 siRNA knockdown cells were treated with 100 µM etoposide 
for 2 hours, followed by etoposide washout and incubation in drug-free medium. 
Levels of TOP2A- and TOP2B- DNA complexes were measured at 0, 0.5, 1 and 2 
hours after etoposide removal using the TARDIS assay (Figure 3.7B). Levels of 
TOP2A-DNA complexes (both in the presence and absence of etoposide) were not 
affected by UBA6 knockdown at any of the time points tested. Unlike UAE1 
knockdown cells in which the levels of TOP2B-DNA complexes were increased after 
2 hours of etoposide exposure, TOP2B-DNA complex levels were unaffected in 
UBA6 knockdown cells at all time points tested. Therefore, the normal removal of 
TOP2-DNA complexes in UAE1 siRNA knockdown cells is not due to UBA6-
dependent ubiquitination. 
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Figure 3.7. siRNA knockdown of ubiquitin activating enzyme UBA6 and the effect on 
TOP2-DNA complex levels measured by TARDIS assay. A) K562 cells were transfected 
with 500 nM non-coding siRNA (CON siRNA) or 500 nM UBA6 siRNA by electroporation. 
Western blotting was used to measure levels of UBA6 protein at 24, 48, 72 and 96 hours 
after electroporation. UBA6 levels were quantified and expressed as the percentage 
remaining compared to the corresponding CON siRNA control, as described in Chapter 2, 
section 2.7.1. B) CON siRNA and UBA6 siRNA knockdown cells were treated with 100 µM 
etoposide (VP-16) for 2 hours, followed by 2 hours incubation in etoposide-free medium. 
Levels of TOP2A- and TOP2B- DNA complexes were measured at 0, 0.5, 1 and 2 hours 
after etoposide removal. Averages represent the mean of median integrated fluorescence 
values from a single experiment (n=1), normalised to average TOP2-DNA complex levels at 
2 hours continuous exposure to 100 µM etoposide (0 hours after VP-16 removal).  
It is possible that the normal reversal of TOP2-DNA complexes in UAE1 knockdown 
or UBA6 knockdown cells is due to residual levels of activated ubiquitin or 
compensatory ubiquitin activation by the alternative UAE. To more completely 
knockdown levels of activated ubiquitin, the TARDIS assay was also performed in 
K562 cells following double siRNA knockdown of UAE1 and UBA6. CON siRNA and 
double UAE1/UBA6 siRNA knockdown cells were treated with 100 µM etoposide for 
2 hours, followed by etoposide washout and incubation in drug-free medium. Levels 
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of TOP2A-DNA complexes were not affected by UAE1/UBA6 siRNA knockdown, 
while a small increase in TOP2B-DNA complexes was detectable 0 hours after 
etoposide removal in a single experiment (Figure 3.8A). 
Despite what appears to be an efficient siRNA knockdown of both UAE1 and UBA6, 
and the subsequent reduction in levels of K48-linked ubiquitin conjugates (Figure 
3.8B), it is plausible that some functional UAE activity remains in UAE1/UBA6 
knockdown cells. In contrast, it is anticipated that chemical inhibition of UAE 
enzymes efficiently blocks the function of any protein present. To compare the 
effectiveness of double UAE1/UBA6 siRNA knockdown with chemical inhibition by 
MLN7243, total levels of ubiquitinated proteins were measured by western blot as an 
indication of UAE activity (Figure 3.8C). Total levels of ubiquitin conjugates were 
reduced in UAE1/UBA6 knockdown cells compared to control cells, as expected 
(compare lane 1 with lane 3). Cells were also treated for 2 hours with 10 µM MG132 
(or 0.1% v/v DMSO) for the enrichment of ubiquitinated proteins upon proteasome 
inhibition. The MG132-induced accumulation of ubiquitin conjugates was 
substantially reduced but still detectable in UAE1/UBA6 knockdown cells (compare 
lane 2 with lane 4). UAE activity was also examined in non-transfected K562 cells 
(no siRNA) treated with 10 µM MG132 alone or in combination with 10 µM 
MLN7243. Unlike UAE1/UBA6 knockdown cells, no ubiquitin conjugates were 
detectable in MLN7243-treated cells even in the presence of MG132 (lane 7). 
Together, this suggests that chemical inhibition of UAE activity by MLN7243 is more 
complete than siRNA knockdown of UAE enzymes, which may explain the 
differences observed in the TARDIS assay. 
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Figure 3.8. Investigating the effect of double siRNA knockdown of UAE1 and UBA6 on 
levels of TOP2-DNA complexes using the TARDIS assay. A) CON siRNA or double 
UAE1/UBA6 siRNA knockdown cells were treated with 100 µM etoposide (VP-16) for 2 
hours followed by 2 hours incubation in etoposide-free medium. Levels of TOP2A- and 
TOP2B- DNA complexes were measured at 0, 0.5, 1 and 2 hours after etoposide removal. 
Averages represent the mean of median integrated fluorescence values from a single 
experiment (n=1), normalised to the average level of TOP2-DNA complexes at 2 hours 
continuous exposure to 100 µM etoposide (0 hours after VP-16 removal). B) Western blot to 
show UAE1 and UBA6 protein levels in CON siRNA and double UAE1/UBA6 siRNA 
knockdown cells. Blots were also probed for K48-linked ubiquitin as an indication of UAE 
activity. Protein levels were quantified and expressed as the percentage remaining 
compared to the corresponding CON siRNA control. C) Ubiquitination assay to compare 
UAE activity in double UAE1/UBA6 siRNA knockdown cells with MLN7243-treated cells. 
K562 cells treated with control siRNA or UAE1 and UBA6 siRNA were incubated with 10 µM 
MG132 to induce the accumulation of ubiquitinated proteins. Non-transfected cells were also 
treated with 10 µM MG132 alone or in combination with 10 µM MLN7243. Western blotting 
was used to compare total levels of ubiquitination by probing with anti-ubiquitin antibody 
clone FK2, which detects all conjugated ubiquitin (mono- and poly-ubiquitinated proteins).    
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3.4.2 Effect of the Nedd8-activating enzyme inhibitor MLN4924 on levels of 
TOP2-DNA complexes 
The high selectivity of MLN7243 for ubiquitin activating enzymes was recently 
demonstrated by Misra et al. (Misra et al., 2017). Nonetheless, other ubiquitin-like 
activating enzymes (such as the SUMO activating enzyme SAE, or Nedd8 activating 
enzyme, NAE) share similar structures to UAE and may therefore be inhibited by the 
relatively high dose of MLN7243 used in this study. However, treatment of cells with 
10 µM MLN7243 did not affect the SUMOylation of TOP2-DNA complexes, as 
detailed in Chapter 4 (Figure 4.12). To test whether MLN7243 slows the removal of 
TOP2-DNA complexes through non-specific targeting of NAE, K562 cells were 
treated with 100 µM etoposide alone or in combination with 3 µM MLN4924, a highly 
specific NAE inhibitor (Soucy et al., 2009). After 2 hours continuous exposure to 
etoposide, etoposide was removed from the culture medium and cells were 
incubated for up to 2 hours in the continued presence of 3 µM MLN4924 or DMSO. 
Levels of TOP2-DNA complexes were measured 0, 0.5, 1 and 2 hours after 
etoposide removal using the TARDIS assay.  
Co-incubation of cells with MLN4924 did not significantly affect levels of TOP2A- or 
TOP2B- DNA complexes at any of the time points tested (Figure 3.9). This suggests 
that the accumulation of TOP2-DNA complexes observed with the UAE inhibitor 
MLN7243 is not due to inhibition of the Nedd8 activating enzyme. Neddylation is 
required for the ubiquitination of proteins by cullin-RING E3 ubiquitin ligases (Boh et 
al., 2011). Therefore, this also suggests that ubiquitination by cullin-RING E3 ligases 
is not involved in the ubiquitin-dependent removal of TOP2-DNA complexes.  
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Figure 3.9. Effect of the Nedd8 activating enzyme (NAE) inhibitor MLN4924 on levels 
of TOP2-DNA complexes, measured using the TARDIS assay. K562 cells were treated 
with 100 µM etoposide alone or in combination with 3 µM MLN4924, a highly specific NAE 
inhibitor. After 2 hours etoposide treatment, cells were then incubated in etoposide-free 
media containing 0.1% DMSO or 3 µM MLN4924. Levels of TOP2A- and TOP2B-DNA 
complexes were measured by TARDIS assay up to 2 hours after etoposide removal (n=1).   
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In summary, the removal of TOP2A- and TOP2B- DNA complexes is significantly 
slowed following chemical inhibition of UAE1 and UBA6 in a manner that is epistatic 
with the proteasomal processing pathway. This effect was observed using three 
separate UAE inhibitors, the most potent of which was MLN7243. Furthermore, the 
ubiquitin-dependent removal of TOP2-DNA complexes does not involve a cullin-
RING E3 ligase, as TOP2-DNA complex levels were unaffected by the neddylation 
inhibitor, MLN4924. Levels of etoposide-induced TOP2B-, but not TOP2A-, DNA 
complexes were increased both after single siRNA knockdown of UAE1 and 
combined knockdown of UAE1 and UBA6. Western blot analysis of total 
ubiquitination levels suggests that the normal reversal of TOP2-DNA complexes in 
UAE1/UBA6 knockdown cells after etoposide removal is due to residual UAE activity, 
which was present in siRNA knockdown cells but not in MLN7243-treated cells. 
Together, this indicates that the proteasomal pathway of TOP2-DNA complex 
processing is ubiquitin-dependent. 
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3.5 A study of TOP2 poison-induced proteasomal degradation of TOP2 
isoforms following continuous drug exposure 
The TOP2 poison-induced degradation of TOP2 was first demonstrated by western 
blot of total TOP2 protein, which showed a proteasome-dependent decrease in total 
TOP2 levels with continuous exposure to the TOP2 poison teniposide (Mao et al., 
2001) and was later demonstrated following etoposide treatment (Zhang et al., 2006; 
Azarova et al., 2007; Fan et al., 2008; Ban et al., 2013; Lee et al., 2016). This 
approach was used here with the intention of testing the effect of UAE inhibition on 
the TOP2 poison-induced degradation of TOP2 isoforms. 
3.5.1 Effect of teniposide and etoposide on total TOP2 levels measured by 
western blot 
K562 cells were treated with 100 µM etoposide alone or in combination with 50 µM 
MG132 for up to 8 hours, and TOP2A levels were measured by western blot. Cell 
lysates were prepared with DNase I for the digestion of genomic DNA and extraction 
of TOP2-DNA complexes, which are otherwise unable to enter the gel for 
electrophoresis (leading to a band depletion effect (Mao et al., 2001)). As reported in 
the literature, levels of TOP2A were reduced with time following exposure to 
etoposide compared to DMSO-treated solvent control cells (Figure 3.10A). While 
MG132 alone did not affect levels of TOP2A protein, proteasome inhibition 
prevented the etoposide-induced decrease in TOP2A levels. Therefore, the 
degradation of TOP2A upon continuous etoposide exposure appears to be 
proteasome dependent. However, although this result was observed in many 
technical replicates (western blots) of the biological sample shown in Figure 3.10, 
etoposide-induced degradation of TOP2A was not observed in another biological 
replicate (see Appendix Table 1 for details). Furthermore, levels of TOP2A were 
noticeably increased following exposure to 1% v/v DMSO compared to untreated (0 
hour) control cells which may interfere with the accurate interpretation of data (Figure 
3.10A). Therefore, higher stock concentrations of etoposide and MG132 were used 
in subsequent experiments to minimise the final solvent concentration. In addition to 
high variability, much of the data obtained could not be used due to technical issues 
such as actin failure or lack of antibody signal (see details in Appendix Table 1). In 
particular, little data was obtained regarding the effect of etoposide treatment on 
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TOP2B levels due to lack of signal with the TOP2B antibody, 4555. Because of this, 
only a single blot was acquired showing the levels of TOP2B following exposure to 
100 µM etoposide, and is shown in Figure 3.10B. TOP2B levels were reduced in 
etoposide-treated cells compared to DMSO-treated cells (Figure 3.10B), as 
previously reported. 
 
Figure 3.10. Effect of continuous etoposide exposure on TOP2 levels measured by 
western blot. A) K562 cells were treated for up to 8 hours with 100 µM etoposide (VP-16) 
alone or in combination with 50 µM MG132, and levels of TOP2A protein were measured by 
western blot (n=2). B) K562 cells were treated with 100 µM etoposide or 1% v/v DMSO, and 
TOP2B levels measured by western blot (n=1). During preparation of cell extracts in A and 
B, chromatin-associated proteins were extracted from DNA through the addition of DNase I.  
The blots shown above were developed by standard ECL (enhanced 
chemiluminescence) methods, followed by detection on x-ray film. Detection of 
chemiluminescence is limited by the number of silver grains on the surface of x-ray 
film, which become activated in the presence of photons. Because of this, film has a 
narrow range of detection which can be rapidly saturated. In contrast, digital western 
blot scanners such as the LiCor C-DiGit blot scanner have a wide dynamic range 
which can be used to accurately quantify small changes in protein levels. The LiCor 
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C-DiGit was used in the current study to investigate the teniposide-induced 
degradation of TOP2 isoforms, previously demonstrated by others (Mao et al., 2001; 
Alchanati et al., 2009). Due to variable results obtained with the previously used 
TOP2B antibody (4555), antibody 30400 was used for the detection of TOP2B 
protein. 
K562 cells were treated with 100 µM teniposide (VM-26) for up to 8 hours alone or in 
combination with 10 µM MG132. Whole cell lysates were prepared as above, and 
analysed by western blot. Blots were developed in ECL solution followed by 
detection using the Li-Cor C-DiGit western blot scanner for 12 minutes. A suitable 
‘exposure’ (i.e. one which does not under- or overexpose the protein signal) was 
selected from a range of digital images. Triplicate blots were quantified and 
combined to give a mean band density, normalised to the actin loading control as 
described in Chapter 2, section 2.7.1.  
Levels of TOP2A were not noticeably affected by continuous exposure to teniposide 
(Figure 3.11A), and quantification of triplicate blots did not reveal any significant 
differences between teniposide-treated cells and a 0 hour untreated control at any of 
the time points tested (Figure 3.11B). Neither were there any significant differences 
in TOP2A levels when teniposide-treated cells were co-incubated with MG132. In 
contrast, levels of TOP2B were reduced with time following continuous exposure to 
teniposide, consistent with the notion that TOP2B is degraded faster than TOP2A. 
Specifically, there was a statistically significant decrease in TOP2B levels following 8 
hours teniposide treatment compared to the 0 hour untreated control (Figure 3.11B). 
However, there was no significant difference in levels of TOP2B following 8 hours 
teniposide exposure compared to untreated control when cells were also treated with 
MG132, showing that the teniposide-induced degradation of TOP2B is proteasome-
dependent.  
69 
 
 
Figure 3.11. Proteasomal degradation of TOP2 isoforms following continuous 
teniposide exposure, as measured by western blot.  A) K562 cells were treated for up to 
8 hours with 100 µM teniposide (VM-26) alone or in combination with 10 µM MG132. During 
preparation of cell extracts, chromatin-associated proteins were extracted from DNA through 
the addition of DNase I to the lysate, followed by solubilisation and heating in buffer 
containing 2% SDS. Total TOP2 levels were measured by western blot, probing for TOP2A 
(antibody 3116) and TOP2B (antibody 30400). Blots were developed using the LiCor C-DiGit 
blot scanner. B) TOP2 levels from three separate experiments were quantified and 
normalised to the 0 hour untreated control. Statistical comparisons were made by unpaired t-
test (n=3). Drug treatments and preparation of whole cell lysates were carried out by R. 
Swan. Western blotting and quantification was performed by E. Trofimowicz.  
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Although the blots presented in Figure 3.10 and Figure 3.11 are consistent with 
published literature, results obtained by western blotting were highly variable and 
susceptible to multiple technical issues. Quantitation can be improved by using the 
LiCor C-DiGit western blot detection system, although high variability between 
experiments remains an issue as demonstrated by the large standard error. While 
variability in protein loading can be accounted for through normalisation to the actin 
control, another important source of variation may be the extraction of drug-stabilised 
TOP2 complexes from DNA. Therefore, western blotting was not used to investigate 
the effect of UAE inhibition on the TOP2 poison-induced proteasomal degradation of 
TOP2 isoforms, as initially intended. 
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3.5.2 Effect of teniposide and etoposide on total TOP2 levels measured by 
immunofluorescence 
The TOP2 poison-induced degradation of TOP2 isoforms was also investigated by 
immunofluorescence. Like western blotting, immunofluorescence measures total 
TOP2 levels (i.e. free and DNA-bound in TOP2-DNA covalent complexes). However, 
detection of DNA-bound TOP2 does not require the prior digestion of DNA with 
nucleases, and therefore does not depend on the complete extraction of TOP2 from 
DNA. In addition, immunofluorescence gives a cell-by-cell measure of TOP2 levels 
which can be easily quantified. 
K562 cells were treated with 250 µM etoposide (VP-16) continuously for 0, 2, 4 or 6 
hours alone or in combination with 10 µM MG132, and total TOP2 levels were 
measured by immunofluorescence. Levels of TOP2A and TOP2B were not 
significantly affected by incubation with 0.6% v/v DMSO or 10 µM MG132 alone 
(Figure 3.12A). TOP2A and TOP2B levels were also unaffected by etoposide 
treatment at any time point tested, either alone or in combination with MG132 (Figure 
3.12B). Therefore, etoposide-induced degradation of TOP2 isoforms was not 
observed by immunofluorescence.  
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Figure 3.12. Effect of continuous etoposide exposure on total TOP2 levels measured 
by immunofluorescence. K562 cells were treated for 0, 2, 4 and 6 hours with A) 0.6% 
DMSO or 10 µM MG132, or B) 250 µM etoposide (VP-16) alone or in combination with 10 
µM MG132. TOP2A and TOP2B levels were measured and quantified by standard 
immunofluorescence. Values represent the mean of medians ± SEM from 3 replicate 
experiments, and are normalised to an untreated (0 hour) control. To compare drug 
treatments within the same time point (e.g. VP-16 alone versus VP-16 in combination with 
MG132 at 6 hours drug exposure), statistical significance was tested by two way ANOVA 
followed by Bonferroni post-test. Where comparisons were made between drug treatment 
(i.e. VP-16 alone) and the 0 hour untreated control, statistical significance was determined 
by unpaired t-test (n=3).   
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Immunofluorescence was also used to investigate the effect of teniposide on total 
levels of TOP2A and TOP2B. K562 cells were treated continuously with 100 µM 
teniposide (VM-26) alone or in combination with 10 µM MG132 for 0, 2, 4 and 6 
hours. Incubation with 0.3% v/v DMSO or 10 µM MG132 alone did not affect levels of 
TOP2A or TOP2B at any of the time points tested (Figure 3.13A). Consistent with the 
western blot data shown above (Figure 3.11), levels of TOP2A did not change at any 
of the time points tested following continuous exposure to 100 µM teniposide alone 
compared to the 0 hour untreated control (Figure 3.13B). Despite this, a statistically 
significant increase in TOP2A levels was detected when cells were co-treated with 
MG132 for 6 hours compared to teniposide alone (p<0.01, two way ANOVA). Given 
that MG132 alone does not affect levels of TOP2 (Figure 3.13A), this implicates a 
synergistic interaction between proteasome inhibition and teniposide. 
Unlike TOP2A, TOP2B levels were significantly decreased following 6 hours 
exposure to teniposide alone compared to the 0 hour untreated control (p=0.0268, t-
test). Co-treatment of cells with MG132 prevented the teniposide-induced decrease 
in TOP2B levels after 6 hours drug exposure, as TOP2B levels were significantly 
higher in the presence of MG132 compared to teniposide alone (p<0.01, two way 
ANOVA). Together, this supports the notion that TOP2B is degraded in a 
proteasome-dependent manner following teniposide exposure. 
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Figure 3.13. Effect of continuous teniposide exposure on total TOP2 levels measured 
by immunofluorescence. Total levels of TOP2A and TOP2B were measured by 
immunofluorescence. K562 cells were treated for 0, 2, 4 and 6 hours with A) 0.3% v/v DMSO 
or 10 µM MG132 as a negative control, or B) with 100 µM teniposide (VM-26) alone or in 
combination with 10 µM MG132. TOP2A and TOP2B levels were measured and quantified 
by standard immunofluorescence. Values represent the mean of medians ± SEM from 3 
replicate experiments, and are normalised to an untreated (0 hour) control. To compare drug 
treatments within the same time point (e.g. VM-26 alone versus VM-26 in combination with 
MG132 at 6 hours drug exposure), statistical significance was tested by two way ANOVA 
followed by Bonferroni post-test. Where comparisons were made between drug treatment 
(i.e. VM-26 alone) and the 0 hour untreated control, statistical significance was determined 
by unpaired t-test (n=3).   
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It is presumed that the TOP2 poison-induced degradation of TOP2 isoforms 
represents the proteolysis of TOP2-DNA complexes, which is a key step in TOP2 
complex repair. It is therefore plausible that western blotting or immunofluorescence 
of total TOP2 levels is not sensitive enough to detect changes in the proportion of 
DNA-bound TOP2 amidst a pool of non-covalently bound TOP2. Indeed, TOP2 is a 
highly abundant enzyme, with approximately 5.7 x 105 monomers of TOP2A, and 4.4 
x 105 monomers of TOP2B in K562 cells (Padget et al., 2000). Therefore, a more 
informative approach may be the direct measurement of TOP2-DNA complexes 
following prolonged exposure to TOP2 poisons. Studies using the TARDIS assay 
(Sunter et al., 2010; Lee et al., 2016) and ICE assay (Fan et al., 2008; Alchanati et 
al., 2009) have shown that DNA-bound TOP2 is degraded in a proteasome-
dependent manner following treatment with TOP2 poisons. Specifically, proteasome 
inhibition slows the removal of etoposide-induced TOP2A- and TOP2B- complexes 
from DNA as shown in Figure 3.4. Here, the TARDIS assay was used to investigate 
the effect of continuous etoposide exposure on the degradation of TOP2-DNA 
complexes. 
K562 cells were treated with 10 µM, 100 µM or 250 µM etoposide for 0, 1, 2, 4 or 6 
hours, and levels of TOP2-DNA complexes were measured by TARDIS assay. 
Etoposide was dissolved in DMSO, and in each condition the final concentration of 
DMSO was 0.5% v/v. As shown previously in Figure 3.1 and Figure 3.2, TOP2A- and 
TOP2B- DNA complexes were detectable upon the exposure of cells to 10 µM 
etoposide, and became saturated at doses above 100 µM (Figure 3.14A). However, 
both TOP2A- and TOP2B- DNA complex levels remained elevated with continuous 
exposure to etoposide at all doses and all time points tested. Therefore, the 
proteasomal degradation of TOP2-DNA complexes is not detectable upon 
continuous etoposide exposure. This could be due to the steady turnover of 
complexes, whereby the rate of TOP2 complex formation is the same as the rate of 
complex processing. This is in contrast to the proteolytic removal of TOP2-DNA 
complexes which is observed following etoposide washout (Figure 3.4). Upon 
etoposide removal, the equilibrium between the formation of new complexes and 
TOP2-DNA complex repair exists in favour of increased complex removal, due to 
both reduced trapping of complexes and increased complex reversal upon etoposide 
withdrawal. 
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Figure 3.14. Effect of continuous etoposide exposure on levels of TOP2-DNA 
complexes measured using the TARDIS assay. A) K562 cells were treated with 10 µM, 
100 µM or 250 µM etoposide (VP-16) (each containing 0.5% v/v DMSO) and levels of 
TOP2A- and TOP2B- DNA complexes were measured at 0, 1, 2, 4 and 6 hours of etoposide 
exposure. B) Effect of 0.5% v/v DMSO on levels of TOP2-DNA complexes. Scatter diagrams 
show raw integrated fluorescence values of TOP2 levels in individual nuclei, and histograms 
show the corresponding median values normalised to a 100 µM etoposide control (n=1).  
Notably, levels of TOP2A- and TOP2B- DNA complexes increased with time 
following incubation in 0.5% v/v DMSO (Figure 3.14B, with individual values from a 
single experiment presented as a scatter diagram, and the corresponding medians 
as a histogram). While TOP2A-DNA complexes were increased to approximately 3% 
of the 100 µM etoposide signal after 4 hours, the induction of TOP2B-DNA 
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complexes was increased to approximately 15% of the 100 µM etoposide control 
after 6 hours. Therefore, DMSO concentration and duration of treatment were 
minimised in all subsequent TARDIS experiments. 
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3.6 Role of the ubiquitin-proteasome system in the processing of etoposide-
induced TOP2-DNA complexes to protein-free DSBs 
The repair of DSBs is orchestrated by multiple post-translational modifications which 
facilitate the recruitment of essential repair factors such as BRCA1 and 53BP1 to 
broken DNA (Bekker-Jensen and Mailand, 2010; Zhao et al., 2014). The so-called 
DNA damage response (DDR) is initiated by kinases ATM and DNA-PK which are 
activated by DSBs, and phosphorylate histones surrounding the DNA break (Paull et 
al., 2000; Burma et al., 2001). Specifically, histone H2AX is phosphorylated at serine 
139 (ɣH2AX) (Rogakou et al., 1998). The phosphorylation of histone H2AX can be 
detected by immunofluorescence using an antibody specific to phospho-histone 
H2AX (Ser139), and this is termed the ɣH2AX assay. While not a direct measure of 
DSBs, the phosphorylation of histone H2AX is a surrogate marker which reflects one 
of the foremost steps in the recognition and repair of DSBs. However, TOP2 poison-
induced DSBs are not recognised by DDR proteins until TOP2 has been removed 
from the TOP2-DNA complex (Martensson et al., 2003; Zhang et al., 2006; Fan et 
al., 2008; Tammaro et al., 2013). Therefore, the processing of TOP2-DNA 
complexes can also be studied through the appearance of protein-free DSBs. Here, 
the ɣH2AX assay was used to investigate the role of the ubiquitin-proteasome 
system in the appearance of etoposide-induced DSBs. 
K562 cells were treated continuously with 10 µM etoposide alone or in combination 
with 10 µM MG132 for up to 4 hours, and levels of protein-free DSBs were measured 
by ɣH2AX assay. Phosphorylation of histone H2AX was detectable within 1 hour of 
etoposide treatment, and remained elevated for the duration of etoposide exposure 
(Figure 3.15A). Proteasomal inhibition significantly reduced etoposide-induced 
ɣH2AX levels following 2 and 4 hours drug exposure (p<0.0001), consistent with a 
role for the proteasome in the appearance of etoposide-induced DSBs (Zhang et al., 
2006; Fan et al., 2008; Sunter, 2008; Tammaro et al., 2013). Co-treatment with 
MG132 also significantly reduced the appearance of etoposide- and mitoxantrone- 
induced DSBs in Nalm-6 cells (see Appendix Figure 2 and 3). 
To determine whether the appearance of etoposide-induced DSBs is ubiquitin-
dependent, the ɣH2AX assay was also performed in K562 cells treated with 10 µM 
etoposide alone or in combination with 10 µM MLN7243 (UAE inhibitor) for up to 4 
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hours. Cells were also treated for 2 hours, followed by removal of etoposide from the 
cell culture medium and incubation in the continued presence of MLN7243 or 0.1% 
v/v DMSO for 2 hours (2+2hr washout, WO), as per the TARDIS assay. Similarly to 
proteasome inhibition, co-treatment of cells with MLN7243 significantly reduced the 
etoposide-induced phosphorylation of histone H2AX following 1, 2 and 4 hours drug 
exposure (Figure 3.15B & C, p<0.05), and after etoposide washout (Figure 3.15B, 
p<0.05). UAE inhibition also significantly reduced the appearance of etoposide- and 
mitoxantrone-induced DSBs in Nalm-6 cell lines (see Appendix Figure 4 and 5). 
Therefore, the processing of drug-stabilised TOP2-DNA complexes to protein-free 
DSBs is ubiquitin-dependent. 
 
Figure 3.15. Inhibition of the ubiquitin-proteasome system and the effect on 
etoposide-induced histone H2AX phosphorylation. K562 cells were treated with 10 µM 
etoposide (VP-16) alone or in combination with A) 10 µM MG132 or B) 10 µM MLN7243 for 
up to 4 hours, and levels of protein-free DSBs were measured by ɣH2AX assay. B) Cells 
were also treated for 2 hours with 10 µM etoposide alone or in combination with 10 µM 
MLN7243, followed by etoposide washout and a further 2 hour incubation in medium 
containing 10 µM MLN7243 or 0.1% v/v DMSO (2+2hr washout, WO). All values represent 
the mean of triplicate experiments ± SEM, normalised to a 1 hour 10 µM etoposide control. 
Statistical comparisons were made by two-way ANOVA followed by Bonferroni post-test 
(n=3). C) Representative images of data shown in B.  
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To further investigate the role of UAE enzymes in the generation of etoposide-
induced DSBs, the ɣH2AX assay was performed in double UAE1/UBA6 siRNA 
knockdown cells and control (CON) siRNA cells treated with 10 µM etoposide for up 
to 4 hours. Consistently, etoposide-induced phosphorylation of histone H2AX was 
significantly reduced in UAE1/UBA6 knockdown cells compared to control cells 
following 1 and 4 hours etoposide treatment (Figure 3.16, p<0.05 and p<0.01, 
respectively), although no significant difference was detected after 2 hours. This is in 
contrast to the TARDIS data shown in Figure 3.8, where siRNA knockdown of UAE1 
and UBA6 did not affect the rate of TOP2-DNA complex removal following etoposide 
washout. While the reason for this is unclear, this could be explained by differences 
between the TARDIS assay and ɣH2AX assay. Firstly, detection of TOP2-DNA 
complexes in the TARDIS assay is isoform-specific, whereas DSBs detected using 
the ɣH2AX assay represent the processing of both TOP2A- and TOP2B- DNA 
complexes. This combined effect may enable the detection of smaller changes in 
levels of TOP2A- and TOP2B- induced DSBs, which are not significantly detected 
when measuring levels of TOP2A- and TOP2B- DNA complexes separately. 
Secondly, the TARDIS assay involves the measurement of TOP2-DNA complexes 
following etoposide removal, and therefore the removal of TOP2-DNA complexes 
upon etoposide washout is due to both active processing by the proteasome and 
spontaneous complex reversal upon completion of the TOP2 reaction cycle. In 
contrast, the ɣH2AX assay was performed following continuous etoposide exposure, 
where the etoposide-induced ɣH2AX signal is produced only upon active processing 
of TOP2-DNA complexes. Hence, the effect of UAE knockdown may be less 
detectable in the TARDIS assay where TOP2 removal occurs in parallel to TOP2 
complex reversal. Nonetheless, this further supports a role for ubiquitination in the 
processing of etoposide-induced DNA damage. 
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Figure 3.16. siRNA knockdown of ubiquitin activating enzymes and the effect on 
etoposide-induced phosphorylation of histone H2AX. CON siRNA or double 
UAE1/UBA6 siRNA knockdown cells were treated with 10 µM etoposide (VP-16) for up to 4 
hours, and levels of protein-free DSBs were measured by ɣH2AX assay. Values represent 
the mean of triplicate experiments ± SEM, normalised to a 1 hour 10 µM etoposide control. 
Statistical comparisons were made by two-way ANOVA followed by Bonferroni post-test 
(n=3).   
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Histone phosphorylation is one of the earliest events in the DDR, occurring before 
the wave of ubiquitination which contributes to DNA repair (Bekker-Jensen and 
Mailand, 2010). To test whether ubiquitination is required for the DNA damage-
induced phosphorylation of histone H2AX, the ɣH2AX assay was repeated in K562 
cells following exposure to 2 Gy ionising irradiation in the presence and absence of 
MLN7243.  
Levels of IR-induced DSBs were measured following 0.5, 1, 2 and 4 hours incubation 
in cell culture medium containing 0.1% v/v DMSO or 10 µM MLN7243. IR-induced 
histone H2AX phosphorylation increased up to 1 hours after irradiation, but began to 
decrease in DMSO-treated cells after 4 hours incubation in drug-free medium 
reflecting effective DNA repair and resolution of DSBs. ɣH2AX levels were not 
significantly affected by UAE inhibition within 2 hours after irradiation, but remained 
significantly higher in MLN7243-treated cells 4 hours post-irradiation (p<0.01, Figure 
3.17). This shows that inhibition of ubiquitination prevents the repair of DSBs, 
consistent with published data (Moudry et al., 2012). Furthermore, ubiquitination is 
not required for the phosphorylation of histone H2AX, supporting the conclusion from 
Figure 1.16 that the role of ubiquitin in the appearance of etoposide-induced DSBs is 
specific to TOP2-mediated damage. 
 
Figure 3.17. Effect of UAE1 inhibition on irradiation-induced ɣH2AX levels. K562 cells 
were treated with 10 µM MLN7243 (or 0.1% v/v DMSO) and exposed to 2Gy X-ray 
irradiation. The ɣH2AX assay was used to measure levels of DSBs at 0.5, 1, 2 and 4 hours 
after irradiation. Values represent the mean of triplicate experiments ±SEM, normalised to a 
1 hour irradiation control. Statistical significance was determined by two-way ANOVA with 
Bonferroni post-test (n=3).   
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3.7 Investigating the role of the BMI1/RING1A E3 ubiquitin ligase in the 
processing of TOP2-DNA complexes 
The BMI1/RING1A E3 ubiquitin ligase has been implicated in the proteasomal 
degradation of TOP2A-DNA complexes (Alchanati et al., 2009). There are over 600 
E3 ubiquitin ligases encoded in the human genome which interact directly with target 
proteins and therefore largely determine substrate specificity. Consequently, 
targeting of E3 ubiquitin ligases with small molecule inhibitors would offer more 
selectivity than upstream targeting of UAE in potential clinical applications. PRT4165 
is a small molecule inhibitor shown to inhibit the self-ubiquitination of BMI1/RING1A 
and the proteasome-dependent degradation of TOP2A-DNA complexes (Alchanati et 
al., 2009). Hence, the role of the BMI1/RING1A ubiquitin ligase in the removal of 
etoposide-induced TOP2 complexes from DNA was investigated using the TARDIS 
assay following treatment of cells with PRT4165. K562 cells were treated with 100 
µM etoposide alone or in combination with 90 µM PRT4165 for 2 hours, followed by 
etoposide washout and incubation in etoposide-free medium containing DMSO or 
PRT4165. Levels of TOP2A- and TOP2B- DNA complexes were measured following 
0, 0.5, 1 and 2 hours incubation in etoposide-free medium.  
Levels of TOP2A-DNA complexes were not affected by co-incubation with PRT4165 
immediately after 2 hours continuous exposure to etoposide (0 hours after VP-16 
removal) (Figure 3.18). However, TOP2A-DNA complexes were significantly higher 
in the presence of PRT4165 1 hour after etoposide removal (p<0.05), in support of a 
role for BMI1/RING1A in the processing of TOP2A-DNA complexes. Levels of 
TOP2B-DNA complexes were also unaffected immediately following 2 hours 
continuous exposure to etoposide (0 hours after VP-16 removal), but were 
significantly increased in the presence of PRT4165 0.5 hours after etoposide 
removal (p<0.05). This indicates a role for BMI1/RING1A in the removal of TOP2B 
complexes from DNA, which was not previously reported by Alchanati et al. 
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Figure 3.18. Effect of the BMI1/RING1A inhibitor PRT4165 on levels of etoposide-
induced TOP2-DNA complexes. K562 cells were treated with 100 µM etoposide (VP-16) 
alone or in combination with 90 µM PRT4165 for 2 hours. Etoposide was removed from the 
culture medium and cells were incubated for a further 2 hours in medium containing 90 µM 
PRT4165 or 0.09% v/v DMSO. Levels of TOP2A- and TOP2B- DNA complexes were 
measured at 0, 0.5, 1 and 2 hours after etoposide removal using the TARDIS assay. Values 
represent the mean of medians ± SEM from triplicate experiments, normalised to a 100 µM 
etoposide control. Statistical comparisons were made by two-way ANOVA followed by 
Bonferroni post-test (n=3).  
To further investigate the role of BMI1/RING1A in the processing of etoposide-
induced TOP2-DNA complexes, the ɣH2AX assay was used to test the effect of 
PRT4165 on the appearance of etoposide-induced DSBs. K562 cells were treated 
with 10 µM etoposide alone or in combination with 90 µM PRT4165 for up to 4 hours. 
Notably, 4 hours incubation with PRT4165 alone induced a small but significant 
increase in histone H2AX phosphorylation (p<0.01). However, inhibition of 
BMI1/RING1A significantly reduced the appearance of etoposide-induced DSBs after 
1, 2 and 4 hours drug exposure (Figure 3.19, p<0.001). Strikingly, histone H2AX 
phosphorylation was completely reduced to background levels after 1 and 2 hours of 
drug treatment. While this could suggest that the induction of etoposide-induced 
DSBs is largely BMI1/RING1A-dependent, it is important to note that PRT4165 has 
also been shown to inhibit the RING1A paralog, RING1B (Ismail et al., 2013), and 
concerns exist regarding its lack of specificity. Nonetheless, PRT4165 does not 
affect the IR-induced phosphorylation of histone H2AX (Ismail et al., 2013), 
suggesting that inhibition of the etoposide-induced ɣH2AX signal by PRT4165 is 
specific to TOP2-mediated damage. 
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Together, the effect of MLN7243 and PRT4165 ubiquitination inhibitors on the 
appearance of etoposide-induced DSBs demonstrates an important role for the 
ubiquitin system in the processing of TOP2 poison-induced DNA damage. While the 
role of the proteasome has already been shown by others, the role of ubiquitinating 
enzymes in the appearance of etoposide-induced DSBs has not yet been reported. 
Therefore, the role of ubiquitin is an important but currently underappreciated aspect 
of TOP2-DNA complex repair.  
 
Figure 3.19. Effect of the BMI1/RING1A inhibitor PRT4165 on etoposide-induced 
histone H2AX phosphorylation. K562 cells were incubated with 10 µM etoposide (VP-16) 
alone or in combination with 90 µM PRT4165 for up to 4 hours, and protein-free DSBs were 
measured by ɣH2AX assay. Values are normalised to a 1 hour 10 µM etoposide control and 
represent the mean integrated fluorescence from triplicate experiments. Statistical 
significance was determined by two-way ANOVA with Bonferroni post-test (n=3).  
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3.8 Investigating the role of transcription in the processing of TOP2-DNA 
complexes 
The proteasomal processing of TOP2-DNA complexes (or a component of it) may be 
transcription dependent, as inhibition of transcription has been reported to prevent 
proteasome-dependent degradation of TOP2-DNA complexes and the appearance 
of etoposide-induced DSBs (Mao et al., 2001; Zhang et al., 2006; Fan et al., 2008; 
Ban et al., 2013; Tammaro et al., 2013). In the current study, the role of transcription 
in the processing of TOP2-DNA complexes was investigated following chemical 
inhibition of transcription. α-Amanitin inhibits transcription by binding to RNA 
polymerase II (RNAPII), and to a lesser extent RNAPIII, thereby preventing the 
incorporation of nucleotides into nascent RNA (Bensaude, 2011). In contrast, the 
major target of DRB (5,6-Dichloro-1-β-Ribo-furanosyl Benzimidazole) is the cyclin-
dependent kinase CDK9, which is responsible for the hyper-phosphorylation of the 
RNAPII C terminal domain during transcription elongation. While α-Amanitin is a 
slow-acting, irreversible inhibitor at relatively low concentrations, DRB reversibly 
inhibits transcription within minutes of addition to cell culture medium but only at high 
working concentrations (Bensaude, 2011).  
The effects of α-Amanitin and DRB on levels of transcription in K562 cells were 
measured by incorporation of 5-ethynyl uridine (EU) into newly synthesised RNA 
transcripts. K562 cells were treated with 10 µg/mL α-Amanitin for 2 or 4 hours, or 
150 µM DRB for 30 minutes or 2 hours, then incubated for 1 hour in the presence of 
1 mM EU. Unexpectedly, α-Amanitin (10 µg/mL) did not affect the production of 
nascent RNA transcripts after 2 or 4 hours incubation (Figure 3.20). This is surprising 
as 10 µg/mL α-Amanitin efficiently inhibits transcription according to previously 
published studies (Anindya et al., 2007; Bensaude, 2011). In contrast, transcription 
was inhibited by approximately 50% following 30 minutes exposure to DRB. 
Inhibition was not further increased by 2 hours exposure to DRB, suggesting that 30 
minutes is sufficient for maximum inhibition with 150 µM DRB. 
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Figure 3.20. Transcription inhibition by α-Amanitin and DRB in K562 cells. K562 cells 
were incubated with 10 µg/mL α-Amanitin or 150 µM DRB for the time indicated. Cells were 
then incubated with 1 mM 5-ethynyl uridine (EU) for 1 hour in the continued presence of 
drug, and transcription inhibition was measured by incorporation of EU into nascent RNA. 
EU levels were quantified by integrated fluorescence per nucleus, and are represented as 
median values normalised to an untreated (0 hour) control (n=1).  
The EU assay was also used to determine the effect of α-Amanitin and DRB on 
transcription in Nalm-6 cells. Nalm-6 cells were treated with 10 µg/mL α-Amanitin for 
4 hours or the indicated concentration of DRB (100, 150 or 300 µM) for 30 minutes. 
As in K562 cells, α-Amanitin did not affect levels of transcription in Nalm-6 cells 
compared to an untreated (H2O) control (Figure 3.21). However, transcription levels 
were reduced by at least 50% in cells treated with DRB at all concentrations tested. 
Therefore, DRB was used for the inhibition of transcription in all subsequent 
experiments. 
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Figure 3.21. Transcription inhibition by α-Amanitin and DRB in Nalm-6 cells. Nalm-6 
cells were treated with 10 µg/mL α-Amanitin for 4 hours, or increasing concentrations of 
DRB for 30 minutes. Cells were then incubated with 1 mM 5-ethynyl uridine (EU) for 1 hour 
in the continued presence of drug, and transcription inhibition was measured by 
incorporation of EU into nascent RNA. EU levels were quantified by integrated fluorescence 
per nucleus, and are represented as median values normalised to an untreated (0 hour) 
control (n=1).  
The role of transcription in the removal of TOP2-DNA complexes was investigated 
using the TARDIS assay. As only 50% transcription inhibition was achieved with 150 
µM DRB, K562 cells were treated with or without 300 µM DRB as used in other 
studies (Tammaro et al., 2013) with the aim of increasing transcription inhibition. 
Cells from each replicate TARDIS experiment were collected for processing via the 
EU assay, which showed on average 75% inhibition of transcription in cells treated 
with 300 µM DRB (Figure 3.22). 
K562 cells were treated with 100 µM etoposide (VP-16) alone or in combination with 
300 µM DRB for 2 hours. Etoposide was then removed from the culture medium and 
cells were incubated for up to 2 hours in the continued presence of 300 µM DRB or 
DMSO. Levels of TOP2A-DNA complexes were not affected by transcription 
inhibition following 2 hours continuous exposure to etoposide (0 hours after VP-16 
removal) (Figure 3.23A). However, levels of remaining TOP2A-DNA complex levels 
were significantly higher 0.5 and 1 hours after etoposide removal (p<0.01), 
suggesting that the removal of TOP2A complexes from DNA is partly transcription-
dependent. Levels of etoposide-induced TOP2B-DNA complexes were not 
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significantly affected by transcription inhibition at any time point tested. This is in 
contrast to previous studies which have demonstrated a transcription-dependent 
mechanism of TOP2B complex processing (Mao et al., 2001; Zhang et al., 2006; Fan 
et al., 2008; Ban et al., 2013; Tammaro et al., 2013). Together, this suggests that 
transcription is involved in the processing of TOP2A-DNA complexes under these 
conditions (where transcription is inhibited by 75%). 
To test for cell-specific effects, the role of transcription was also investigated in the 
Nalm-6 cell line. Nalm-6 cells were treated with 100 µM etoposide alone or in 
combination with 150 µM DRB for 2 hours, followed by 2 hours incubation in medium 
containing DRB or DMSO. Levels of TOP2A- and TOP2B- DNA complexes were 
measured using the TARDIS assay. As shown in K562 cells, the level of etoposide-
induced TOP2A-DNA complexes remaining 0.5 and 1 hours after etoposide removal 
were higher in the presence of DRB compared to DMSO-treated cells, while levels of 
TOP2B-DNA complexes were unaffected by transcription inhibition at all time points 
(Figure 3.23B). Therefore, transcription is involved in the processing of TOP2A-DNA 
complexes in myeloid and lymphoblastic cell lines. 
 
Figure 3.22. Transcription inhibition by DRB in K562 cells. K562 cells from each 
TARDIS experiment were collected following 2 hours exposure to 100 µM etoposide (VP-16) 
with or without 300 µM DRB, and inhibition of transcription was measured using the EU 
assay. Median integrated fluorescence (representing average EU levels per nucleus) were 
normalised to the DMSO negative control. Averages represent the mean of medians ± SEM 
from triplicate experiments (n=3) 
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Figure 3.23. Effect of transcription inhibition on levels of etoposide-induced TOP2-
DNA complexes, measured using the TARDIS assay. A) K562 cells were treated with 100 
µM etoposide (VP-16) alone or in combination with 300 µM DRB for 2 hours. Etoposide was 
removed from the culture medium and cells were collected (0 hours after VP-16 removal) or 
incubated for a further 2 hours in etoposide-free medium containing 300 µM DRB or 0.4% 
v/v DMSO. TOP2A- and TOP2B- DNA complexes were measured at 0, 0.5, 1 and 2 hours 
after etoposide removal using the TARDIS assay. Median integrated fluorescence was 
normalised to a 100 µM etoposide control, and statistical comparisons were made by two-
way ANOVA followed by Bonferroni post-test (n=3). B) Nalm-6 cells were treated with 100 
µM etoposide alone or in combination with 150 µM DRB for 2 hours, followed by a further 2 
hour incubation in etoposide-free medium containing 150 µM DRB or 0.2% DMSO. TOP2A- 
and TOP2B- DNA complexes were measured at 0, 0.5, 1 and 2 hours after etoposide 
removal using the TARDIS assay (n=1).   
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To further investigate the role of transcription in the processing of TOP2-DNA 
complexes, the ɣH2AX assay was used to test the effect of transcription inhibition on 
the appearance of etoposide-induced DSBs. K562 cells were treated with 10 µM 
etoposide (VP-16) alone or in combination with 300 µM DRB continuously for up to 4 
hours, and DSBs were measured following 0, 1, 2 and 4 hours of drug treatment. 
Alternatively, cells were treated for 2 hours with etoposide alone or in combination 
with DRB for 2 hours, followed by etoposide removal and 2 hours incubation in the 
continued presence of DMSO or DRB, respectively. Exposure of cells to DRB alone 
did not affect levels of phosphorylated histone H2AX. Furthermore, co-incubation of 
cells with DRB and etoposide did not significantly affect levels of etoposide-induced 
DSBs following 1 or 2 hours drug exposure, nor after etoposide washout (Figure 
3.24). However, after 4 hours continuous drug exposure there was a statistically 
significant decrease in levels of etoposide-induced DSBs in the presence of DRB 
compared to etoposide alone (p<0.001). Therefore, the appearance of DSBs is partly 
transcription-dependent following 4 hours continuous exposure to etoposide, 
consistent with a role for transcription in the processing of TOP2-DNA complexes to 
DSBs. 
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Figure 3.24. Effect of transcription inhibition on the etoposide-induced 
phosphorylation of histone H2AX. K562 cells were treated with 10 µM etoposide (VP-16) 
alone or in combination with 300 µM DRB for up to 4 hours. Alternatively, cells were treated 
with etoposide for 2 hours followed by a further 2 hour incubation in etoposide-free medium 
containing DRB or 0.4% v/v DMSO (2+2). Protein-free DSBs were measured by ɣH2AX 
assay, and all data normalised to a 1 hour 10 µM etoposide control. Values represent the 
mean of median integrated fluorescence from at least 3 replicate experiments. Statistical 
comparisons were made by two-way ANOVA with Bonferroni post-test (n<8).   
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3.9 Investigating other mechanisms of TOP2-DNA complex processing 
Studies using the TARDIS assay have shown that inhibition of the proteasome does 
not completely prevent the removal of TOP2-DNA complexes (Lee et al., 2016) (also 
see Figure 3.4). In this assay, the ongoing removal of TOP2 from DNA under 
conditions of proteasome inhibition could be attributed to the reversible nature of 
TOP2-DNA complexes (upon the removal of etoposide) or the active removal of 
TOP2 by alternative mechanisms. Besides the proteasomal pathway, other 
mechanisms have been described which can remove covalently bound TOP2 from 
DNA, and these are outlined in Chapter 1. In this section, the contribution of these 
pathways to the processing of TOP2-DNA complexes is investigated using TARDIS 
and the ɣH2AX assay.  
3.9.1 The nucleolytic processing pathway 
TOP2-DNA complexes can be removed via a nuclease-dependent pathway involving 
Mre11 of the MRN complex or CtIP, which cleaves the DNA (Hartsuiker et al., 2009; 
Lee et al., 2012; Aparicio et al., 2016). To better understand the contribution of the 
nucleolytic pathway to the removal of TOP2-DNA complexes, the TARDIS assay 
was performed in etoposide-treated cells in the presence and absence of mirin, an 
inhibitor of the Mre11 nuclease. 
K562 cells were treated with 100 µM etoposide (VP-16) alone or in combination with 
100 µM mirin and/or 10 µM MG132 for 2 hours. Etoposide was removed from the 
culture medium and cells were incubated for up to 2 hours in the continued presence 
of mirin, MG132, mirin and MG132, or DMSO as indicated. Levels of TOP2A- and 
TOP2B- DNA complexes were measured at 0, 0.5, 1 and 2 hours after etoposide 
removal. As previously demonstrated, levels of remaining TOP2A-DNA complexes 
were increased in the presence of MG132 at 0.5, 1 and 2 hours after etoposide 
removal (Figure 3.25). In addition, levels of TOP2B-DNA complexes were increased 
0.5 hours after etoposide removal when the proteasome was inhibited. However, 
levels of etoposide-induced TOP2A- and TOP2B- DNA complexes were unaffected 
by the treatment of cells with mirin, and this was true at all time points tested. 
Furthermore, no additive effect was observed when etoposide-treated cells were 
incubated with both mirin and MG132, suggesting that Mre11 does not significantly 
contribute to the removal of TOP2-DNA complexes as measured by the TARDIS 
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assay. This is in contrast to previously published data, whereby incubation of 
TARDIS slides with recombinant Mre11 significantly reduced levels of etoposide-
induced TOP2-DNA complexes, indicating Mre11-dependent removal of drug-
induced TOP2 complexes in vitro (Lee et al., 2012). Lee et al. also demonstrated an 
increase in basal levels of TOP2-DNA complexes in the absence of TOP2 poison 
following treatment of K562 cells with 100 µM mirin, which was not observed in the 
current study. An important difference between these studies is the duration of mirin 
incubation, which was a maximum of 4 hours in the present study and 24 hours in 
the aforementioned study (Lee et al., 2012). Therefore, prolonged exposure of cells 
with mirin may be required to inhibit Mre11 nuclease activity. 
 
Figure 3.25. Effect of Mre11 inhibition on levels of etoposide-induced TOP2-DNA 
complexes. K562 cells were treated with 100 µM etoposide (VP-16) alone or in combination 
with 10 µM MG132 and/or 100 µM mirin for 2 hours. Etoposide was removed from the 
culture medium and cells were collected (0 hours after VP-16 removal) or incubated for up to 
2 hours in the continued presence of 10 µM MG132 and/or 100 µM mirin. Levels of TOP2-
DNA complexes were determined using the TARDIS assay. Values represent the median 
integrated fluorescence from a single experiment, and are normalised to a 100 µM etoposide 
control (n=1).  
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The role of Mre11 in the processing of TOP2-DNA complexes to protein-free DSBs 
was also investigated using the ɣH2AX assay. K562 cells were treated with 10 µM 
etoposide (VP-16) alone or in combination with 100 µM mirin for up to 4 hours. 
Alternatively, cells were treated with etoposide alone or in combination with mirin for 
2 hours, followed by incubation in etoposide-free medium containing DMSO or mirin, 
respectively. Co-incubation of cells with mirin did not affect the appearance of 
etoposide-induced ɣH2AX signal with continuous drug exposure, suggesting that 
Mre11 does not contribute significantly to the processing of TOP2-DNA complexes to 
DSBs. In contrast, levels of etoposide-induced DSBs were significantly increased in 
the presence of mirin following 2 hours incubation in etoposide-free medium (2+2hr 
washout, p>0.01), indicating inhibition of DSB repair. This is consistent with the role 
of Mre11 in homologous recombination, which is partly involved in the repair 
etoposide-induced DNA damage (de Campos-Nebel et al., 2010; Liu and Huang, 
2016). Furthermore, this suggests that exposure of cells to mirin for 4 hours is 
sufficient to inhibit Mre11, although this should be confirmed in future studies. 
 
 
Figure 3.26. Effect of Mre11 inhibition on etoposide-induced ɣH2AX levels. K562 cells 
were treated with 10 µM etoposide (VP-16) alone or in combination with 100 µM mirin for up 
to 4 hours. Alternatively, cells were treated with 10 µM etoposide alone or in combination 
with 100 µM mirin for 2 hours, followed by 2 hours incubation in etoposide-free medium 
containing DMSO or mirin, respectively (2+2hr washout, WO). Cells were collected following 
0, 1, 2 and 4 hours of drug treatment, and levels of histone H2AX phosphorylation were 
measured by ɣH2AX assay. Values represent the mean of triplicate experiments ± SEM, 
normalised to a 1 hour 10 µM etoposide control. Statistical comparisons were made by two-
way ANOVA followed by Bonferroni post-test (n=3).  
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3.9.2 Proteasome-independent processing by TDP2 
TDP2 is a 5’-phosphodiesterase which directly cleaves the 5’-phosphotyrosyl bond 
between DNA and the TOP2 active site tyrosine (Cortes Ledesma et al., 2009; Zeng 
et al., 2011; Schellenberg et al., 2012; Gao et al., 2014). This bond becomes 
accessible once the bulk of the TOP2 protein has been degraded by the 
proteasome, and is subsequently cleaved by TDP2 to produce ligatable ends for 
NHEJ (Gómez-Herreros et al., 2013; Gao et al., 2014). However, a proteasome-
independent mechanism of removal was also recently described whereby TDP2 
removes TOP2-DNA complexes in cooperation with the ZATT SUMO ligase 
(formerly known as ZNF451) (Schellenberg et al., 2017), which is expressed in K562 
cells (see Appendix Figure 6). To determine the relative contribution of TDP2-
mediated TOP2 removal from DNA, the TARDIS assay was performed in TDP2 
siRNA knockdown cells in the presence and absence of the proteasome inhibitor 
MG132. 
K562 cells were electroporated in the presence of 500 nM non-coding (CON siRNA) 
or 500 nM TDP2 siRNA, and levels of TDP2 protein were measured by western blot 
after 24, 48 and 72 hours (Figure 3.27). TDP2 protein was reduced at all time points 
tested, but most notably after 48 hours after electroporation where only 2% TDP2 
protein remained compared to control siRNA-treated cells. TDP2 levels began to 
recover after 72 hours, and therefore all experiments with TDP2 knockdown cells 
were performed 48 hours after electroporation. 
 
Figure 3.27. siRNA knockdown of TDP2 in K562 cells. K562 cells were transfected with 
500 nM non-coding siRNA (CON siRNA) or 500 nM TDP2 siRNA by electroporation. 
Western blotting was used to measure levels of TDP2 protein at 24, 48 and 72 hours after 
electroporation. TDP2 levels were quantified and expressed as the percentage remaining 
compared to the corresponding CON siRNA control.  
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CON siRNA or TDP2 siRNA knockdown cells were treated with 100 µM etoposide 
(VP-16) alone or in combination with 10 µM MG132 for 2 hours. Etoposide was 
removed from the culture medium, and levels of TOP2A- and TOP2B- DNA 
complexes were measured following 0, 0.5, 1 and 2 hours incubation in etoposide-
free medium containing MG132 or DMSO. Figure 3.28A shows the siRNA-mediated 
knockdown of TDP2 in cells from each replicate experiment. The efficiency of siRNA 
knockdown was variable between experiments, with levels of detectable TDP2 
protein ranging from 0% to 27% (compared to control siRNA-treated cells).  
 
Figure 3.28. siRNA knockdown of TDP2 in cells from replicate TARDIS experiments. 
CON siRNA and TDP2 siRNA knockdown cells were collected from 4 replicate TARDIS 
experiments, and TDP2 levels were tested by western blot. TDP2 levels were quantified and 
expressed as the percentage remaining compared to the corresponding CON siRNA control, 
as described in Chapter 2, section 2.7.1.  
As previously shown, inhibition of the proteasome did not significantly affect levels of 
TOP2A- or TOP2B- DNA complexes following 2 hours continuous exposure to 
etoposide (0 hours after VP-16 removal, Figure 3.29), but did increase remaining 
TOP2 complex levels after etoposide removal. This was true in cells treated with 
both control siRNA and TDP2 siRNA. Importantly, TDP2 knockdown did not 
significantly affect levels of etoposide-induced TOP2A- or TOP2B-DNA complexes at 
any of the time points tested, suggesting that TDP2 alone does not contribute 
significantly to the removal of TOP2-DNA complexes in K562 cells. Furthermore, 
TDP2 knockdown did not affect levels of etoposide-induced TOP2A- or TOP2B- DNA 
complexes when the proteasome was inhibited. Therefore, proteasome-independent 
removal of TOP2-DNA complexes by TDP2 was not detected in K562 cells using the 
TARDIS assay. 
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Figure 3.29. Effect of TDP2 knockdown on the proteasome-independent removal of 
TOP2-DNA complexes measured using the TARDIS assay. CON siRNA or TDP2 siRNA 
knockdown cells were treated with 100 µM etoposide (VP-16) alone or in combination with 
10 µM MG132 for 2 hours. Following etoposide washout, cells were collected or incubated 
for a further 2 hours in etoposide-free medium containing 10 µM MG132 or 0.1% v/v DMSO. 
TOP2-DNA complex levels were measured at 0, 0.5, 1 and 2 hours after etoposide removal. 
Replicate experiments were normalised to a 2 hour 100 µM etoposide control, and 
compared by two-way ANOVA with Bonferroni post-test (n=3 for TOP2A, and n=4 for 
TOP2B).   
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Schellenberg et al. report that TDP2 specifically targets SUMOylated TOP2-DNA 
complexes, which accumulate in TDP2 knockout cells when the proteasome is 
inhibited (Schellenberg et al., 2017). It is therefore possible that changes in levels of 
SUMO-modified TOP2-DNA complexes could be detected by measuring only TOP2 
complexes that are SUMOylated. To test this, TARDIS slides were also probed for 
SUMO-2/3 conjugates. The stringent conditions utilised during the TARDIS lysis 
procedure effectively remove all non-covalently bound proteins from DNA whilst 
TOP2 complexes remain covalently attached in the presence of etoposide (see 
Figure 3.3). Therefore, it is anticipated that the only SUMO conjugates present on 
TARDIS slides are SUMOylated TOP2-DNA complexes. Consistent with this, 
SUMO-2/3 conjugates were not detectable on TARDIS slides in the absence of 
etoposide, but were readily detectable in control siRNA and TDP2 siRNA knockdown 
cells following 2 hours incubation in 100 µM etoposide (0 hours after VP-16 removal, 
Figure 3.30).  
While probing of TARDIS slides for TOP2A or TOP2B reveals a proteasome-
dependent increase in remaining TOP2-DNA complex levels after etoposide removal 
(Figure 3.4), levels of SUMOylated TOP2-DNA complexes were not significantly 
affected by co-incubation of control cells with MG132 when TARDIS slides were 
probed for SUMO-2/3 conjugates. This was true both after continuous etoposide 
exposure (0 hours after VP-16 removal) and at all time points after etoposide 
removal. This suggests that the proteasome is not involved in the regulation of 
SUMOylated TOP2-DNA complexes. Furthermore, levels of SUMOylated TOP2 
were not affected by TDP2 knockdown compared to control cells, suggesting that 
TDP2 alone does not remove SUMO-2/3-TOP2 from DNA. TDP2 knockdown did not 
affect levels of SUMOylated TOP2-DNA complexes even when the proteasome was 
inhibited. Therefore, the proteasome-independent removal of SUMOylated TOP2-
DNA complexes was not observed in K562 cells following TDP2 knockdown. This is 
in contrast to what has been previously reported in TDP2 knockout MEFs using the 
ICE assay, whereby TDP2 knockout led to the accumulation of SUMO-2/3-TOP2 
complexes within 30 minutes of etoposide washout (Schellenberg et al., 2017).  
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Figure 3.30. Effect of TDP2 knockdown on the proteasome-independent removal of 
SUMOylated TOP2-DNA complexes measured using the TARDIS assay. CON siRNA or 
TDP2 siRNA knockdown cells were treated with 100 µM etoposide (VP-16) alone or in 
combination with 10 µM MG132 for 2 hours. Following etoposide washout, cells were 
collected or incubated for a further 2 hours in etoposide-free medium containing 10 µM 
MG132 or 0.1% v/v DMSO. Levels of SUMO conjugates were measured at 0, 0.5, 1 and 2 
hours after etoposide removal. The TARDIS assay was performed as previously described, 
except for the inclusion of 10 mM NEM in lysis buffers to inhibit DUB enzymes, and probing 
of slides with anti-SUMO-2/3 antibody. Replicate experiments were normalised to a 2 hour 
100 µM etoposide control, and compared by two-way ANOVA with Bonferroni post-test 
(n=3).   
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The role of TDP2 in the proteasome-independent removal of TOP2-DNA complexes 
was also investigated using the ɣH2AX assay. Previous publications have shown 
that TDP2 knockout does not affect the appearance of etoposide-induced DSBs but 
significantly slows DSB repair (Gómez-Herreros et al., 2013). However, in the 
presence of MG132, the number of etoposide-induced ɣH2AX foci were reported to 
be significantly reduced by TDP2 knockout, suggesting that TDP2 removes TOP2-
DNA complexes in the absence of proteasomal activity (Schellenberg et al., 2017).  
To investigate this, CON siRNA or TDP2 siRNA cells (shown in Figure 3.29A) were 
treated with 100 µM etoposide alone or in combination with 10 µM MG132 for 2 
hours. Etoposide was removed from the culture medium and cells were incubated in 
the continued presence of MG132 or DMSO. ɣH2AX levels were measured at 0, 0.5, 
1, 2 and 3 hours after etoposide removal. In control cells, the level of etoposide-
induced DSBs (as measured by ɣH2AX fluorescence) are gradually decreased with 
time following incubation in etoposide-free medium, reflecting DNA repair (Figure 
3.31). siRNA knockdown of TDP2 did not significantly affect the appearance of 
etoposide-induced DSBs, further supporting the notion that TDP2 alone does not 
remove TOP2 complexes from DNA. Surprisingly, the rate of DSB repair (as 
measured by the disappearance of ɣH2AX signal) was also unaffected in TDP2 
knockdown cells, in contrast to published data in TDP2 knockout cells (Gómez-
Herreros et al., 2013). 
In the presence of MG132, the appearance of etoposide-induced DSBs were greatly 
reduced in both CON siRNA and TDP2 siRNA knockdown cells (Figure 3.31), as 
previously shown. However, TDP2 knockdown did not affect levels of etoposide-
induced histone H2AX phosphorylation in the presence of MG132. Therefore, the 
proteasome-independent removal of TOP2-DNA complexes by TDP2 was not 
detected in TDP2 knockdown cells using the γH2AX assay. An important difference 
between this study and others (Gómez-Herreros et al., 2013; Schellenberg et al., 
2017) is the use of TDP2 knockdown and TDP2 knockout cells, respectively. Indeed, 
low levels of TDP2 protein may still be present in knockdown cells, which may be 
sufficient for TOP2 complex removal. Furthermore, histone H2AX phosphorylation is 
quantified here by integrated fluorescence per nucleus, whereas quantification of 
γH2AX by Schellenberg et al. is achieved by counting foci numbers. Unlike IR-
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induced ɣH2AX foci which are relatively uniform and easy to count in an automated 
manner, etoposide-induced ɣH2AX foci vary in size and fluorescence intensity. 
Therefore, it is plausible that the numbers of foci are affected without affecting the 
overall fluorescence of the nucleus. This would suggest that small changes in levels 
of ɣH2AX foci are not detected by integrated fluorescence. Nonetheless, 
measurement of integrated fluorescence is an automated process and therefore less 
susceptible to human error or investigator bias. 
 
Figure 3.31. Effect of TDP2 siRNA knockdown on etoposide-induced ɣH2AX levels. 
CON siRNA and TDP2 siRNA knockdown cells were treated with 100 µM etoposide (VP-16) 
alone or in combination with 10 µM MG132. Cells were collected after 2 hours continuous 
drug exposure (0 hours after VP-16 removal) or incubated for up to 3 hours in etoposide-free 
medium containing 10 µM MG132 or 0.1% v/v DMSO. Levels of protein-free DSBs were 
measured using the ɣH2AX assay. Values represent mean of medians ± SEM, normalised to 
a 1 hour 100 µM etoposide control and compared by two-way ANOVA with Bonferroni post-
test (n=3).   
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3.10 Discussion 
In this chapter, the role of the ubiquitin-proteasome system in the processing of 
etoposide-induced TOP2-DNA complexes was investigated by small molecule 
inhibition and siRNA knockdown of ubiquitin activating enzymes. While current 
evidence suggests that TOP2A-DNA complexes are degraded in a ubiquitin-
dependent manner (Alchanati et al., 2009), conflicting reports exist regarding the role 
of ubiquitin in the processing of TOP2B-DNA complexes (Mao et al., 2001; Ban et 
al., 2013). Here, the removal of both TOP2A- and TOP2B- DNA complexes was 
slowed in the presence of UAE inhibitor MLN7243, suggesting that the processing of 
both TOP2A- and TOP2B- DNA complexes is partly ubiquitin-dependent. 
Furthermore, chemical inhibition or siRNA knockdown of UAE1 and UBA6 
significantly reduced the appearance of etoposide-induced DSBs in a manner 
specific to topoisomerase-mediated damage. 
Although western blotting and immunofluorescence could be used to examine the 
proteasomal degradation of TOP2B, the processing of TOP2-DNA complexes was 
further investigated using the TARDIS assay. This approach is more informative as it 
enables the direct measurement of TOP2-DNA complexes in an easily quantifiable 
manner. Moreover, the proteasomal degradation of TOP2A-DNA complexes was 
observed using the TARDIS assay but not by western blot or immunofluorescence, 
suggesting changes in levels of TOP2-DNA complexes are difficult to detect in a pool 
of total TOP2 protein. TOP2A is removed at a slower rate than TOP2B, which is also 
indicated by the longer half-life of TOP2A complexes in the TARDIS assay.  
Combination studies with MLN7243 and MG132 show that UAE and the proteasome 
operate via the same pathway in the removal of TOP2-DNA complexes, thereby 
supporting the role of ubiquitin-dependent proteolysis. However, these data do not 
exclude the possibility that UAE activity is required for the ubiquitination of another 
protein involved in TOP2-DNA complex repair rather than TOP2 itself. Indeed, it is 
important to note that inhibition of UAE will induce widespread disruption of the 
ubiquitin-proteasome system, and will affect the ubiquitination of many proteins. 
Because of this, a more favourable approach is the inhibition of specific E3 ubiquitin 
ligases, which restricts inhibition to a more defined group of substrates. Strikingly, 
inhibition of the BMI1/RING1A ubiquitin ligase greatly reduced the appearance of 
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etoposide-induced DSBs and slowed the removal of both TOP2A- and TOP2B- 
complexes from DNA, suggesting that TOP2-DNA complex processing can be 
targeted downstream of UAE enzymes. 
The TARDIS assay was also used to investigate other pathways contributing to 
TOP2-DNA complex removal. For example, the role of transcription was addressed 
by the co-treatment of cells with DRB. Surprisingly, inhibition of transcription slowed 
the removal of TOP2A- but not TOP2B- DNA complexes. This is in contrast to 
published data which has shown a transcription-dependent mechanism for the 
removal of both TOP2A- and TOP2B- DNA complexes (Mao et al., 2001; Fan et al., 
2008; Ban et al., 2013; Tammaro et al., 2013). Numerous studies have shown that 
like proteasome inhibition, treatment of cells with DRB prevents the etoposide- or 
teniposide- induced degradation of TOP2A and TOP2B as measured by western 
blotting (Mao et al., 2001; Zhang et al., 2006; Fan et al., 2008; Ban et al., 2013). 
Transcription inhibition, but not replication inhibition, also prevents the 
phosphorylation of DNA damage-dependent proteins such as histone H2AX, RPA, 
Chk1 and Chk2 following etoposide treatment (Fan et al., 2008; Tammaro et al., 
2013). Ban et al. propose that the collision of TOP2B complexes with RNA 
polymerase II leads to the proteasomal degradation of TOP2 via RNA polymerase II-
associated AAA ATPases (Ban et al., 2013). However, the data presented in Figure 
3.23 and Figure 3.24 suggest that TOP2B complexes can be removed by the 
proteasome even in the absence of ongoing transcription. However, it cannot be fully 
excluded that the transcription-dependent removal of TOP2B complexes may still 
have occurred in DRB-treated cells due to incomplete inhibition of transcriptional 
activity. 
Importantly, inhibition of the proteasome, UAE or transcription did not completely 
prevent the removal of TOP2 complexes from DNA. The TARDIS assay was used to 
examine the role of other processing pathways including the nuclease-dependent 
removal of TOP2 by Mre11 and proteasome-independent removal by TDP2. 
However, disruption of these alternative pathways did not significantly affect TOP2-
DNA complex processing as measured by TARDIS or ɣH2AX assay. While this may 
be due to incomplete inhibition of these pathways (for example by mirin or TDP2 
knockdown), this suggests that the proteasome- and ubiquitin- independent removal 
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of TOP2 complexes observed using the TARDIS assay is largely due to the 
spontaneous reversal of complexes and completion of the TOP2 reaction 
mechanism upon etoposide removal. This further indicates that the ubiquitin- and 
proteasome- dependent processing of TOP2-DNA complexes is a major repair 
pathway. 
In summary, this study shows that ubiquitination is partly required for the processing 
of both TOP2A- and TOP2B- DNA complexes, and is therefore an important layer of 
regulation in the repair of etoposide-induced DNA damage. Inhibition of the ubiquitin-
proteasome system with proteasome inhibitors or UAE inhibitors significantly 
increases the half-life of TOP2-DNA complexes, which may increase drug 
cytotoxicity (see Chapter 6). In addition, the appearance of protein-free DSBs is 
significantly reduced. While protein-free DSBs can lead to cell death, aberrant NHEJ 
repair of these breaks are associated with leukaemogenic chromosome 
translocations. Therefore, combination therapies of ubiquitin-proteasome inhibitors 
with TOP2 poisons could prove beneficial in a clinical setting by maintaining drug 
efficacy whilst also reducing genotoxicity. 
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Chapter 4 Studying the post-translational modifications of TOP2-
DNA complexes 
4.1 Introduction 
Ubiquitination involves the conjugation of ubiquitin to the lysine residues of target 
proteins. Whilst most typically associated with proteasomal degradation, there are 
many consequences of ubiquitination including changes in enzymatic activity, protein 
localisation and protein-protein interactions. As described in Chapter 1, ubiquitin is 
involved in the regulation of multiple cellular pathways. In the previous chapter, it 
was shown that ubiquitination is required for the efficient removal of TOP2-DNA 
complexes and the subsequent appearance of etoposide-induced DSBs. This effect 
was epistatic with the role of the proteasome, suggesting that the proteasomal 
degradation of TOP2-DNA complexes is ubiquitin dependent. It was hypothesised 
that UAE activity facilitates the processing of TOP2-DNA complexes through the 
ubiquitination of TOP2. However, these data do not eliminate the possibility that UAE 
activity could be required for the ubiquitination of another protein involved in removal 
or repair. Therefore, the principle aim of the current chapter was to investigate the 
ubiquitination of TOP2 following etoposide treatment. 
The ubiquitin-dependent degradation of TOP2A has been shown in response to 
various stresses, including glucose starvation (Yun et al., 2004), HDAC inhibition 
(Chen et al., 2011) and treatment with teniposide (Alchanati et al., 2009). In the latter 
study, an increase in TOP2A molecular weight (presumed to be TOP2A 
ubiquitination) was observed in HeLa cells following teniposide treatment. This was 
further increased in cells overexpressing the E3 ubiquitin ligase BMI1/RING1A, 
which was thereby identified as the E3 ubiquitin ligase required for the proteasomal 
degradation of TOP2A-, but not TOP2B-, DNA complexes. Consistently, TOP2A 
ubiquitination was also observed in vitro when Flag-TOP2A immunoprecipitates were 
incubated with recombinant BMI1/RING1A (Alchanati et al., 2009). Chen et al. also 
show a decrease in TOP2A electrophoretic mobility when cells are treated with 
HDAC inhibitors (Chen et al., 2011). However, TOP2 poison-induced ubiquitination 
of TOP2 has not been adequately demonstrated using more recently developed 
methods which are now available for the study of protein ubiquitination. In particular, 
overexpression of tagged ubiquitin or ubiquitinating enzymes may lead to the 
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artificial ubiquitination of proteins which would not otherwise be ubiquitinated, or may 
disrupt normal ubiquitin physiology (Emmerich and Cohen, 2015). Indeed, Ban et al. 
were not able to detect ubiquitinated TOP2B in cells expressing HA-tagged ubiquitin 
either in the presence and absence of etoposide, while TOP2A ubiquitination was 
not investigated in this study (Ban et al., 2013). However, at least 32 TOP2B 
ubiquitination sites have been detected by mass spectrometry in the absence of 
TOP2 poison (Kim et al., 2011). Known ubiquitination sites in TOP2A and TOP2B 
are displayed in Chapter 1, Figure 1.7. 
The study of protein ubiquitination is particularly challenging due to rapid reversal by 
deubiquitinase enzymes (DUBs) and the potential degradation of ubiquitinated 
proteins by the proteasome. Furthermore, ubiquitination of small subpopulations of 
protein can be difficult to detect due to low stoichiometry. Consequently, changes in 
levels of ubiquitinated protein may escape detection by measuring total protein 
levels, for example by western blot (Kim et al., 2011). Nonetheless, western blotting 
can be used to specifically study ubiquitinated proteins by first isolating and enriching 
ubiquitinated proteins using antibodies or Tandem Ubiquitin Binding Entities 
(TUBEs). TUBEs contain multiple ubiquitin binding domains which bind ubiquitinated 
proteins with high affinity (Hjerpe et al., 2009; Wilson et al., 2012). This is preferable 
to immunoprecipitation, as binding of TUBEs to ubiquitinated proteins has also been 
shown to protect proteins from deubiquitination and proteasomal degradation (Hjerpe 
et al., 2009; Wilson et al., 2012; Emmerich and Cohen, 2015). This approach was 
used here to investigate the conjugation of TOP2 with endogenous ubiquitin before 
and after exposure of cells to etoposide. 
Closely related to ubiquitin is the ubiquitin-like (UBL) protein known as SUMO (small 
ubiquitin-like modifier). There are four SUMO isoforms in human cells (SUMO-1, 
SUMO-2/3 and SUMO-4) which are also conjugated to target lysines in a 3-step 
enzymatic cascade (Geiss-Friedlander and Melchior, 2007). While not initially 
associated with proteasomal degradation, SUMOylation can lead to protein 
degradation through the regulation of protein ubiquitination. For example, SUMO-
targeted ubiquitin ligases (STUbLs) are E3 ubiquitin ligases containing a SUMO-
interacting motif which binds non-covalently to SUMOylated proteins, leading to their 
ubiquitination (Geoffroy and Hay, 2009).  
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SUMOylation of TOP2A is essential for proper chromosome segregation (Bachant et 
al., 2002; Azuma et al., 2003; Takahashi et al., 2006; Higgins, 2012). Specifically, 
SUMOylation of the TOP2A C terminal domain leads to the recruitment of Claspin 
and Haspin to mitotic centromeres, which are involved in the activation and 
localisation of Aurora B, respectively (Ryu et al., 2015; Clarke and Azuma, 2017). 
However, studies have also shown that TOP2A and TOP2B are SUMOylated 
following treatment with etoposide or teniposide (Mao et al., 2000; Agostinho et al., 
2008; Schellenberg et al., 2017). Importantly, TOP2 poison-induced SUMOylation of 
TOP2 may not be related to the formation of TOP2-mediated DNA damage but due 
to changes in protein confirmation, as TOP2 SUMOylation is also observed following 
exposure to the catalytic inhibitors, ICRF-193 and ICRF-187 which trap TOP2 on 
DNA without stabilising TOP2-DNA covalent complexes (Mao et al., 2000; Isik et al., 
2003; Agostinho et al., 2008; Schellenberg et al., 2017). Consistent with this, the 
accessibility of a known SUMOylation site in TOP2A (Lys662) is increased upon 
DNA binding, leading to more efficient SUMOylation by the E3 SUMO ligase, PIASɣ 
(Ryu et al., 2010; Wendorff et al., 2012). TOP2 SUMOylation has been implicated in 
the proteasome-independent removal and repair of TOP2-DNA complexes through 
direct removal by TDP2 (Schellenberg et al., 2017). In the current study, the 
ubiquitination and SUMOylation of TOP2-DNA complexes was investigated using the 
TARDIS assay. Given the highly quantifiable nature of TARDIS, this provided a 
useful platform to test the effects of various ubiquitin-proteasome system inhibitors 
on levels of ubiquitinated and SUMOylated TOP2-DNA complexes. 
4.2 Aims 
Multiple ubiquitination sites have been identified on both TOP2A and TOP2B (Kim et 
al., 2011) (Figure 1.7, Chapter 1), but little is known about their function. In particular, 
evidence is lacking regarding the ubiquitination of TOP2 in response to TOP2 
poisons like etoposide. Therefore, TOP2 ubiquitination was investigated here using 
TUBEs and by immunoprecipitation of endogenous ubiquitin. Furthermore, the 
ubiquitination and SUMOylation of TOP2-DNA complexes was investigated using the 
TARDIS assay. 
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4.3 TOP2-DNA complexes are ubiquitinated 
In this study, the TARDIS assay was adapted to investigate the post-translational 
modifications of TOP2-DNA complexes including ubiquitination and SUMOylation. As 
shown in Chapter 3, the stringent lysis conditions used during the TARDIS assay 
effectively remove non-covalently bound proteins from DNA, including RNA 
polymerase II and Ku70/80. Therefore only covalently-bound TOP2 is present on 
TARDIS slides in the presence of etoposide, which can be probed using anti-
ubiquitin and anti-SUMO antibodies. 
To investigate whether etoposide-induced TOP2-DNA complexes are conjugated to 
ubiquitin, K562 cells were treated with 100 µM etoposide (or 0.2% v/v DMSO) for 2 
hours, and ubiquitinated TOP2-DNA complexes were visualised using the TARDIS 
assay. Slides were probed using linkage-specific anti-ubiquitin antibodies which 
detect K48-linked ubiquitin or K63-linked ubiquitin chains. Alternatively, all 
conjugated ubiquitin (mono- and poly- ubiquitin) was detected using anti-ubiquitin 
monoclonal antibody (clone FK2). No ubiquitin conjugates were detected in DMSO-
treated cells, further corroborating that all ubiquitinated proteins (such as histones) 
are effectively removed from TARDIS slides (Figure 4.1). However, ubiquitin 
conjugates were easily detected on TARDIS slides following etoposide exposure, 
indicating the presence of ubiquitinated TOP2-DNA complexes. Specifically, K48-
linked and K63-linked ubiquitin chains were detected, which are typically associated 
with proteasomal degradation and signalling pathways, respectively. 
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Figure 4.1. Detection of ubiquitin conjugates on TARDIS slides following etoposide 
treatment. K562 cells were treated with 100 µM etoposide (VP-16) or 0.2% v/v DMSO for 2 
hours. TOP2-DNA complexes were isolated as per the TARDIS assay and probed for K48-
linked ubiquitin (APU2), K63-linked ubiquitin (APU3) and all conjugated ubiquitin (FK2). IF 
indicates where specific proteins were detected by immunofluorescence.  
Like TOP2A and TOP2B, levels of ubiquitinated TOP2-DNA complexes can be 
quantified by integrated fluorescence. This was used to examine the effect of the 
UAE inhibitor MLN7243 on the ubiquitination of TOP2-DNA complexes. K562 cells 
were treated with 100 µM etoposide alone or in combination with 10 µM MLN7243 
for 2 hours, and ubiquitinated TOP2-DNA complexes were quantified using the 
TARDIS assay. As shown above, levels of ubiquitinated TOP2-DNA complexes were 
significantly increased when cells were treated with etoposide compared to untreated 
DMSO control. However, in the presence of MLN7243 the etoposide-induced 
ubiquitin signal was significantly reduced (p=0.0003) and no longer significantly 
different from background levels. This suggests that UAE activity is completely 
abolished in cells treated with MLN7243, consistent with western blot data shown in 
Chapter 3 (Figure 3.4B and Figure 3.5D). Therefore, MLN7243 is a highly effective 
UAE inhibitor which completely inhibits TOP2 ubiquitination. 
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Figure 4.2. Effect of UAE inhibitor MLN7243 on levels of ubiquitinated TOP2-DNA 
complexes. K562 cells were treated with 100 µM etoposide (VP-16) alone or in combination 
with 10 µM MLN7243 for 2 hours, and levels of ubiquitinated TOP2-DNA complexes were 
measured using the TARDIS assay. A) Representative images of TARDIS slides probed for 
all conjugated ubiquitin (anti-ubiquitin antibody clone FK2). B) Quantification of ubiquitinated 
TOP2-DNA complexes. Values represent mean of medians ± SEM from triplicate 
experiments and are normalised to a 2 hour 100 µM etoposide control. Statistical 
comparisons were made by unpaired t-test (n=3).  
In the previous chapter, it was also shown that residual levels of ubiquitination 
remain in UAE1/UBA6 siRNA knockdown cells which are not present in cells treated 
with MLN7243. To further investigate this, CON siRNA or double UAE1/UBA6 siRNA 
knockdown cells were treated with 100 µM etoposide or 0.2% v/v DMSO for 2 hours, 
and the TARDIS assay was used to measure levels of ubiquitinated TOP2-DNA 
complexes. Ubiquitinated TOP2-DNA complexes were significantly induced in CON 
siRNA cells treated with etoposide (p=0.0007, Figure 4.3), as expected. Moreover, 
levels of ubiquitin conjugates were significantly reduced in UAE1/UBA6 siRNA 
knockdown cells (p=0.0041), indicating inhibition of UAE activity. Although reduced, 
etoposide still induced ubiquitinated TOP2-DNA complexes in knockdown cells, 
which remained significantly above background levels (p=0.0005) indicating 
incomplete knockdown of UAE activity. This supports the notion that chemical 
inhibition of UAE by MLN7243 is more effective than siRNA knockdown. 
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Figure 4.3. Effect of double UAE1 and UBA6 siRNA knockdown on levels of 
ubiquitinated TOP2-DNA complexes. CON siRNA or double UAE1/UBA6 siRNA 
knockdown cells were treated with 100 µM etoposide (VP-16) or 0.2% DMSO for 2 hours, 
and levels of ubiquitinated TOP2-DNA complexes were measured by TARDIS assay. A) 
Representative images of TARDIS slides probed for TOP2A or conjugated ubiquitin (anti-
ubiquitin antibody clone FK2). B) Quantification of ubiquitinated TOP2-DNA complexes. 
Values represent mean of medians ± SEM from triplicate experiments and are normalised to 
a 2 hour 100 µM etoposide control. Statistical comparisons were made by unpaired t-test 
(n=3).  
Finally, the TARDIS assay was used to test the effect of the BMI1/RING1A inhibitor 
PRT4165 on the ubiquitination of TOP2-DNA complexes. BMI1/RING1A is an E3 
ubiquitin ligase shown to ubiquitinate TOP2A in vitro, and in response to teniposide 
treatment in cells overexpressing BMI1/RING1A (Alchanati et al., 2009). K562 cells 
were treated with 100 µM etoposide alone or in combination with 90 µM PRT4165 for 
2 hours. As shown above, levels of ubiquitinated TOP2-DNA complexes on TARDIS 
slides were significantly increased in the presence of etoposide (Figure 4.4A). In the 
presence of PRT4165, levels of ubiquitinated TOP2-DNA complexes were 
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significantly reduced compared to etoposide alone (p=0.0026, Figure 4.4B), though 
remained significantly higher than background levels (p=0.0257). This suggests that 
other E3 ubiquitin ligases are also involved in the ubiquitination of TOP2-DNA 
complexes. Notably, the ubiquitin TARDIS assay does not distinguish between 
ubiquitinated TOP2A- and ubiquitinated TOP2B- DNA complexes. It is reported by 
Alchanati et al. that BMI1 is not required for the proteasomal degradation of TOP2B 
after teniposide treatment (Alchanati et al., 2009). Therefore, residual levels of 
ubiquitinated TOP2 complexes could be due to the ubiquitination of TOP2B-DNA 
complexes. Nonetheless, this shows that PRT4165 inhibits the ubiquitination of 
TOP2, whether TOP2A, TOP2B or both. Thus, ubiquitination is partly BMI1/RING1A-
dependent. 
 
Figure 4.4. Effect of the BMI1/RING1A inhibitor PRT4165 on levels of ubiquitinated 
TOP2-DNA complexes. K562 cells were treated with 100 µM etoposide (VP-16) alone or in 
combination with 90 µM PRT4165 for 2 hours, and levels of ubiquitinated TOP2-DNA 
complexes were measured using the TARDIS assay. A) Representative images of TARDIS 
slides probed for all conjugated ubiquitin (anti-ubiquitin antibody clone FK2). B) 
Quantification of ubiquitinated TOP2-DNA complexes. Values represent mean of medians ± 
SEM from triplicate experiments and are normalised to a 2 hour 100 µM etoposide control. 
Statistical comparisons were made by unpaired t-test (n=3).   
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4.4 Effect of proteasome inhibition on levels of ubiquitinated TOP2-DNA 
complexes 
Proteasome inhibition leads to the accumulation of ubiquitinated proteins which are 
otherwise degraded. To investigate whether ubiquitinated TOP2-DNA complexes are 
degraded by the proteasome, K562 cells were treated with 100 µM etoposide alone 
or in combination with 10 µM MG132 for 2 hours, and levels of ubiquitinated TOP2-
DNA complexes were measured by TARDIS assay. 
Paradoxically, there was a significant decrease in levels of ubiquitinated TOP2-DNA 
complexes when cells were co-treated with MG132 compared to etoposide alone (p= 
0.0352, Figure 4.5A). This is contrary to the proteasome inhibitor-induced 
accumulation of ubiquitin conjugates which is anticipated when ubiquitinated proteins 
are normally degraded by the proteasome. However, proteasome inhibition can also 
lead to inhibition of ubiquitination due to depletion of the free ubiquitin pool, which is 
no longer recycled from degraded ubiquitin conjugates (Xu et al., 2004). 
Furthermore, proteasome inhibition leads to the redistribution of ubiquitin from the 
nucleus to the cytoplasm, which is largely attributed to the deubiquitination of highly 
abundant monoubiquitinated proteins such as histone H2A (Dantuma et al., 2006). 
Interestingly, mass spectrometry analysis of the ubiquitin-modified proteome has 
shown that many proteins are deubiquitinated in response to proteotoxic stress (Kim 
et al., 2011; Udeshi et al., 2012). It is therefore plausible that TOP2 is 
deubiquitinated in response to proteasome inhibition. 
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Figure 4.5. Effect of proteasome inhibition on levels of ubiquitinated TOP2-DNA 
complexes, investigated using the TARDIS assay. K562 cells were treated with 100 µM 
etoposide (VP-16) alone or in combination with 10 µM MG132 for 2 hours, and levels of 
ubiquitinated TOP2-DNA complexes measured using the TARDIS assay. A) Quantification of 
ubiquitinated TOP2-DNA complexes. Values represent mean of medians ± SEM from 
triplicate experiments and are normalised to a 2 hour 100 µM etoposide control. Statistical 
comparisons were made by unpaired t-test (n=3). B) Representative images of TARDIS 
slides probed for all conjugated ubiquitin (anti-ubiquitin antibody clone FK2).  
To investigate the potential role of deubiquitinase enzymes (DUBs) in the MG132-
induced decrease in ubiquitinated TOP2-DNA complexes, cells were treated with 
PR-619, a broad-spectrum DUB inhibitor (Tian et al., 2011; Seiberlich et al., 2012). 
Firstly, a PR-619 dose-response experiment was conducted to determine the 
concentration of PR-619 required to efficiently inhibit DUB enzymes, indicated by the 
accumulation of ubiquitin conjugates on a western blot. While levels of ubiquitin 
conjugates were not significantly affected in the presence of 2 µM PR-619, there was 
a 141% increase in levels of ubiquitinated proteins when K562 cells were treated for 
2 hours with 5 µM PR-619 compared to untreated control (Figure 4.6), and therefore 
5 µM PR-619 was used to inhibit DUBs in subsequent experiments.  
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Figure 4.6. Inhibition of deubiquitinases (DUBs) by PR-619 shown by western blot. 
K562 cells were treated with 0, 2, 5, 10 or 20 µM PR-619 (each containing equivalent 
volumes of DMSO), and levels of ubiquitinated proteins were determined by western blot. 
Blots were probed for all conjugated ubiquitin using the anti-ubiquitin antibody clone FK2, 
and developed using the LiCor C-DiGit western blot scanner. Levels of ubiquitin conjugates 
were quantified and expressed as a percentage increase compared to untreated control.  
To investigate the effect of DUB inhibition on levels of ubiquitinated TOP2-DNA 
complexes, K562 cells were treated with 100 µM etoposide alone or in combination 
with 10 µM MG132 and 5 µM PR-619 for 2 hours. Intriguingly, treatment of cells with 
5 µM PR-619 alone induced a small but significant increase in TOP2A-DNA 
complexes (p=0.0108), suggesting PR-619 itself can poison TOP2 (Figure 4.7A). 
Consistently, there was also a small but significant increase in ubiquitin signal 
following PR-619 treatment (p=0.0059) (Figure 4.7B). However, PR-619 did not 
affect levels of etoposide-induced ubiquitinated TOP2-DNA complexes, suggesting 
that etoposide-induced TOP2-DNA complexes are not deubiquitinated in the 
absence of MG132.  
As previously shown, co-treatment of cells with MG132 reduced the levels of 
etoposide-induced ubiquitinated TOP2-DNA complexes (Figure 4.7B). However, 
when etoposide-treated cells were incubated with both PR-619 and MG132, PR-619 
prevented the MG132-induced decrease in ubiquitinated TOP2-DNA complexes. In 
fact, levels of ubiquitinated TOP2-DNA complexes were significantly increased 
compared to etoposide alone, suggesting that DUB inhibition not only prevents the 
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MG132-induced deubiquitination of TOP2-DNA complexes, but also reveals the 
MG132-dependent accumulation of ubiquitinated TOP2-DNA complexes. Therefore, 
ubiquitinated TOP2-DNA complexes are deubiquitinated upon proteasome inhibition, 
but are also degraded by the proteasome. Notably, the MG132-induced 
accumulation of TOP2-DNA complexes was not observed when TARDIS slides were 
probed for total TOP2A-DNA complex levels (Figure 4.7A), suggesting that only a 
small proportion of TOP2-DNA complexes are ubiquitinated and degraded by the 
proteasome.   
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Figure 4.7. Effect of proteasome inhibition and DUB inhibition on levels of 
ubiquitinated TOP2-DNA complexes. K562 cells were treated with 100 µM etoposide (VP-
16) alone or in combination with 10 µM MG132 and/or 5 µM PR-619. TARDIS slides were 
probed for A) TOP2A and B) all conjugated ubiquitin (anti-ubiquitin antibody clone FK2). 
Values represent the mean of medians ± SEM of triplicate experiments, normalised to a 2 
hour 100 µM etoposide control. Statistical comparisons were made by unpaired t-test (n=3).   
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Studies have shown that the deubiquitination of histone H2A occurs within 5 minutes 
of MG132 addition, with approximately half of the monoubiquitinated histone H2A 
pool remaining after 30 minutes (Dantuma et al., 2006). Therefore, MG132-induced 
deubiquitination is time-dependent, suggesting that shorter incubations with MG132 
could be used to inhibit the proteasome without inducing the deubiquitination of 
TOP2-DNA complexes. To investigate this, K562 cells were treated with 10 µM 
MG132 for 30, 60 or 120 minutes, and proteasome inhibition was assessed by the 
accumulation of ubiquitinated proteins, detected by western blot. Probing of blots 
with the anti-ubiquitin antibody clone FK2 also reveals a 23 kDa band corresponding 
to a highly abundant monoubiquitinated protein, likely to be histone H2A (Mimnaugh 
et al., 1997). Although not a direct measure of monoubiquitinated histone H2A, this 
was used as an indication of MG132-induced deubiquitination.  
Figure 4.8A shows the accumulation of ubiquitin conjugates within 30 minutes of 
MG132 exposure, demonstrating proteasomal inhibition. Levels of the 23kDa 
monoubiquitinated protein were gradually decreased with time of MG132 treatment, 
reflecting MG132-induced deubiquitination. Consistent with Dantuma et al., levels of 
this protein were reduced but still present following 30 minutes MG132 treatment 
(18% remaining compared to untreated control), and further reduced to 9% and 3% 
following 1 and 2 hours of proteasome inhibition, respectively (Figure 4.8A). 
Therefore, the MG132-induced deubiquitination of histone H2A is time-dependent.  
To investigate the potential time-dependent effect of MG132 on levels of etoposide-
induced ubiquitinated TOP2-DNA complexes, the ubiquitin TARDIS assay was 
performed where 10 µM MG132 was added at various time points during a 2 hour 
incubation of cells with 100 µM etoposide. Specifically, MG132 was added 
simultaneously with etoposide as previously in Figure 4.5 (i.e. MG132 was present 
for the full 2 hour incubation with etoposide), or MG132 was added in the final hour 
or final 30 minutes of incubation with etoposide.  
Levels of etoposide-induced ubiquitinated TOP2-DNA complexes were significantly 
reduced following 2 hours co-incubation with MG132, as previously shown 
(p=0.0444) (Figure 4.8B). This was also true when MG132 was added in the final 
hour of etoposide treatment (p=0.0007), indicating that the deubiquitination of TOP2-
DNA complexes occurs within 1 hour of incubation with MG132. In contrast, levels of 
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etoposide-induced ubiquitinated TOP2-DNA complexes were not affected when 
MG132 was added in the final 30 minutes of drug incubation. Therefore, the 
deubiquitination of TOP2-DNA complexes is not detectable within 30 minutes of 
proteasome inhibition. This delay is likely due to the time-dependent depletion of free 
ubiquitin following proteasome inhibition, and the subsequent redistribution of 
ubiquitin from the nucleus. Notably, MG132-induced deubiquitination reportedly 
occurs within 5 minutes of drug addition (Dantuma et al., 2006) and therefore the 
rate of TOP2 deubiquitination at 30 minutes MG132 exposure may be undetectable 
due to an equivalent rate of MG132-induced accumulation of ubiquitinated TOP2-
DNA complexes. This suggests that, like histone H2A, TOP2 is deubiquitinated in 
response to proteotoxic stress in order to replenish the free ubiquitin pool. It is 
therefore possible that proteasomal inhibition may prevent the processing of TOP2-
DNA complexes through the inhibition of TOP2 ubiquitination, rather than by 
inhibition of TOP2 degradation. 
122 
 
 
Figure 4.8. Investigating the effect of increasing MG132 exposure on levels of 
ubiquitinated TOP2-DNA complexes using the TARDIS assay. A) K562 cells were 
treated with 10 µM MG132 for 30, 60 or 120 minutes, and total levels of ubiquitinated 
proteins were measured by western blot. Levels of the 23 kDa monoubiquitinated protein 
(presumed to be histone H2A) were quantified and expressed as percentage remaining 
compared to untreated control. B) K562 cells were treated with 100 µM etoposide alone or in 
combination with 10 µM MG132 for 30, 60 or 120 minutes, and levels of ubiquitinated TOP2-
DNA complexes were measured by TARDIS assay. Values represent mean of medians ± 
SEM from triplicate experiments and are normalised to a 2 hour 100 µM etoposide control. 
Statistical comparisons were made by unpaired t-test (n=3).  
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As shown in Figure 4.7A, treatment with PR-619 alone induced stable TOP2A-DNA 
complexes. Therefore a PR-619 dose-response experiment was performed to 
investigate the effect of PR-619 as a potential TOP2 poison. K562 cells were treated 
with increasing concentrations of PR-619 for 2 hours, and levels of TOP2-DNA 
complexes were measured by the TARDIS assay. Strikingly, PR-619 induced 
TOP2A-DNA complexes in a dose-dependent manner (Figure 4.9A). Indeed, the 
induction of TOP2A-DNA complexes by 10 µM PR-619 was even greater than 
TOP2A complex levels induced by 100 µM etoposide. PR-619 also induced a dose-
dependent increase in levels of ubiquitinated TOP2-DNA complexes (Figure 4.9B). 
Interestingly, PR-619-induced TOP2-DNA complexes appear unevenly distributed 
across the nuclei (Figure 4.9C), unlike the diffuse, pan-nuclear pattern that is 
observed upon etoposide treatment (not shown). These TOP2A foci colocalise with 
ubiquitin conjugates, further demonstrating that PR-619-induced TOP2-DNA 
complexes are ubiquitinated. 
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Figure 4.9. Stabilisation of TOP2A-DNA complexes by PR-619. K562 cells were treated 
with the indicated concentration of PR-619 for 2 hours (or 100 µM etoposide for 
comparison), and levels of TOP2-DNA complexes were quantified using the TARDIS assay 
(n=1). Scatter diagrams in A) and B) show the raw integrated fluorescence per nucleus of 
TOP2A and all conjugated ubiquitin (anti-ubiquitin antibody clone FK2), respectively. C) 
Representative images (40x objective) of ubiquitinated TOP2-DNA complexes in the 
presence of 20 µM PR-619.  
125 
 
4.4.1 Effect of transcription inhibition on the ubiquitination of TOP2-DNA 
complexes 
It is suggested that the proteasome-dependent processing of TOP2-DNA complexes 
is transcription-dependent (Mao et al., 2001; Fan et al., 2008; Ban et al., 2013; 
Tammaro et al., 2013). Indeed, while inhibition of transcription did not significantly 
affect the formation of TOP2-DNA complexes, co-incubation of cells with DRB 
significantly slowed the removal of etoposide-induced TOP2A-DNA complexes, as 
shown in Chapter 3 (Figure 3.23). To investigate whether the ubiquitination of TOP2-
DNA complexes is also transcription-dependent, K562 cells were treated for 2 hours 
with 100 µM etoposide alone or in combination with 300 µM DRB. Strikingly, the 
ubiquitination of etoposide-induced TOP2-DNA complexes was significantly reduced 
in the presence of DRB compared to etoposide alone (p=0.0381, Figure 4.10). This 
suggests that the ubiquitination of TOP2-DNA complexes is partly transcription-
dependent. Notably, levels of ubiquitinated TOP2-DNA complexes remained 
significantly above background even in the presence of DRB, which could be due to 
incomplete inhibition of transcription or other pathways leading to TOP2 
ubiquitination. Nonetheless, this indicates that transcription is involved in the 
ubiquitination of TOP2. 
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Figure 4.10. Effect of transcription inhibition on levels of TOP2-DNA complexes. K562 
cells were treated with 100 µM etoposide (VP-16) alone or in combination with 300 µM DRB 
for 2 hours. Levels of ubiquitinated TOP2-DNA complexes were determined by TARDIS 
assay. A) Quantification of ubiquitinated TOP2-DNA complexes. Values represent mean of 
medians ± SEM of triplicate experiments, normalised to a 100 µM etoposide control. 
Statistical comparisons were made by unpaired t-test (n=3). B) Representative images of 
data presented in A.   
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4.5 TOP2-DNA complexes are SUMOylated 
TOP2-DNA complexes are SUMOylated in response to TOP2 poisons (Mao et al., 
2000; Agostinho et al., 2008; Schellenberg et al., 2017), and this was investigated 
using the TARDIS assay. SUMO-2 and SUMO-3 are 97% identical, and thereby 
referred to as SUMO-2/3 (Geiss-Friedlander and Melchior, 2007). K562 cells were 
treated with 100 µM etoposide or 0.2% v/v DMSO, and levels of SUMOylated TOP2-
DNA complexes were measured by probing TARDIS slides with anti-SUMO-2/3 
antibodies. Indeed, SUMO-2/3 conjugates were readily detectable on TARDIS slides 
following the treatment of cells with etoposide (Figure 4.11). SUMO-2/3 conjugates 
were not detected in the absence of etoposide, demonstrating that other chromatin-
associated SUMO conjugates are removed during TARDIS lysis. The presence of 
etoposide-induced SUMO-1 conjugates on TARDIS slides was not investigated in 
the current study, but has been shown by others (Jobson, 2004). 
 
Figure 4.11. Detection of SUMO-2/3 conjugates on TARDIS slides following etoposide 
treatment. K562 cells were treated with 100 µM etoposide for 2 hours, and processed 
according to the TARDIS assay. Levels of SUMOylated TOP2-DNA complexes were 
visualised and quantified by probing slides with anti-SUMO-2/3 antibody.  
While the specificity of MLN7243 for ubiquitin activating enzymes over other UBL-like 
enzymes has been demonstrated by others (Misra et al., 2017), the TARDIS assay 
was used to test the effect of the UAE inhibitor MLN7243 on the SUMOylation of 
TOP2-DNA complexes. K562 cells were treated with 100 µM etoposide alone or in 
combination with 10 µM MG132 or 10 µM MLN7243 for 2 hours. Notably, co-
incubation of cells with MG132 did not significantly affect levels of SUMOylated 
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TOP2-DNA complexes, suggesting SUMOylated TOP2-DNA complexes are not 
regulated by the proteasome. Furthermore, MLN7243 treatment did not affect levels 
of SUMOylated TOP2-DNA complexes, suggesting that MLN7243 selectively inhibits 
UAE activity without affecting SUMO activating enzyme (SAE) activity. This confirms 
that the effect of MLN7243 on the removal of TOP2-DNA complexes (shown in 
Chapter 3) is not due to targeting of SUMO. 
 
Figure 4.12. Effect of proteasome inhibition and the UAE inhibitor MLN7243 on levels 
of SUMOylated TOP2-DNA complexes. A) K562 cells were treated with 100 µM etoposide 
(VP-16) alone or in combination with 10 µM MG132 or 10 µM MLN7243 for 2 hours. Levels 
of SUMOylated TOP2-DNA complexes were determined by TARDIS assay. Values 
represent the mean of medians ± SEM of triplicate experiments, normalised to a 2 hour 100 
µM etoposide control. Statistical comparisons were made by unpaired t-test (n=3). B) 
Representative images of data shown in A.  
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4.6 Investigating the ubiquitination of TOP2 using Tandem Ubiquitin Binding 
Entities (TUBEs) 
A major limitation of the TARDIS assay is the inability to compare the ubiquitination 
of etoposide-induced TOP2-DNA complexes with the ubiquitination of non-covalently 
bound TOP2 in untreated cells. Therefore, it is not possible to deduce whether TOP2 
is ubiquitinated in response to etoposide, or if TOP2 is already ubiquitinated before it 
is trapped in the TOP2-DNA complex. To address this, TOP2 ubiquitination was 
investigated before and after etoposide treatment using Tandem Ubiquitin Binding 
Entities (TUBEs). 
4.6.1 Using TUBEs to study the ubiquitination of Rpb1 upon transcription 
inhibition 
TUBEs contain multiple repeats of ubiquitin binding domains which bind 
ubiquitinated proteins with high affinity (Hjerpe et al., 2009; Wilson et al., 2012). 
Commercially available TUBEs also contain an affinity tag such as GST or biotin, 
which can be pulled down by affinity purification, followed by analysis of ubiquitinated 
proteins by western blot. Anindya et al. used this approach to demonstrate that 
Rpb1, the large subunit of RNA polymerase II, is ubiquitinated in response to 
transcription inhibition by α-Amanitin (Anindya et al., 2007). This experiment was 
replicated here in order to optimise an effective TUBE protocol using TUBE2 linked 
to GST (GST-TUBE2). 
K562 cells were treated with α-Amanitin (or H2O solvent control) for 4 hours, and 
whole cell lysates were prepared with the addition of DNase I and sonication to 
facilitate the release of chromatin-associated proteins from DNA. Ubiquitinated 
proteins were then isolated by incubation of the lysate with GST-TUBE2 and 
analysed by western blotting. Equal volumes of whole cell lysate before (input) and 
after ubiquitin pulldown (flow-through) were probed for all ubiquitinated proteins (FK2 
antibody) to test pulldown efficiency. Indeed, ubiquitinated proteins were detectable 
in the input of both untreated and α-Amanitin-treated cells but were completely 
undetectable in the flow-through, indicating highly efficient isolation of ubiquitinated 
proteins by GST-TUBE2 (Figure 4.13). Notably, a significant proportion of Rpb1 
remained in the flow-through, suggesting that not all Rpb1 is ubiquitinated upon 
transcription inhibition. Alternatively, transcription inhibition may be incomplete. 
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Following elution from glutathione beads, levels of ubiquitinated Rpb1 were 
measured by probing ubiquitinated proteins with anti-Rpb1 antibody. Blots were also 
probed with anti-ubiquitin FK2 antibody as a loading control (Figure 4.13). As 
previously shown (Anindya et al., 2007), Rpb1 ubiquitination was increased in α-
Amanitin-treated cells compared to untreated cells. Therefore, TUBEs can be used 
to reliably study protein ubiquitination. 
 
Figure 4.13. Ubiquitination of RNA polymerase II in response to transcription 
inhibition. K562 cells were treated with 10 µg/mL α-Amanitin or H2O for 4 hours, and 
ubiquitinated proteins were isolated by incubating cell lysates with GST-TUBE2. Western 
blotting was used to measure levels of ubiquitinated proteins and ubiquitinated Rpb1 (RNA 
polymerase II large subunit) following GST-TUBE pulldown. Levels of Rpb1 and ubiquitin 
conjugates were also measured in whole cell lysates before and after ubiquitin pulldown, 
indicated by In (input) and FT (flow-through), respectively.  
The α-Amanitin-induced ubiquitination of Rpb1 was then used to examine the effect 
of double UAE1/UBA6 siRNA knockdown and MLN7243 treatment on the 
ubiquitination of a known substrate. Figure 4.14A shows that total levels of ubiquitin 
conjugates are reduced in whole cell lysates (input) of UAE1/UBA6 siRNA 
knockdown and MLN7243-treated cells compared to control cells. However, ubiquitin 
conjugates are still detectable in UAE1/UBA6 siRNA knockdown cells, indicating 
incomplete knockdown of ubiquitination. Consistently, UAE1 levels were reduced but 
still detectable in UAE1/UBA6 siRNA knockdown cells. Nonetheless, incubation of 
lysates with GST-TUBE2 efficiently isolated ubiquitinated proteins in control and 
UAE1/UBA6 knockdown cells, which were depleted in the flow-through. 
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Ubiquitinated proteins were then eluted from glutathione beads and levels of 
ubiquitinated Rpb1 were measured by western blot. As expected, levels of 
ubiquitinated Rpb1 were increased in CON siRNA cells following treatment with α-
Amanitin (Figure 4.14B). However, Rpb1 ubiquitination was abrogated in both 
UAE1/UBA6 siRNA knockdown cells and cells treated with MLN7243. Therefore, 
inhibition of UAE activity by both siRNA knockdown or acute chemical inhibition is 
sufficient to inhibit α-Amanitin-induced Rpb1 ubiquitination. 
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Figure 4.14. Ubiquitination of RNA polymerase II in double UAE1/UBA6 siRNA 
knockdown cells and MLN7243-treated cells. K562 cells (no siRNA) were treated with 10 
µM MLN7243 alone or in combination with 10 µg/mL α-Amanitin for 2 hours. CON siRNA 
and double UAE1/UBA6 siRNA cells were also treated with 10 µg/mL α-Amanitin or H2O for 
2 hours, and ubiquitinated proteins were isolated by GST-TUBE pulldown. A) Western blot to 
show levels of ubiquitin conjugates in CON siRNA, UAE1/UBA6 siRNA knockdown and 
MLN7243-treated K562 cells before (In) and after (FT) ubiquitin pulldown. B) Ubiquitin 
conjugates in CON siRNA, UAE1/UBA6 siRNA knockdown and MLN7243-treated K562 cells 
were isolated by GST-TUBE pulldown and levels of ubiquitinated Rpb1 were measured by 
western blot.   
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4.6.2 Using TUBEs to study TOP2 ubiquitination 
This approach was used to investigate the ubiquitination of TOP2 in the presence 
and absence of 100 µM etoposide. Whole cell lysates were prepared in the presence 
of DNase I (and the DUB inhibitor, NEM) for the release of etoposide-induced TOP2 
covalent complexes from DNA and analysis by western blot. Overall ubiquitination 
was markedly increased in the whole cell lysate of etoposide-treated cells, likely 
reflecting DNA damage-induced ubiquitination (Figure 4.15). However, levels of 
TOP2A were reduced in whole cell lysates from etoposide-treated cells compared to 
untreated cells, indicating incomplete extraction of TOP2 from DNA. This suggests 
that a more effective method of TOP2 extraction is required for the analysis of TOP2-
DNA complexes by western blotting. Various conditions were investigated to 
optimise the extraction of TOP2-DNA complexes, such as the inclusion of a 
sonication step and adjustment of sonication conditions. However, sonication did not 
increase the yield of TOP2 in etoposide-treated cells (see Appendix Table 2 and 3 
for details). Because of this, experiments were commenced using DNase I, though in 
the future should be performed using a more efficient nuclease such as benzonase 
(Turbonuclease). Alternatively, the decrease of TOP2A levels in etoposide-treated 
cells could be due to the TOP2 poison-induced proteasomal degradation of TOP2A 
previously shown by others using western blotting techniques (Fan et al., 2008; 
Alchanati et al., 2009). While etoposide-induced degradation of TOP2A was not 
observed within 2 hours treatment in K562 cells by western blotting (Chapter 3, 
Figure 3.10), it is possible that proteasomal degradation is more readily detectable in 
a pool of ubiquitinated TOP2A as opposed to total TOP2A levels. 
As above, whole cell lysates were subjected to ubiquitin pulldown with GST-TUBE1 
and levels of total ubiquitin conjugates were measured in lysates before (input) and 
after (flow-through) ubiquitin pulldown. While levels of ubiquitinated proteins were 
slightly reduced in the flow-through, many ubiquitin conjugates remained indicating a 
poor ubiquitin pulldown (Figure 4.15). Despite an apparently inefficient pulldown, 
ubiquitinated TOP2A (Ub-TOP2A) was still detected when eluted proteins were 
probed for TOP2A. Notably, an additional band (corresponding to GST) was 
observed in samples containing GST-TUBE1, as the TOP2A antibody used was 
raised to a GST-fusion protein. To prevent this from interfering with the interpretation 
of results, proteins were adequately separated by running gradient gels for longer, 
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and ~178 kDa Ub-TOP2A was identified by comparison with a ladder of protein 
standards with known molecular weight. Ub-TOP2A was present in both untreated 
and etoposide-treated cells, suggesting that TOP2A is ubiquitinated before the 
addition of etoposide. Paradoxically, no ubiquitin conjugates were detected when 
eluted proteins were probed with anti-ubiquitin FK2 antibody. This may be due to low 
pulldown efficiency, whereby levels of isolated ubiquitinated proteins are below the 
range of detection.  
 
Figure 4.15. Investigating the ubiquitination of TOP2 with GST-TUBEs. K562 cells were 
treated with 100 µM etoposide (VP-16) or 0.2% DMSO for 2 hours. Ubiquitin conjugates 
were isolated from K562 cell lysates by incubation with GST-TUBE1, and analysed by 
western blotting (with serial dilution of the sample indicated by 1:2). Ubiquitinated proteins 
bound to GST-TUBE1 (as well as whole cell lysates before (In) and after (FT) ubiquitin 
pulldown) were probed for all conjugated ubiquitin and TOP2A. Blots were developed using 
the LiCor C-DiGit western blot scanner.  
MultiDsk2 is another ubiquitin binding reagent which can be used to isolate 
ubiquitinated proteins while also protecting them from DUBs and proteasomal 
degradation (Wilson et al., 2012). Like TUBEs, MultiDsk2 contains a tandem 
ubiquitin binding domain (Dsk2) which binds all ubiquitin chains with high affinity, and 
a GST tag which can be pulled down with glutathione beads. MultiDsk2 was also 
used to investigate the ubiquitination of TOP2 in the presence and absence of 100 
µM etoposide. 
Whole cell lysates were prepared from DMSO- or etoposide- treated cells and 
probed for all ubiquitin conjugates before and after ubiquitin pulldown with MultiDsk2. 
Levels of ubiquitinated proteins were not noticeably reduced in the flow-through 
135 
 
compared to input samples, indicating an inefficient ubiquitin pulldown (Figure 
4.16A). Furthermore, TOP2A was not readily detectable in whole cell lysates using 
the LiCor C-DiGit western blot scanner, but could be detected upon prolonged 
exposure on film (Figure 4.16B). Despite this, Ub-TOP2A was detectable after the 
elution of ubiquitinated proteins from glutathione beads (Figure 4.16A). As shown 
previously using GST-TUBE1, Ub-TOP2A was detected in both untreated and 
etoposide-treated cells, with levels appearing slightly reduced after etoposide 
treatment. Together, studies using TUBEs and MultiDsk2 show that TOP2A is 
ubiquitinated before etoposide treatment. However, the efficiency of ubiquitin 
pulldown was poor, and therefore a large proportion of ubiquitinated TOP2A may 
have been lost in the supernatant. Because of this and various other technical issues 
(detailed in Appendix Tables 2 and 3), TOP2 ubiquitination was also investigated by 
immunoprecipitation. 
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Figure 4.16. Investigating the ubiquitination of TOP2 with MultiDsk2. A) K562 cells were 
treated with 100 µM etoposide (VP-16) or 0.2% DMSO for 2 hours, and ubiquitinated 
proteins were isolated by incubation of cell lysate with MultiDsk2. Levels of ubiquitin 
conjugates and TOP2A were measured by western blot, and developed using the LiCor C-
DiGit western blot scanner. Whole cell lysate before and after ubiquitin pulldown are 
indicated by In (input) and FT (flow-through), respectively, and 1:2 indicates serial dilution of 
the sample. B) Prolonged film exposure of TOP2A blot shown in A.   
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4.7 Investigating the ubiquitination of TOP2 by immunoprecipitation 
K562 cells were treated with 100 µM etoposide for 2 hours, and whole cell lysate 
was prepared with the inclusion of DNase I. All ubiquitinated proteins were then 
immunoprecipitated by incubating lysates with anti-ubiquitin FK2 antibody, and 
analysed by western blotting. Figure 4.17A shows the levels of ubiquitinated proteins 
present in whole cell lysate (input) and the highly efficient depletion of ubiquitin 
conjugates in whole cell lysate after ubiquitin IP (flow-through). Ubiquitin IPs were 
then probed for TOP2A to examine levels of Ub-TOP2A in untreated and etoposide-
treated cells from three individual experiments (Figure 4.17B). Consistent with TUBE 
data, ubiquitinated TOP2A was detected in both untreated and etoposide-treated 
cells, suggesting that TOP2A is ubiquitinated before etoposide addition. However, 
levels of ubiquitinated TOP2A appeared to be decreased in the presence of 
etoposide. This could be due to the inefficient extraction of TOP2 from DNA, or due 
to the proteasomal degradation of TOP2A reported by others (Zhang et al., 2006; 
Fan et al., 2008; Alchanati et al., 2009). Alternatively, TOP2 ubiquitination may be 
decreased in response to etoposide treatment. 
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Figure 4.17. Effect of etoposide treatment on levels of ubiquitinated TOP2A, measured 
by immunoprecipitation. K562 cells were treated with 100 µM etoposide or 0.2% v/v 
DMSO for 2 hours. Whole cell lysates were prepared in the presence of DNase I to facilitate 
the release of TOP2 complexes from DNA, and subjected to immunoprecipitation with anti-
ubiquitin FK2 antibody. A) Levels of ubiquitinated proteins in whole cell lysates before and 
after ubiquitin IP were measured by western blot. B) Levels of TOP2A in ubiquitin IPs with 
and without etoposide treatment were measured by western blot. Blot shows three biological 
replicates ran on a precast 4-20% gradient gel (n=3).   
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However, when probing IPs for TOP2A, there was an accumulation of TOP2A at the 
top of the blot which suggested that not all protein was able to enter the precast 4-
20% gradient gel. Therefore, the same lysates were subjected to another 
immunoprecipitation with anti-ubiquitin FK2 antibody and run on a self-cast 5% gel, 
which allows better separation of large proteins. No TOP2A protein was detected at 
the top of the blot, suggesting all protein had effectively migrated into the gel. Figure 
4.18A shows the successful immunodepletion of ubiquitinated proteins from whole 
cell lysates after ubiquitin IP. In contrast to Figure 4.17B, levels of Ub-TOP2A were 
increased in the presence of etoposide (Figure 4.18B).  Therefore, the amount of Ub-
TOP2A detected in etoposide-treated cells depends on the gel running conditions 
used. Specifically, more Ub-TOP2A is detected when a 5% gel is used, suggesting 
that larger pore sizes are required for the entry of large (>170 kDa) ubiquitinated 
proteins into the gel. In addition, the composition of the stacking gel in commercially 
available precast gels is unknown, and may interfere with the migration of larger 
proteins. Because of this variability and the substantial differences in results from 
separate IPs with the same lysate, it is not possible to conclude how levels of Ub-
TOP2A change in the presence of etoposide without further experimentation. 
Nonetheless, these studies show that at least a proportion of TOP2A is ubiquitinated 
without etoposide treatment. 
Ub-TOP2A is detected as a discrete band rather than the canonical polyubiquitinated 
smear which is typically associated with proteasomal degradation. Indeed, while 
K48-linked ubiquitin and K63-linked ubiquitin chains were detected on TOP2-DNA 
complexes using linkage-specific antibodies in the TARDIS assay (Figure 4.1), 
ubiquitin chains were not detectable by western blot. Therefore, the proteasomal 
processing of TOP2-DNA complexes may not involve canonical K48-linked 
ubiquitination of TOP2. 
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Figure 4.18. Effect of etoposide treatment on levels of ubiquitinated TOP2A, measured 
by immunoprecipitation. K562 cells were treated with 100 µM etoposide or 0.2% v/v 
DMSO for 2 hours. Whole cell lysates were prepared in the presence of DNase I to facilitate 
the release of TOP2 complexes from DNA, and subjected to immunoprecipitation with anti-
ubiquitin FK2 antibody. A) Levels of ubiquitinated proteins in whole cell lysates before and 
after ubiquitin IP were measured by western blot. B) Levels of TOP2A in ubiquitin IPs with 
and without etoposide treatment were measured by western blot. Blot shows three biological 
replicates run on a 5% gel (n=3).  
While some of the blots presented above were also probed for TOP2B, ubiquitinated 
TOP2B was not successfully detected by any of the approaches used. However, 
TOP2B was also undetectable in whole cell lysates before ubiquitin pulldown, 
suggesting the possibility of various technical issues which are outlined in Appendix 
Tables 2 and 3. Therefore, it was not possible to investigate the ubiquitination of 
TOP2B before and after etoposide treatment. 
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4.8 Discussion 
In the current chapter, the ubiquitination of TOP2 was investigated using multiple 
approaches. Firstly, the TARDIS assay was adapted to detect and quantify ubiquitin 
and SUMO chains on TOP2-DNA complexes. In doing so, both ubiquitin and SUMO-
2/3 was detected on TOP2, the latter of which has been previously shown in 
response to etoposide and catalytic TOP2 inhibitors such as ICRF-187 and ICRF-
193 (Isik et al., 2003; Agostinho et al., 2008; Schellenberg et al., 2017). Secondly, 
the ubiquitination of TOP2 was investigated through the isolation of ubiquitinated 
proteins using TUBEs. Unlike the TARDIS assay, this allowed the visualisation of 
TOP2 ubiquitination before the addition of etoposide, and suggested that TOP2A is 
also ubiquitinated before etoposide treatment. Thirdly, TOP2 ubiquitination was 
investigated by immunoprecipitation.  
Studies with TUBEs suggested that levels of Ub-TOP2A do not change significantly 
with etoposide treatment. However, the pulldown of ubiquitin with TUBEs and 
MultiDsk2 was highly variable (see Appendix Tables 2 and 3 for details), and 
therefore a significant proportion of ubiquitinated proteins were lost in the 
supernatant. Because of this, levels of Ub-TOP2A may not be representative of the 
entire Ub-TOP2A pool. These experiments were also susceptible to other technical 
issues, such as the potentially incomplete extraction of TOP2 complexes from 
etoposide-treated cells even after digestion of the lysate with DNase I. Indeed, these 
conditions may be sufficient to extract RNA polymerase II but not covalently-bound 
TOP2. It is also difficult to adequately conclude the effect of etoposide on the 
ubiquitination of TOP2A following ubiquitin IP, as two separate analyses of the same 
biological samples generated opposing results depending on the percentage gel 
used. Probing blots for TOP2B was also problematic due to absence of TOP2B 
signal and other technical issues. Thus, it is difficult to conclude how levels of Ub-
TOP2 change (if at all) after etoposide treatment. However, these experiments show 
that TOP2A is ubiquitinated both before and after etoposide exposure. 
Alchanati et al. show the polyubiquitination of TOP2A in response to teniposide 
treatment, which is significantly increased when BMI1 and RING1A were 
overexpressed in HeLa cells (Alchanati et al., 2009). However, polyubiquitination of 
TOP2A (denoted by a high molecular weight smear on a western blot) was not 
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observed in the current study with any of the approaches used. Indeed, 
polyubiquitinated TOP2 was not detectable even after the enrichment of all ubiquitin 
chains with TUBEs or MultiDsk2. Therefore, the teniposide-induced 
polyubiquitination of TOP2 may be a teniposide-specific effect, or a non-
physiological consequence of protein overexpression which is driven by an excess of 
BMI1/RING1A protein. Instead, Ub-TOP2A was observed in the present study as a 
discrete band which may correspond to monoubiquitination, multi-monoubiquitination 
(i.e. monoubiquitination at multiple lysine residues) or short ubiquitin chains (e.g. di-
ubiquitin). This is in contrast to TARDIS data which showed the presence of K48- 
and K63-linked ubiquitin chains on TOP2-DNA complexes. Notably, the detection of 
ubiquitin chains by fluorescence microscopy required long exposure times (>1 
second), suggesting that K48- and K63-linked ubiquitin chains are present on TOP2-
DNA complexes at low levels. While it is difficult to accurately compare signals with 
different antibodies, visualisation of all conjugated ubiquitin (using the anti-ubiquitin 
antibody clone FK2) on TARDIS slides required shorter exposure times (~400 msec), 
which could be due to the detection of other, more abundant ubiquitin chains such as 
monoubiquitin on TOP2-DNA complexes. Therefore, it is possible that the western 
blotting techniques used are not sensitive enough to detect the polyubiquitination of 
TOP2. Alternatively, the ubiquitin-dependent processing of TOP2-DNA complexes 
may not involve the polyubiquitination of TOP2, which typically leads to proteasomal 
degradation.  
The TARDIS assay was also used to test the effect of various ubiquitin-proteasome 
system inhibitors on levels of ubiquitinated etoposide-induced TOP2-DNA 
complexes. Co-treatment of cells with etoposide and MG132 revealed a dynamic 
regulation of TOP2 ubiquitination by deubiquitinase enzymes, which occurs upon 
proteasome inhibition. This suggests that, like histone H2A, TOP2 is a highly 
abundant monoubiquitinated protein which can be deubiquitinated to provide free 
ubiquitin during proteotoxic stress. When DUBs were inhibited, there was a 
proteasome-dependent accumulation of ubiquitinated TOP2-DNA complexes which 
may be due to ubiquitin-dependent proteasomal degradation of TOP2 complexes. In 
the absence of MG132, the ubiquitination of etoposide-induced TOP2-DNA 
complexes was partly transcription-dependent. Transcription has already been 
implicated in the processing of drug-stabilised TOP2-DNA complexes, as inhibition of 
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transcription prevents the degradation of TOP2 following etoposide treatment (Mao 
et al., 2001; Fan et al., 2008; Ban et al., 2013; Tammaro et al., 2013) and slows the 
removal of TOP2A-DNA complexes (Chapter 3, Figure 3.23). 
In summary, these results indicate that ubiquitinated TOP2-DNA complexes are 
degraded by the proteasome, but not via canonical K48-linked polyubiquitination. 
Instead, TOP2A is monoubiquitinated both before and after etoposide treatment. 
TUBE experiments show that levels of Ub-TOP2A do not change in response to 
etoposide treatment, but do not show whether the nature of TOP2A ubiquitination 
changes in response to etoposide. For example, mass spectrometry could be used 
to test for changes in the ubiquitination of specific lysine residues before and after 
etoposide treatment. Indeed, trapping of TOP2 on DNA may reveal an otherwise 
concealed ubiquitination site, as previously shown for the SUMOylation of TOP2A at 
Lys662 (Ryu et al., 2010; Wendorff et al., 2012). In addition, protein ubiquitination 
can lead to many consequences besides degradation by the proteasome. Indeed, 
TOP2 ubiquitination may not lead directly to proteasomal degradation but to the 
recruitment of other proteins involved in removal or repair. For example, VCP/p97 is 
an AAA ATPase which binds and extracts ubiquitinated proteins from chromatin, 
thereby facilitating their proteasomal degradation (Verma et al., 2011; Meyer et al., 
2012; Dantuma et al., 2014; van den Boom et al., 2016). The potential role of 
VCP/p97 in the removal of TOP2-DNA complexes is investigated in Chapter 5. 
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Chapter 5 A role for VCP/p97 in the proteasomal processing of 
TOP2-DNA complexes 
5.1 Introduction 
VCP/p97 is a AAA ATPase (ATPase associated with diverse cellular activities) which 
is increasingly recognised as an important mediator of the ubiquitin-proteasome 
system. Proteasomal degradation involves the translocation of proteins through the 
narrow core of the 20S catalytic subunit, which requires protein unfolding. While this 
is largely mediated by the ATPases associated with the 19S regulatory subunit, 
some (but not all) proteins require the additional unfoldase activity of VCP/p97 
(Beskow et al., 2009; Heidelberger et al., 2018). Indeed, VCP/p97 is transiently 
associated with the proteasome (Besche et al., 2009), and this interaction is 
stabilised in conditions of proteotoxic stress, including proteasome inhibition (Isakov 
and Stanhill, 2011). 
Each protomer of the hexameric VCP/p97 complex contains two highly conserved 
ATPase domains (D1 and D2), which utilise energy from ATP binding and hydrolysis 
to induce conformational changes in the substrate, leading to protein unfolding and 
remodelling (Rouiller et al., 2000; DeLaBarre and Brunger, 2005). While VCP/p97 
itself can bind ubiquitin (Pye et al., 2007), the N terminal domain of VCP/p97 
mediates important interactions with the major ubiquitin adaptor proteins, p47 and 
Ufd1 (Meyer et al., 2012). Both p47 and Ufd1 bind ubiquitinated proteins but form 
structurally distinct complexes with VCP/p97, directing VCP/p97 to separate 
functional pathways (Meyer et al., 2000; Pye et al., 2007). For example, while p47 is 
most associated with membrane fusion events at the endoplasmic reticulum, Ufd1 
(together with Npl4) mediates the degradative functions of VCP/p97. Consistently, 
knockdown of Ufd1 reduces the association between VCP/p97 and the proteasome 
(Isakov and Stanhill, 2011). 
In addition to the role of VCP/p97 at the proteasome, VCP/p97 is a protein 
segregase that can extract proteins from protein complexes and cellular structures, 
thereby facilitating their proteasomal degradation (Meyer et al., 2012). This is 
particularly evident during the DNA damage response, where VCP/p97 (in complex 
with Ufd1-Npl4) ensures the timely removal and degradation of various repair factors 
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from chromatin, including CSB, L3MBTL1 and Rad52 (Acs et al., 2011; Bergink et 
al., 2013; Dantuma et al., 2014; He et al., 2016). In particular, VCP/p97 enables the 
extraction of stalled RNA polymerase II (RNAPII) following UV-induced DNA 
damage, leading to RNAPII proteolysis (Verma et al., 2011; Lafon et al., 2015; He et 
al., 2017a). Intriguingly, VCP/p97 can extract proteins which are sterically trapped on 
DNA, including the Ku70/80 complex (van den Boom et al., 2016).  
Inactivation of a temperature-sensitive Cdc48 (the yeast VCP/p97 homolog) 
increases levels of ubiquitinated TOP2 (Wei et al., 2017), suggesting that Cdc48 is 
involved in the proteasomal degradation of TOP2 in yeast. Furthermore, Cdc48 co-
operates together with the non-specific protease Wss1 in the degradation of DNA-
protein crosslinks including topoisomerase I (TOP1) covalent complexes (Stingele et 
al., 2014; Balakirev et al., 2015). Interestingly, other AAA ATPase activities have 
been implicated in the proteasomal processing of TOP2-DNA complexes. 
Specifically, Ban et al propose that the clearance of etoposide-induced TOP2B-DNA 
complexes involves the unfolding of TOP2B by 19S AAA ATPases associated with 
elongating RNAPII, leading to TOP2B proteolysis (Ban et al., 2013). It was therefore 
hypothesised that VCP/p97 could facilitate the proteasomal degradation of TOP2-
DNA complexes by unfolding and extracting TOP2 from DNA.   
5.2 Aims 
The aim of the current chapter was to investigate the potential role of VCP/p97 as a 
protein segregase in the removal of etoposide-induced TOP2-DNA complexes. This 
was achieved using the TARDIS assay to measure the removal of TOP2 complexes 
from DNA following chemical inhibition or siRNA knockdown of VCP/p97. In addition, 
the role of VCP/p97 in the processing of TOP2-DNA complexes to protein-free DSBs 
was examined using the ɣH2AX assay. 
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5.3 Chemical inhibition or siRNA knockdown of VCP/p97 increases levels of 
etoposide-induced TOP2-DNA complexes 
The role of VCP/p97 in the processing of TOP2-DNA complexes was investigated 
using NMS-873, an allosteric inhibitor of VCP/p97. NMS-873 binds VCP/p97 
between the D1 and D2 ATPase domains, thereby inhibiting the conformational 
change in VCP/p97 which occurs upon ATP binding (Rouiller et al., 2000; Magnaghi 
et al., 2013). This conformational change is required for the unfolding and 
remodelling of substrate proteins, and NMS-873 is therefore a potent inhibitor of 
ATPase activity.  
The effect of NMS-873 on the removal of TOP2 complexes from DNA was 
investigated using the TARDIS assay. K562 cells were treated with 100 µM 
etoposide (VP-16) alone or in combination with 5 µM NMS-873 and/or 10 µM 
MG132. After 2 hours, etoposide was removed from the cell culture medium and 
cells were incubated for a further 2 hours in the continued presence of DMSO, NMS-
873 or MG132. Levels of TOP2A- and TOP2B- DNA complexes were measured 
immediately after 2 hours continuous exposure to etoposide (0 hours after VP-16 
removal), and 0.5, 1 and 2 hours after etoposide removal. As previously shown in 
Chapter 3, co-incubation of cells with MG132 did not affect overall levels of 
etoposide-induced TOP2A- or TOP2B- DNA complexes following 2 hours continuous 
etoposide exposure (Figure 5.1). However, proteasome inhibition significantly 
increased remaining levels of TOP2A- and TOP2B- DNA complexes after etoposide 
removal, reflecting the role of proteasomal degradation in the removal of TOP2-DNA 
complexes. 
Interestingly, levels of both TOP2A- and TOP2B- DNA complexes were significantly 
increased in the presence of NMS-873 following 2 hours continuous exposure to 
etoposide (p<0.05 and p<0.001, respectively). Levels of remaining TOP2A-DNA 
complexes were also significantly higher in the presence of NMS-873 0.5 and 1 hour 
after etoposide removal (p<0.001 and p<0.01, respectively). In contrast, no 
significant differences were observed in levels of TOP2B-DNA complexes at any 
time point after etoposide removal. Therefore, inhibition of VCP/p97 increases 
TOP2A- and TOP2B- DNA complex levels. 
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To further investigate whether VCP/p97 is involved in the proteasomal processing of 
TOP2-DNA complexes, etoposide-treated cells were incubated with both 10 µM 
MG132 and 5 µM NMS-873. Dual inhibition of the proteasome and VCP/p97 did not 
additively increase levels of TOP2A- or TOP2B- DNA complexes compared to each 
inhibitor alone, suggesting that these pathways are epistatic. Together, this suggests 
that VCP/p97 is involved in the proteasomal processing of TOP2A- and TOP2B- 
DNA complexes.  
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Figure 5.1. Effect of the VCP/p97 inhibitor NMS-873 on levels of TOP2-DNA 
complexes. K562 cells were treated with 100 µM etoposide (VP-16) alone or in combination 
with 10 µM MG132 and/or 5 µM NMS-873 for 2 hours. Cells were collected after 2 hours 
continuous drug exposure (0 hours after VP-16 removal), or following 0.5, 1 and 2 hours 
further incubation in etoposide-free medium containing MG132, NMS-873 or DMSO. Levels 
of TOP2A- and TOP2B- DNA complexes were measured using the TARDIS assay. Values 
represent the mean of medians ± SEM from triplicate experiments, normalised to a 2 hour 
100 µM etoposide control. Statistical significance was determined by two-way ANOVA with 
Bonferroni post-test (n=3).  
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As shown in Chapter 4, the TARDIS assay can also be used to visualise and 
quantify ubiquitinated TOP2-DNA complexes. To investigate the effect of VCP/p97 
inhibition on levels of ubiquitinated TOP2-DNA complexes, K562 cells were treated 
with 100 µM etoposide (VP-16) alone or in combination with 5 µM NMS-873 for 2 
hours. Levels of ubiquitinated TOP2-DNA complexes were then measured by 
probing TARDIS slides with anti-ubiquitin FK2 antibody (which detects mono- and 
poly- ubiquitin). Inhibition of VCP/p97 led to the significant accumulation of 
ubiquitinated TOP2-DNA complexes on DNA (Figure 5.2), although this may simply 
be a consequence of increased TOP2 complex levels irrespective of ubiquitination 
status, as shown in Figure 5.1. 
 
Figure 5.2. Effect of VCP/p97 inhibition on levels of ubiquitinated TOP2-DNA 
complexes.A) K562 cells were treated with 100 µM etoposide (VP-16) alone or in 
combination with 5 µM NMS-873 for 2 hours, and levels of ubiquitinated TOP2-DNA 
complexes were measured using the TARDIS assay. Values represent the mean of medians 
± SEM from 3 independent experiments, normalised to a 2 hour 100 µM etoposide control. 
Statistical comparisons were made by unpaired t-test (n=3). B) Representative images of 
data shown in A.  
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The role of VCP/p97 in the processing of etoposide-induced TOP2-DNA complexes 
was also investigated following siRNA knockdown of VCP/p97. K562 cells were 
electroporated with 500 nM non-coding (CON siRNA) or VCP/p97 siRNA, and levels 
of VCP/p97 were measured after 24, 48, 72 and 96 hours. Levels of VCP/p97 were 
reduced to 38% within 24 hours of transfection with VCP/p97 siRNA compared to 
CON siRNA, and further reduced to 22% after 72 hours (Figure 5.3). All subsequent 
experiments in VCP/p97 knockdown cells were performed 72 hours after 
electroporation.  
 
Figure 5.3. siRNA knockdown of VCP/p97. K562 cells were transfected with 500 nM non-
coding (CON) siRNA or VCP/p97 siRNA by electroporation. Cells were collected 24, 48, 72 
and 96 hours after electroporation, and VCP/p97 protein levels were measured by western 
blot. VCP/p97 levels were quantified and expressed as percentage remaining compared to 
the corresponding CON siRNA-treated control.  
The effect of VCP/p97 knockdown on the removal of TOP2-DNA complexes was 
investigated using the TARDIS assay. CON siRNA or VCP/p97 siRNA knockdown 
cells were treated with 100 µM etoposide (VP-16) for 2 hours, then incubated for a 
further 2 hours in etoposide-free medium. Levels of TOP2A- and TOP2B- DNA 
complexes were measured following 0, 0.5, 1 and 2 hours after etoposide removal. 
As shown in Figure 5.4A, VCP/p97 protein levels were reduced by at least 83% in 
VCP/p97 siRNA knockdown cells compared to control siRNA-treated cells in all 
triplicate TARDIS experiments. However, levels of TOP2A-DNA complexes were not 
significantly affected at any of the time points tested (Figure 5.4B). In contrast, levels 
of TOP2B-DNA complexes were significantly increased in VCP/p97 knockdown cells 
following 2 hours continuous exposure to etoposide (0 hours after VP-16 removal, 
p<0.01), as previously shown following chemical inhibition of VCP/p97. 
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Figure 5.4. siRNA knockdown of VCP/p97 and the effect on levels of etoposide-
induced TOP2-DNA complexes. A) The siRNA knockdown of VCP/p97 in cells from 
triplicate TARDIS experiments was tested by western blot. VCP/p97 levels were quantified 
and expressed as percentage remaining compared to the corresponding CON siRNA-treated 
control. B) CON siRNA or VCP/p97 siRNA knockdown cells were treated with 100 µM 
etoposide (VP-16) for 2 hours. Cells were collected or incubated for up to 2 hours in 
etoposide-free medium, and levels of TOP2A- and TOP2B- DNA complexes were measured 
following 0, 0.5, 1 and 2 hours after etoposide removal using the TARDIS assay. Values 
represent mean of medians ± SEM from 3 separate experiments, normalised to a 2 hour 100 
µM etoposide control. Statistical significance was determined by two-way ANOVA with 
Bonferroni post-test (n=3).  
5.4 Investigating the role of VCP/p97 in the appearance of etoposide-induced 
DSBs 
As detailed in Chapter 3, removal of TOP2 from drug-stabilised TOP2-DNA 
complexes is required before the enzyme-mediated DSB can be detected by DNA 
damage response proteins. Therefore, to further examine the role of VCP/p97 in the 
removal of TOP2-DNA complexes, the ɣH2AX assay was used to test the effect of 
VCP/p97 inhibition on the appearance of etoposide-induced DSBs. 
K562 cells were treated continuously with 10 µM etoposide alone or in combination 
with 5 µM NMS-873 for up to 4 hours. As expected, incubation of cells with etoposide 
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alone led to the significant induction of protein-free DSBs (Figure 5.5). However, in 
the presence of NMS-873 the appearance of etoposide-induced DSBs was 
significantly reduced following 1 and 2 hours drug exposure (p<0.001 and p<0.05, 
respectively), though were not significantly different at later time points. This 
suggests that VCP/p97 is involved in the processing of TOP2-DNA complexes to 
protein-free DSBs. 
 
Figure 5.5. Effect of VCP/p97 inhibition on levels of etoposide-induced 
phosphorylation of histone H2AX. A) K562 cells were treated with 10 µM etoposide (VP-
16) alone or in combination with 5 µM NMS-873 for up to 4 hours, and levels of protein-free 
DSBs were measured by ɣH2AX assay. Values represent mean of medians ± SEM of 
triplicate experiments, normalised to a 1 hour 10 µM etoposide control. Statistical 
comparisons were made by two-way ANOVA followed by Bonferroni post-test (n=3). B) 
Representative images of data shown in A.  
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The ɣH2AX assay was also performed using the VCP/p97 siRNA knockdown cells 
shown in Figure 5.4A. Consistently, levels of etoposide-induced histone H2AX 
phosphorylation were significantly reduced in VCP/p97 knockdown cells compared to 
control cells, and this was true at all time points tested (Figure 5.6, p<0.001). Levels 
of etoposide-induced DSBs in VCP/p97 knockdown cells were 50% lower than 
control cells within 2 hours of etoposide exposure, compared to only 10% in NMS-
873-treated cells. This may suggest that VCP/p97 activity is more efficiently inhibited 
by siRNA knockdown than small molecule inhibition. Notably, VCP/p97 knockdown 
did not completely prevent the appearance of etoposide-induced DSBs, which could 
be due to VCP/p97-independent pathways of TOP2 complex removal or incomplete 
knockdown of VCP/p97 (Figure 5.4A). 
 
Figure 5.6. Effect of siRNA-mediated VCP/p97 knockdown on etoposide-induced 
phosphorylation of histone H2AX. K562 cells transfected with 500 nM control (CON) 
siRNA or 500 nM VCP/p97 siRNA were treated with 10 µM etoposide (VP-16) for up to 4 
hours. Levels of protein-free DSBs were measured after 0, 1, 2 or 4 hours continuous 
etoposide exposure using the ɣH2AX assay. Values represent mean of medians ± SEM from 
3 separate experiments, normalised to a 1 hour 10 µM etoposide non-electroporated control. 
Statistical comparisons were made by two-way ANOVA with Bonferroni post-test (n=3).   
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VCP/p97-dependent extraction of proteins from chromatin is regulated by 
ubiquitination. Specifically, VCP/p97 is directed to ubiquitinated substrates by 
ubiquitin adaptor proteins, such as Ufd1-Npl4 or p47. While p47 is mostly associated 
with membrane fusion events, Ufd1-Npl4 has been implicated in many VCP/p97-
dependent processes, including chromatin-associated degradation (CAD) (Acs et al., 
2011; Verma et al., 2011; Vaz et al., 2013; van den Boom et al., 2016; He et al., 
2017a; Stach and Freemont, 2017). In particular, Ufd1-Npl4 is involved in the 
removal of sterically trapped Ku70/80 and stalled RNAPII from DNA (Verma et al., 
2011; van den Boom et al., 2016; He et al., 2017a). Thus, the potential role of Ufd1-
Npl4 in the VCP/p97-dependent processing of etoposide-induced TOP2-DNA 
complexes was investigated by siRNA knockdown. 
K562 cells were electroporated in the presence of 500 nM Ufd1 siRNA and 500 nM 
Npl4 siRNA, or 1 µM non-coding (CON) siRNA as a negative control. Cells were 
collected after 24, 48 and 72 hours after electroporation, and levels of Ufd1 and Npl4 
protein were analysed by western blotting (Figure 5.7A). Ufd1 levels were reduced to 
24% after 24 hours, and were undetectable after 48 hours. Npl4 levels were also 
reduced, with 30% of Npl4 protein remaining after 48 hours. All subsequent 
experiments with dual Ufd1/Npl4 siRNA knockdown cells were performed 48 hours 
after electroporation. 
The effect of Ufd1/Npl4 siRNA knockdown on the processing of etoposide-induced 
TOP2-DNA complexes to protein-free DSBs was then investigated by ɣH2AX assay. 
CON siRNA or double Ufd1/Npl4 siRNA knockdown cells were treated with 10 µM 
etoposide for up to 4 hours, and levels of ɣH2AX signal were measured following 0, 
1, 2 and 4 hours continuous etoposide exposure. Alternatively, cells were treated 
with 10 µM etoposide for 2 hours, followed by 2 hours incubation in etoposide-free 
medium (2+2hr washout, WO). Levels of etoposide-induced DSBs were unaffected 
by Ufd1/Npl4 knockdown at any of the time points tested (Figure 5.7B). This 
suggests that Ufd1-Npl4 is not involved in the VCP/p97-dependent processing of 
TOP2-DNA complexes to DSBs. Alternatively, siRNA knockdown of Ufd1 and Npl4 
may be incomplete. 
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Figure 5.7. Dual siRNA knockdown of Ufd1 and Npl4 and the effect on etoposide-
induced phosphorylation of histone H2AX. A) K562 cells were transfected with 500 nM 
Ufd1 siRNA and 500 nM Npl4 siRNA, or 1 µM control (CON) siRNA by electroporation. Cells 
were collected 24, 48 and 72 hours after electroporation, and Ufd1 and Npl4 protein levels 
were measured by western blot. Protein levels were quantified and expressed as percentage 
remaining compared to the corresponding CON siRNA-treated control. B) 48 hours after 
electroporation, Ufd1-Npl4 siRNA knockdown cells were treated with 10 µM etoposide (VP-
16) or DMSO for up to 4 hours. Levels of protein-free DSBs were measured after 0, 1, 2 and 
4 hours continuous etoposide exposure using the ɣH2AX assay. Alternatively, cells were 
treated with 10 µM etoposide for 2 hours, followed by incubation in etoposide-free medium 
for a further 2 hours (2+2hr washout, WO). Values represent mean of medians ± SEM from 
3 separate experiments, normalised to a 1 hour 10 µM etoposide non-electroporated control. 
Statistical comparisons were made by two-way ANOVA with Bonferroni post-test (n=3).  
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5.5 VCP/p97 interacts with TOP2A and TOP2B 
The functional association between TOP2 and VCP/p97 was further investigated by 
immunoprecipitation. VCP/p97 was efficiently immunoprecipitated from the lysates of 
DMSO- and etoposide- treated K562 cells, as shown by the depletion of VCP/p97 in 
whole cell lysate after IP (i.e. flow through, Figure 5.8A). TOP2A was detectable in 
the input of both untreated and etoposide-treated cells, indicating that TOP2-DNA 
complexes were extracted during the preparation of lysates with DNase I. 
VCP/p97 IPs were performed in triplicate and analysed by western blotting (Figure 
5.8B). As expected, VCP/p97 was readily detectable by western blot, as well as the 
known VCP/p97-interacting protein, YOD1. Interestingly, TOP2A was consistently 
detected following VCP/p97 IP in untreated cells, while TOP2B was occasionally but 
not always detected. Importantly, this association was not due to non-specific 
binding of TOP2 to the IP antibody or protein-G sepharose beads, as TOP2A was 
not detectable following a mock actin IP (Figure 5.8C). This suggests that VCP/p97 
interacts with both TOP2 isoforms in cells. 
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Figure 5.8. Co-immunoprecipitation of VCP/p97 and TOP2 isoforms. K562 cells were 
treated with 100 µM etoposide (VP-16) or 0.2% v/v DMSO for 2 hours. VCP/p97 and 
VCP/p97-interacting proteins were isolated from cell lysates by immunoprecipitation with 
anti-VCP/p97 antibody. A) Levels of VCP/p97 and TOP2A in whole cell extract before (input) 
and after (flow through, FT) VCP/p97 IP were measured by western blotting. B) Triplicate 
VCP/p97 IPs were analysed by SDS-PAGE followed by western blotting to test for the 
presence of TOP2 isoforms. IPs were probed for TOP2A, TOP2B, VCP/p97 and YOD1 (a 
known interactor of VCP/p97). C) Cell lysates from A and B were also subjected to actin IP. 
Western blot shows TOP2A levels in actin immunoprecipitates, and in whole cell lysates 
before (input) and after (flow through, FT) actin IP.
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Surprisingly, the interaction between VCP/p97 and TOP2 was reduced in etoposide-
treated cells in all three experiments. During the preparation of whole cell extracts, 
DNase I was added to the lysate to digest the DNA and release chromatin-
associated proteins including TOP2. Levels of TOP2A in the whole cell extract 
(input) of etoposide-treated cells shown in Figure 5.8A are slightly reduced 
compared to untreated cells. In contrast, the level of TOP2A in the input samples 
shown in Figure 5.8C appear to be the same in both DMSO- and etoposide- treated 
cells. This suggests that the extraction of TOP2-DNA complexes with DNase I is 
highly variable, and may not be sufficient to remove all covalently bound TOP2 from 
DNA in the presence of etoposide. Therefore, the absence of TOP2 in the VCP/p97 
IPs of etoposide-treated cells may be due to a band depletion effect, whereby not all 
TOP2 is able to enter the gel.  
To further investigate this, VCP/p97 IPs were repeated following treatment of cell 
lysate with benzonase, an alternative nuclease with 34-fold greater activity than 
DNase I (Benedik and Strych, 1998). Indeed, addition of benzonase instantly 
reduced the viscosity of the lysate indicating highly efficient digestion of DNA. Other 
amendments were made to further optimise the IP experiment, including separation 
of proteins on a non pre-cast 8% gel (where the composition of the stacking gel is 
known) and co-treatment of cells with the DUB inhibitor PR-619 (to enrich 
ubiquitinated proteins without inhibiting the proteasome, which otherwise leads to 
deubiquitination of TOP2-DNA complexes, see Chapter 4, Figure 4.7). Lysates were 
subjected to VCP/p97 IP and analysed by western blotting (Figure 5.9). TOP2A (and 
VCP/p97) was equally detectable in the input of both untreated and etoposide-
treated cells, suggesting all drug-stabilised TOP2-DNA complexes were successfully 
extracted from DNA following digestion with benzonase. Furthermore, levels of 
VCP/p97 were reduced in the flow through, indicating successful 
immunoprecipitation of VCP/p97. Levels of TOP2A were also reduced in the flow 
through compared to the input, suggesting that some TOP2A protein was pulled out 
together with VCP/p97. However, TOP2A was not detectable following VCP/p97 IP 
in this experiment, in contrast to Figure 5.8. 
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Therefore, VCP/p97 IPs are highly variable, with TOP2A detected in only 3 of 4 
experiments and TOP2B detected in only 2 of 3 replicate experiments. Furthermore, 
VCP/p97 was not detectable following TOP2A or TOP2B IP in a reciprocal IP 
experiment (data not shown). This could be due to the unstable nature of the 
VCP/p97 interaction with protein substrates. Because of this, detection of VCP/p97-
protein interactions frequently requires the expression of a “substrate-trapping” 
VCP/p97 mutant (p97-E578Q), in which mutation of the D2 ATPase domain prevents 
the release of protein substrates. Indeed, the interaction of VCP/p97 with other 
proteins such as RNAPII and Ku70/80 was not observed with wild-type VCP/p97 but 
was readily detectable with the p97-EQ mutant (van den Boom et al., 2016; He et al., 
2017a). Therefore, the interaction between VCP/p97 and TOP2 should be verified 
using another experimental approach. 
 
Figure 5.9. Immunoprecipitation of VCP/p97 following preparation of lysates with 
benzonase. K562 cells were treated with 100 µM etoposide (VP-16) or 0.2% v/v DMSO for 
2 hours, alone or in combination with 5 µM PR-619 (a DUB inhibitor). Cell lysates were 
prepared using benzonase to extract chromatin-associated proteins from DNA, followed by 
immunoprecipitation with anti-VCP/p97 antibody. Levels of VCP/p97 and TOP2A in whole 
cell extract before (input) and after (flow through, FT) VCP/p97 IP, and in VCP/p97 
immunoprecipitates were analysed by SDS-PAGE followed by western blotting. A mock IP 
was also performed using an actin IP antibody as a control.  
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5.6 Discussion 
While initially identified as a chaperone for the delivery of ubiquitinated proteins to 
the proteasome (Dai and Li, 2001), VCP/p97 also facilitates proteasomal 
degradation by unfolding and extracting proteins from cellular structures, including 
chromatin (Beskow et al., 2009; Meyer et al., 2012). Here, inhibition of VCP/p97 
increased levels of drug-stabilised TOP2A- and TOP2B- DNA complexes suggesting 
that VCP/p97 is involved in the removal of TOP2 complexes from DNA. This effect 
was epistatic with the role of the proteasome, indicating that VCP/p97 partakes in the 
proteasomal processing of TOP2-DNA complexes. Consistently, VCP/p97 inhibition 
or siRNA knockdown significantly reduced the appearance of etoposide-induced 
DSBs. Furthermore, immunoprecipitation experiments suggested a previously 
unreported interaction between VCP/p97 and TOP2. Therefore, VCP/p97 is an 
important factor involved in the processing of drug-stabilised TOP2-DNA complexes 
to protein-free DSBs. 
The suggestion that AAA ATPases could be involved in the proteasomal processing 
of TOP2-DNA complexes was first made by Ban et al., who propose that the 
clearance of TOP2B-DNA complexes involves 19S AAA ATPases associated with 
elongating RNAPII (Ban et al., 2013). In this model, collision of RNAPII with 
stabilised TOP2B-DNA complexes leads to the activation of RNAPII-associated 19S 
AAA ATPases and subsequent recruitment of the 20S proteasome. Importantly, this 
model does not involve the ubiquitination of TOP2B, as the proteasome is directly 
recruited to the stalled RNAPII which serves as the primary DNA damage signal. 
In contrast, VCP/p97 is a ubiquitin-dependent enzyme which is recruited to 
ubiquitinated proteins through ubiquitin adaptor proteins such as p47 and Ufd1-Npl4. 
In Chapter 4, it was shown that TOP2A is ubiquitinated in both the presence and 
absence of etoposide. While K48- and K63- linked chains were detected on TOP2-
DNA complexes using the TARDIS assay, ubiquitin pulldown experiments suggested 
that TOP2A is largely monoubiquitinated. Polyubiquitin and monoubiquitin chains are 
known to bind VCP/p97 and Ufd1-Npl4 (Park et al., 2005; Pye et al., 2007; Song et 
al., 2015). Indeed, Ufd1 contains two ubiquitin binding sites which can bind both 
poly- and mono- ubiquitin (Park et al., 2005; Pye et al., 2007). However, double 
siRNA knockdown of Ufd1 and Npl4 did not affect the appearance (or 
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disappearance) of etoposide-induced DSBs, suggesting that Ufd1-Npl4 is not 
required for the VCP/p97-dependent removal of TOP2-DNA complexes. Many 
VCP/p97-associated ubiquitin adaptor proteins have been described which could be 
involved in the processing of TOP2-DNA complexes (Stach and Freemont, 2017). 
FAF1 is another ubiquitin adaptor protein which has been recently implicated in 
chromatin-associated degradation (Franz et al., 2016; van den Boom et al., 2016; 
Stach and Freemont, 2017). Like Ufd1-Npl4, FAF1 can also contribute to the 
removal of trapped Ku70/80 rings from DNA (van den Boom et al., 2016). While Ufd1 
was identified as the principle adaptor protein involved in the VCP/p97-dependent 
removal of Ku70/80 from chromatin, van den Boom et al. show that FAF1 can also 
extract Ku70/80 from DNA when levels of Ufd1 are depleted. The potential role of 
other VCP/p97-associated adaptor proteins should be investigated in future studies. 
VCP/p97 can also bind SUMOylated proteins both directly and via Ufd1, including 
the chromatin-associated DNA damage response protein Rad52 (Nie et al., 2012; 
Bergink et al., 2013). It is known that TOP2-DNA complexes are SUMOylated in 
response to TOP2 poisons (Mao et al., 2000; Agostinho et al., 2008; Schellenberg et 
al., 2017), and therefore VCP/p97 could be involved in the processing of 
SUMOylated TOP2-DNA complexes. Cdc48 (the yeast VCP/p97 homolog) functions 
together with the non-specific protease Wss1 in the degradation of SUMOylated 
protein-DNA adducts, including TOP1 (Balakirev et al., 2015). The effect of VCP/p97 
inhibition on levels of SUMOylated TOP2-DNA complexes was not tested in this 
study, but could be investigated using the TARDIS assay to measure levels of 
SUMOylated TOP2-DNA complexes in the presence and absence of the VCP/p97 
inhibitor, NMS-873. However, given that levels of SUMOylated TOP2-DNA 
complexes are not affected by proteasome inhibition (Chapter 3, Figure 1.29 and 
Chapter 4, Figure 4.12), SUMOylation of TOP2 is unlikely to be involved in the 
regulation of the VCP/p97- and proteasome- dependent processing pathway. 
It is unclear exactly how VCP/p97 facilitates the proteasomal degradation of TOP2-
DNA complexes. However, levels of TOP2-DNA complexes were increased following 
inhibition of VCP/p97 with the allosteric inhibitor NMS-873, directly implicating a role 
for VCP/p97 ATPase activity. Therefore, VCP/p97 is not required simply as a 
scaffold for the delivery of ubiquitinated TOP2 to the proteasome but is likely 
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required for protein unfolding. TOP2 unfolding by VCP/p97 may facilitate the 
translocation of TOP2 through the narrow 20S core, or may enable TOP2 proteolysis 
by extracting TOP2 from DNA. The data presented here indicate a new model of 
TOP2-DNA complex processing by the proteasome, involving the prior unfolding of 
ubiquitinated TOP2-DNA complexes by VCP/p97. 
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Chapter 6 Effect of ubiquitin-proteasome system inhibitors on the 
response to TOP2 poisons 
6.1 Introduction 
Proteasome inhibitors increase the cytotoxicity of TOP2 poisons (Ogiso et al., 2000; 
Congdon et al., 2008b; von Metzler et al., 2009; Lee et al., 2016), and are now FDA- 
and EMA-approved for the treatment of multiple myeloma in combination with other 
chemotherapeutic drugs, including the TOP2 poison doxorubicin. The proteasome is 
involved in many cellular processes including NFκB activation, cell cycle control and 
DNA repair, and this contributes to the potentiation of TOP2 poisons with 
proteasome inhibitors (Ceruti et al., 2006; Jacquemont and Taniguchi, 2007; 
Congdon et al., 2008a; Takeshita et al., 2009; von Metzler et al., 2009). However, 
the proteasome is also involved in the regulation of TOP2 levels and in the removal 
and repair of TOP2-DNA complexes (Ogiso et al., 2000; Congdon et al., 2008b; Lee 
et al., 2016). Therefore, proteasome inhibition may also improve TOP2 poison 
efficacy by prolonging the half-life of drug-induced TOP2-DNA complexes. 
While TOP2B levels remain relatively constant throughout the cell cycle, TOP2A 
levels are regulated by the proteasome in a cell-cycle dependent manner (Woessner 
et al., 1991; Salmena et al., 2001; Eguren et al., 2014). Specifically, levels of TOP2A 
are increased during G2/M phase, where TOP2A mediates the decatenation of sister 
chromatids (DiNardo et al., 1984; Uemura et al., 1987; Clarke et al., 1993; Sumner, 
1995; Porter and Farr, 2004; Bower et al., 2010). After chromosome segregation, 
TOP2A is rapidly degraded in a proteasome-dependent manner, with most TOP2A 
protein degraded during early G1 phase (Salmena et al., 2001). TOP2A is also 
degraded by the proteasome in response to various stresses, including glucose 
starvation, hypoxia and treatment with TOP2 poisons (Mao et al., 2001; Yun et al., 
2004; Alchanati et al., 2009). In each instance, TOP2A degradation occurs in a 
ubiquitin-dependent manner but involves different E3 ubiquitin ligases. For example, 
TOP2A is ubiquitinated by the APC/C complex during early G1 phase (Salmena et 
al., 2001; Eguren et al., 2014), the ECV ligase in response to glucose starvation 
(Yun et al., 2009), Fbw7 in response to HDAC inhibition (Chen et al., 2011), and 
BMI1/RING1A in response to TOP2 poisons (Alchanati et al., 2009).  
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In Chapter 3, it was shown that the proteasomal degradation of etoposide-induced 
TOP2A- and TOP2B- DNA complexes is ubiquitin dependent. Therefore, inhibition of 
relevant E3 ubiquitin ligases may also improve the efficacy of TOP2 poisons by 
preventing the processing and removal of TOP2-DNA complexes. Consistently, 
others have shown that inhibition of the BMI1/RING1A ubiquitin ligase increases the 
cytotoxicity of teniposide in a synergistic manner (Alchanati et al., 2009). HDM2 is a 
RING ubiquitin ligase also implicated in the proteasomal degradation of TOP2A, as 
overexpression of Mdm2 (the murine homolog of human HDM2) is associated with 
increased TOP2A degradation and reduced sensitivity to the TOP2 poison etoposide 
(Nayak et al., 2007). In the current chapter, the XTT assay was used to test the 
effects of BMI1/RING1A inhibition and HDM2 inhibition on the growth-inhibitory 
effects of four clinically relevant TOP2 poisons. 
The processing of TOP2-DNA complexes by the proteasome leads to the liberation 
of protein-free DSBs (Zhang et al., 2006; Fan et al., 2008; Tammaro et al., 2013) 
(see also Figure 3.15). Importantly, TOP2 poison-induced DSBs can participate in 
oncogenic chromosomal translocations following aberrant NHEJ repair, which lead to 
the development of therapy-related leukaemia (Malik et al., 2006; Kantidze and 
Razin, 2007; Cowell and Austin, 2012; Cowell et al., 2012). This suggests that 
proteasomal inhibition may also reduce TOP2 poison genotoxicity by reducing the 
appearance of protein-free DSBs and the likelihood of abnormal DSB repair. In 
support of this, proteasome inhibition significantly reduced etoposide-induced 
plasmid integration (Azarova et al., 2007), and reduced levels of mitoxantrone-
induced micronuclei in K562 cells (Lee, 2016). In Chapter 3, it was shown that the 
appearance of etoposide-induced DSBs is also ubiquitin-dependent (Figure 3.15 and 
Figure 3.16), suggesting that TOP2 poison genotoxicity could also be modulated by 
targeting ubiquitinating enzymes upstream of proteasomal degradation. Hence, 
another aim of the current study was to test the effect of UAE inhibition on the overall 
genotoxicity of etoposide, investigated using the micronucleus assay. 
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6.2 Aims 
The aim of the current study was to investigate the effect of specific ubiquitination 
inhibitors on the growth inhibitory effects of four clinically relevant TOP2 poisons; 
mitoxantrone (an anthracenedione), mAMSA (an acridine), etoposide (an 
epipodophyllotoxin) and doxorubicin (an anthracycline). Additionally, Nalm-6TOP2A+/- 
and Nalm-6TOP2B-/- cells were used to investigate the role of each TOP2 isoform in 
the potentiation of TOP2 poisons with specific E3 ubiquitin ligase inhibitors. The 
micronucleus assay was also used to investigate the effect of the UAE inhibitor 
MLN7243 on the overall genotoxicity of etoposide. 
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6.3 TOP2 expression in Nalm-6 cell lines 
Nalm-6 cells are a human pre-B ALL cell line in which genes can be efficiently 
inactivated by gene targeting (Toyoda et al., 2008). Therefore, Nalm-6 cell lines with 
reduced TOP2A or null for TOP2B expression were used to investigate the roles of 
each TOP2 isoform in the potentiation of TOP2 poisons with ubiquitination inhibitors. 
As Nalm-6TOP2A-/- cells are non-viable, Nalm-6 cells heterozygous for TOP2A (Nalm-
6TOP2A+/- cells) were used to examine the effect of reduced TOP2A expression on the 
response to TOP2 poisons, while TOP2B is absent in Nalm-6TOP2B-/- cells. TOP2 
expression in each cell line was confirmed by immunofluorescence (Figure 6.1). 
 
Figure 6.1. Expression of TOP2 isoforms in Nalm-6 cell lines. Levels of TOP2A and 
TOP2B in Nalm-6 wild-type (WT), Nalm-6TOP2A+/- and Nalm-6TOP2B-/- cells, measured by 
immunofluorescence.   
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6.4 Effect of UAE inhibition on the growth-inhibitory effects of TOP2 poisons 
As shown in Chapter 3, inhibition of ubiquitin activating enzyme (UAE) activity 
prevents the removal and repair of etoposide-induced TOP2-DNA complexes. To 
investigate the effect of UAE inhibition on the growth inhibitory effects of TOP2 
poisons, the XTT assay was first used to determine a sub-lethal dose of the UAE 
inhibitor MLN7243 (equivalent to 20% growth inhibition (Willmore et al., 2004)) for 
use in combination assays.  
The IC20 (concentration at 20% growth inhibition) of MLN7243 was determined by 
treating K562 or Nalm-6 wild type cells with increasing concentrations of MLN7243 
alone. Cells were seeded in 96 well plates and incubated for 24 hours prior to drug 
treatment. Cells were incubated in the presence of MLN7243 for 120 hours, followed 
by staining with XTT reagent. The optical density (OD450nm) of each well was 
measured using the Biorad 550 microplate reader, and used to plot a MLN7243 
dose-response curve. MLN7243 inhibited the growth of both K562 and Nalm-6 cells 
in a dose-dependent manner (Figure 6.2A and B, respectively). The growth of K562 
cells was inhibited by 20% following 120 hours exposure to 47 nM MLN7243. Nalm-6 
cells were significantly less sensitive to MLN7243, with an average IC20 of 400 nM. 
 
Figure 6.2. MLN7243 IC20 determination in Nalm-6 and K562 cells. K562 cells (A) or 
Nalm-6 wild-type cells (B) were treated with increasing concentrations of MLN7243 for 120 
hours. Inhibition of growth was measured by XTT assay and a dose-response curve was 
plotted to determine the IC20 (concentration at 20% growth inhibition) of MLN7243 in each 
cell line. Error bars represent the mean ± SEM of 3 separate experiments.
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To examine the effect of MLN7243 on the growth inhibitory effects of TOP2 poisons, 
Nalm-6 wild type cells were treated with increasing concentrations of TOP2 poison 
alone or in combination with 400 nM MLN7243. TOP2 poisons included mitoxantrone 
(MTX), etoposide (VP-16), mAMSA and doxorubicin. The effect of MLN7243 on the 
growth inhibitory effects of each TOP2 poison was quantified by a potentiation factor 
(Pf50), which was calculated as a ratio of the IC50 of TOP2 poison alone and the IC50 
of TOP2 poison in combination with MLN7243 (Equation 1). Therefore, a Pf50 value 
of 2 indicates a two-fold decrease in the TOP2 poison IC50. Potentiation was deemed 
statistically significant if there was a significant difference between the IC50 of TOP2 
poison alone versus IC50 of TOP2 poison in combination with MLN7243, as 
determined by unpaired t-test. 
Equation 1 
𝑃𝑜𝑡𝑒𝑛𝑡𝑖𝑎𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 (𝑃𝑓50) =
𝐼𝐶50 𝑜𝑓 𝑇𝑂𝑃2 𝑝𝑜𝑖𝑠𝑜𝑛 𝑎𝑙𝑜𝑛𝑒
𝐼𝐶50 𝑜𝑓 𝑇𝑂𝑃2 𝑝𝑜𝑖𝑠𝑜𝑛 + 𝑀𝐿𝑁7243
 
Strikingly, co-incubation of Nalm-6 wild type cells with MLN7243 significantly 
reduced the IC50 of all TOP2 poisons tested (Figure 6.3). For example, the IC50 of 
mitoxantrone was reduced from 5.23 nM to 1.70 nM in the presence of MLN7243, 
equating to a Pf50 of 3.26 (p=0.0004). Individual IC50 and Pf50 values from triplicate 
experiments are displayed in Table 1. The potentiation of doxorubicin with MLN7243 
was noticeably lower than other TOP2 poisons (with a Pf50 of 2.20), but was 
nonetheless statistically significant (p=0.0006). This shows that the growth inhibitory 
effects of TOP2 poisons are substantially increased following UAE inhibition. 
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Figure 6.3. Effect of MLN7243 on the growth inhibitory effects of TOP2 poisons in 
Nalm-6 WT cells. Nalm-6 wild-type (WT) cells were treated with increasing concentrations 
of TOP2 poison alone or in combination with 400 nM MLN7243 for 120 hours, and growth 
inhibition was measured by XTT assay. The IC50 (concentration at 50% growth inhibition) of 
each TOP2 poison alone or in combination with MLN7243 was determined by plotting dose-
response curves. Error bars represent the mean ± SEM of at least 3 separate experiments.   
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    IC50 (nM)     
  n 
TOP2 poison 
alone 
TOP2 poison + 
MLN7243 
Pf50 p value 
Mitoxantrone 
 
 
 
1 5.25 2.3 2.28  
 
*** 
2 5.45 1.35 4.04 
3 5 1.45 3.45 
Mean 5.23 1.70 3.26 0.0004 
Etoposide 
 
 
 
1 144 38 3.79  
 
*** 
2 172 63 2.73 
3 175 58 3.02 
Mean 163.67 53.00 3.18 0.0009 
mAMSA 
 
 
 
1 41 14 2.93  
 
*** 
2 44 13.5 3.26 
3 48 13.5 3.56 
Mean 44.33 13.67 3.25 0.0001 
Doxorubicin 
 
 
 
1 25 13.3 1.88  
 
*** 
2 23.6 11.3 2.09 
3 23.7 9 2.63 
Mean 24.10 11.20 2.20 0.0006 
Table 1. IC50 of TOP2 poisons and the effect of MLN7243 in Nalm-6 wild type cells. IC50 
values of TOP2 poisons alone or in combination with 400 nM MLN7243 are shown from 
three replicate experiments. Individual replicates were used to calculate the Pf50 values from 
each experiment, which were then used to calculate the mean Pf50. Statistical significance 
was determined using an unpaired t-test to compare the IC50 of TOP2 poison alone and the 
IC50 of TOP2 poison in combination with MLN7243 (n=3).  
To investigate the role of TOP2B in the potentiation of TOP2 poisons with MLN7243, 
the XTT assay was repeated in Nalm-6TOP2B-/- cells. Nalm-6TOP2B-/- cells were treated 
with increasing concentrations of mitoxantrone (MTX), etoposide (VP-16), mAMSA 
or doxorubicin for 120 hours, alone or in combination with 400 nM MLN7243. As 
shown in Nalm-6 wild type cells, MLN7243 significantly reduced the IC50 of all TOP2 
poisons tested in Nalm-6TOP2B-/- cells (Figure 6.4, Table 2). For example, the IC50 of 
etoposide was reduced from 169 nM to 104.33 nM in the presence of MLN7243, 
giving a Pf50 of 1.63 (p=0.0001). However, the Pf50 values of mitoxantrone, etoposide 
and mAMSA were significantly smaller in Nalm-6TOP2B-/- cells compared to the 
respective Pf50 values in Nalm-6 wild type cells (p=0.0342, p=0.0086, and p=0.0008). 
For example, the Pf50 of mAMSA is almost 2-fold greater in Nalm-6 wild type cells 
compared to Nalm-6TOP2B-/- cells (Pf50 = 3.25 in wild type cells, compared to Pf50 = 
1.25 in Nalm-6TOP2B-/- cells). In contrast, the potentiation of doxorubicin by MLN7243 
treatment was not significantly affected by TOP2B knockout, suggesting that the 
potentiation of doxorubicin by MLN7243 is mediated via TOP2-independent 
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mechanisms. Alternatively, the potentiation of doxorubicin with MLN7243 may be 
mediated by TOP2A. With the exception of doxorubicin, this suggests that the 
potentiation of MLN7243 is mediated by both TOP2A and TOP2B. Importantly, the 
concentration of MLN7243 used in combination assays with Nalm-6TOP2B-/- cells 
corresponds to the IC20 of MLN7243 previously determined in Nalm-6 wild type cells. 
Indeed, the IC20 of MLN7243 in Nalm-6TOP2B-/- cells was not measured in this study, 
and so we cannot eliminate the possibility that Nalm-6TOP2B-/- cells are simply less 
sensitive to MLN7243. 
 
Figure 6.4. Effect of MLN7243 on the growth inhibitory effects of TOP2 poisons in 
Nalm-6TOP2B-/- cells. Nalm-6TOP2B-/- cells were treated with increasing concentrations of TOP2 
poison alone or in combination with 400 nM MLN7243 for 120 hours, and growth inhibition 
was measured by XTT assay. The IC50 (concentration at 50% growth inhibition) of each 
TOP2 poison alone or in combination with MLN7243 was determined by plotting dose-
response curves. Error bars represent the mean ± SEM of at least 3 separate experiments.   
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    IC50 (nM)       
  n 
TOP2 poison 
alone 
TOP2 poison 
+ MLN7243 
Pf50 p value 
Pf50 
TOP2B-/- 
vs WT 
Mitoxantrone 
 
 
 
1 20.8 13.5 1.54  
 
*** 
 
 
* 
2 19 12 1.58 
3 21 12.2 1.72 
Mean 20.27 12.57 1.62 0.0006 0.0342 
Etoposide 
 
 
1 168 113 1.49  
 
 
*** 
 
 
 
** 
2 170 100 1.70 
3 169 100 1.69 
Mean 169.00 104.33 1.63 0.0001 0.0086 
mAMSA 
 
 
 
1 136 136 1.00  
 
NS 
 
 
*** 
2 138 100 1.38 
3 136 99 1.37 
Mean 136.67 111.67 1.25 0.1095 0.0008 
Doxorubicin 
 
 
 
1 28.5 17 1.68  
 
** 
 
 
NS 
2 28.8 10.3 2.80 
3 25.4 13.7 1.85 
Mean 27.57 13.67 2.11 0.0033 0.8385 
Table 2. IC50 of TOP2 poisons and the effect of MLN7243 in Nalm-6TOP2B-/- cells. IC50 
values of TOP2 poisons alone or in combination with 400 nM MLN7243 are shown from 
three replicate experiments. Individual replicates were used to calculate the Pf50 values from 
each experiment, which were then used to calculate the mean Pf50. Statistical significance 
was determined using an unpaired t-test to compare the IC50 of TOP2 poison alone and the 
IC50 of TOP2 poison in combination with MLN7243 (n=3). Unpaired t-test was also used to 
compare the Pf50 values of each TOP2 poison in Nalm-6TOP2B-/- cells with that of Nalm-6 wild 
type cells.  
Nalm-6 cells contain wild type p53 (Adachi et al., 2006), which mediates cell cycle 
arrest or apoptosis in response to DNA damage through the transcriptional activation 
of various genes, including p21 and Bcl-2. p53 is degraded by the proteasome in a 
ubiquitin-dependent manner, and therefore inhibition of ubiquitination may increase 
TOP2 poison cytotoxicity through the upregulation of p53. In contrast, K562 cells are 
null for p53 (Law et al., 1993). To test the effect of MLN7243 in the absence of 
functional p53, the XTT potentiation assay was also performed in K562 cells. 
K562 cells were treated with increasing concentrations of mitoxantrone (MTX), 
etoposide (VP-16), mAMSA or doxorubicin alone or in combination with 47 nM 
MLN7243 (the IC20 of MLN7243 in these cells), and growth inhibition was measured 
by XTT assay (Figure 6.5). MLN7243 significantly reduced the IC50 of mitoxantrone 
from 14.33 nM to 8.17 nM, giving a Pf50 value of 1.74 (p=0.0275) (Table 3). In 
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addition, the IC50 of mAMSA was significantly reduced from 49 to 36 nM (p=0.0193, 
Pf50=1.4). While statistically significant, the Pf50 values of mitoxantrone and mAMSA 
with MLN7243 in K562 cells are noticeably smaller than those observed in Nalm-6 
wild type cells. Furthermore, MLN7243 did not significantly affect the IC50 of 
etoposide or doxorubicin in K562 cells but did in Nalm-6 wild type cells. Therefore, 
the effect of MLN7243 on the growth inhibitory effects of TOP2 poisons varies in 
different cell lines. While this could be due to other cell-specific differences, the 
sensitivity of Nalm-6 cells to the combination of TOP2 poisons with MLN7243 may 
be attributed to the upregulation of functional p53 protein, which is no longer 
proteasomally degraded. However, the potential upregulation of p53 following 
MLN7243 treatment was not determined in this study. 
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Figure 6.5. Effect of MLN7243 on the growth inhibitory effects of TOP2 poisons in 
K562 cells. K562 cells were treated with increasing concentrations of TOP2 poison alone or 
in combination with 47 nM MLN7243 for 120 hours, and growth inhibition was measured by 
XTT assay. The IC50 (concentration at 50% growth inhibition) of each TOP2 poison alone or 
in combination with MLN7243 was determined by plotting dose-response curves. Error bars 
represent the mean ± SEM of at least 3 separate experiments.
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  IC50 (nM)     
n 
TOP2 poison 
alone 
TOP2 poison + 
MLN7243 
Pf50 p value 
Mitoxantrone 
 
 
 
1 17 9 1.89  
 
* 
2 15 8 1.88 
3 11 7.5 1.47 
Mean 14.33 8.17 1.74 0.0275 
Etoposide 
 
 
 
1 252 195 1.29  
 
 
NS 
2 177 198 0.89 
3 160 140 1.14 
Mean 196.33 177.67 1.11 0.6119 
mAMSA 
 
 
 
1  45 39  1.15  
 
* 
2  55 30  1.83 
3  47 39  1.21 
Mean  49 36   1.40 0.0193  
Doxorubicin 
 
 
 
1 20 19 1.05  
 
NS 
2 24 22 1.09 
3 27 20.5 1.32 
Mean 23.67 20.50 1.15 0.2243 
Table 3. IC50 of TOP2 poisons and the effect of MLN7243 in K562 cells. IC50 values of 
TOP2 poisons alone or in combination with 47 nM MLN7243 are shown from three replicate 
experiments. Individual replicates were used to calculate the Pf50 values from each 
experiment, which were then used to calculate the mean Pf50. Statistical significance was 
determined using an unpaired t-test to compare the IC50 of TOP2 poison alone and the IC50 
of TOP2 poison in combination with MLN7243 (n=3).  
6.1 Effect of specific E3 ubiquitin ligase inhibition on the growth-inhibitory 
effects of TOP2 poisons 
BMI1/RING1A is directly implicated in the ubiquitin-dependent degradation of TOP2A 
following teniposide treatment, and inhibition of BMI1/RING1A increases the 
cytotoxicity of teniposide in a synergistic manner (Alchanati et al., 2009). HDM2 is 
another E3 ubiquitin ligase implicated in the downregulation of TOP2A upon 
etoposide treatment, although this may be due to the HDM2-dependent export of 
TOP2A from the nucleus, as previously described for p53 (Nayak et al., 2007). 
Inhibition of E3 ubiquitin ligases may improve the efficacy of TOP2 poisons without 
inhibiting proteasomal activity. To investigate this, the XTT potentiation assay was 
performed in Nalm-6 cells following treatment with TOP2 poisons alone or in 
combination with specific E3 ubiquitin ligase inhibitors. 
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6.1.1 Effect of BMI1/RING1A inhibition on the growth-inhibitory effects of TOP2 
poisons 
PRT4165 is a small molecule inhibitor of the E3 ubiquitin ligase BMI1/RING1A which 
was shown to inhibit the teniposide-induced degradation of TOP2A-DNA complexes 
and the auto-ubiquitination of BMI1/RING1A (Alchanati et al., 2009). The IC20 of 
PRT4165 (concentration at 20% growth inhibition) in each cell line was determined 
by XTT assay. As these values were not significantly different between cell lines, the 
average IC20 of PRT4165 (35µM) was used in all subsequent experiments. 
 
Figure 6.6. PRT4165 IC20 determination in Nalm-6 cell lines. Nalm-6 wild-type (WT), 
Nalm-6TOP2A+/- and Nalm-6TOP2B-/- cells were treated with increasing concentrations of 
PRT4165 for 120 hours. Inhibition of growth was measured by XTT assay and a dose-
response curve was plotted to determine the IC20 (concentration at 20% growth inhibition) of 
PRT4165 in each cell line. Error bars represent the mean ± SEM of 3 separate experiments.  
Nalm-6 cells were treated with increasing concentrations of TOP2 poison alone or in 
combination with 35 µM PRT4165, and growth inhibition was measured by XTT 
assay (Table 4, see also Figure 6.7 – Figure 6.10). Incubation of cells with PRT4165 
significantly reduced the IC50 of mitoxantrone (p=0.0454), mAMSA (p=0.0021) and 
etoposide (p=0.0263). This effect was greatest with mAMSA, producing a mean Pf50 
of 1.83 (Table 4). In contrast, the IC50 of doxorubicin was not significantly affected by 
BMI1/RING1A inhibition (IC50 = 13.8nM compared to 12.9nM with doxorubicin 
alone). This suggests that the growth inhibitory effect of TOP2 poisons (excluding 
doxorubicin) can be increased by inhibition of the BMI1/RING1A ubiquitin ligase. 
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Figure 6.7. Effect of BMI1/RING1A inhibition on the growth inhibitory effect of 
mitoxantrone in Nalm-6 cell lines. Nalm-6 wild-type (WT), Nalm-6TOP2A+/- and Nalm-6TOP2B-/- 
cells were treated with increasing concentrations of mitoxantrone alone or in combination 
with 35 µM PRT4165 for 120 hours, and growth inhibition was measured by XTT assay. The 
IC50 (concentration at 50% growth inhibition) of mitoxantrone alone or in combination with 
PRT4165 was determined by plotting dose-response curves. Error bars represent the mean 
± SEM of at least 3 separate experiments.  
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Figure 6.8. Effect of BMI1/RING1A inhibition on the growth inhibitory effect of 
etoposide (VP-16) in Nalm-6 cell lines. Nalm-6 wild-type (WT), Nalm-6TOP2A+/- and Nalm-
6TOP2B-/- cells were treated with increasing concentrations of etoposide (VP-16) alone or in 
combination with 35 µM PRT4165 for 120 hours, and growth inhibition was measured by 
XTT assay. The IC50 (concentration at 50% growth inhibition) of etoposide alone or in 
combination with PRT4165 was determined by plotting dose-response curves. Error bars 
represent the mean ± SEM of at least 3 separate experiments.  
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Figure 6.9. Effect of BMI1/RING1A inhibition on the growth inhibitory effect of mAMSA 
in Nalm-6 cell lines. Nalm-6 wild-type (WT), Nalm-6TOP2A+/- and Nalm-6TOP2B-/- cells were 
treated with increasing concentrations of mAMSA alone or in combination with 35 µM 
PRT4165 for 120 hours, and growth inhibition was measured by XTT assay. The IC50 
(concentration at 50% growth inhibition) of mAMSA alone or in combination with PRT4165 
was determined by plotting dose-response curves. Error bars represent the mean ± SEM of 
at least 3 separate experiments.  
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Figure 6.10. Effect of BMI1/RING1A inhibition on the growth inhibitory effect of 
doxorubicin in Nalm-6 cell lines. Nalm-6 wild-type (WT), Nalm-6TOP2A+/- and Nalm-6TOP2B-/- 
cells were treated with increasing concentrations of doxorubicin alone or in combination with 
35 µM PRT4165 for 120 hours, and growth inhibition was measured by XTT assay. The IC50 
(concentration at 50% growth inhibition) of doxorubicin alone or in combination with 
PRT4165 was determined by plotting dose-response curves. Error bars represent the mean 
± SEM of at least 3 separate experiments.  
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In order to examine the role of each TOP2 isoform in the potentiation of TOP2 
poisons with PRT4165, growth inhibition assays were also performed Nalm-6TOP2A+/- 
and Nalm-6TOP2B-/- cells (Figure 6.7 – Figure 6.10). Nalm-6TOP2A+/- and Nalm-6TOP2B-/- 
cells are more resistant to TOP2 poisons, as demonstrated by an increase in TOP2 
poison IC50. Consistent with published data, knockout of TOP2B conferred greater 
resistance to mAMSA and mitoxantrone (MTX), while Nalm-6TOP2A+/- cells were most 
resistant to etoposide (VP-16) and doxorubicin compared to wild type cells (Toyoda 
et al., 2008; Lee et al., 2016). Therefore, both TOP2A and TOP2B are important 
drug targets which mediate TOP2 poison-induced growth inhibition. 
PRT4165 did not significantly affect the IC50 of mAMSA in Nalm-6TOP2A+/- cells 
(p=0.6755, Pf50 = 1.33), but significantly reduced the IC50 of mAMSA in Nalm-6TOP2B-/- 
cells similarly to wild-type (p=0.0129, Pf50 = 1.85) (Table 4). This suggests that 
TOP2B is dispensable for the potentiation of mAMSA with PRT4165. In contrast, the 
potentiation of etoposide with PRT4165 remained significant in both Nalm-6TOP2A+/- 
cells and Nalm-6TOP2B-/- cells (p=0.0165 and p=0.0119, respectively). Similarly, 
potentiation of mitoxantrone with PRT4165 was also observed in Nalm-6TOP2A+/- cells 
and Nalm-6TOP2B-/- cells (Pf50=1.67 and 1.76, respectively, compared to 1.45 in Nalm-
6 wild type cells). As in Nalm-6 wild-type cells, PRT4165 did not affect the IC50 of 
doxorubicin in Nalm-6TOP2A+/- or Nalm-6TOP2B-/- cells (p=0.1933, 0.5640, respectively). 
  
  
Nalm-6 WT Nalm-6TOP2A+/- Nalm-6TOP2B-/- 
Pf50 SEM Pf50 SEM Pf50 SEM 
Mitoxantrone (n=6) 1.45 0.16 1.36 0.17 1.76 0.15 
mAMSA (n=3) 1.83 0.20 1.33 0.48 1.85 0.21 
VP-16 (n=3) 1.42 0.11 1.58 0.08 1.62 0.12 
Doxorubicin (n=3) 0.94 0.03 0.89 0.03 0.94 0.03 
Table 4. Potentiation factor (Pf50) values of TOP2 poisons in combination with 
PRT4165 in Nalm-6 cell lines. Potentiation factors were calculated by dividing the IC50 of 
TOP2 poison alone by the IC50 of TOP2 poison in combination with PRT4165. Pf50 values 
represent the mean Pf50 from at least three biological replicates.  
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6.1.2 Effect of HDM2 inhibition on the growth-inhibitory effects of TOP2 
poisons 
While best known for its role in the ubiquitin-dependent proteasomal degradation of 
p53, HDM2 has also been implicated in the downregulation of TOP2A following 
etoposide treatment (Nayak et al., 2007). The effect of HDM2 inhibition of the growth 
inhibitory effects of TOP2 poisons was investigated using the XTT assay following 
co-treatment of cells with HLI373. HLI373 is a small molecule HDM2 inhibitor of the 
HLI98 class of compounds shown to inhibit the ubiquitination and proteasomal 
degradation of p53, leading to p53-dependent cell death (Kitagaki et al., 2008). While 
many HDM2 inhibitors target the HDM2-p53 interaction, the HLI98 class of HDM2 
inhibitors specifically inhibit the E3 ubiquitin ligase activity of HDM2 (Yang et al., 
2005), and hence will affect the ubiquitination of other HDM2 substrates. The precise 
mechanism of inhibition by the HLI98 family of inhibitors is unclear, but may involve 
the inhibition of the HDM2 RING finger domain (which is essential for E3 ligase 
activity) or inhibition of the interaction of HDM2 with E2 conjugating enzymes (Yang 
et al., 2005). 
Firstly, the IC20 of HLI373 in Nalm-6 wild type, Nalm-6TOP2A+/- and Nalm-6TOP2B-/- cells 
was determined by XTT assay for use in combination experiments. Cells were 
treated with increasing concentrations of HLI373 for 120 hours. As expected, HLI373 
efficiently inhibited the growth of each Nalm-6 cell line (Figure 6.11). There were no 
significant differences between the IC20 of HLI373 in each cell line, and so an 
average concentration of 2.7 µM HLI373 was used in all subsequent potentiation 
experiments in Nalm-6 cell lines. 
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Figure 6.11. HLI373 IC20 determination in Nalm-6 cell lines. Nalm-6 wild-type (WT), Nalm-
6TOP2A+/- and Nalm-6TOP2B-/- cells were treated with increasing concentrations of HLI373 for 
120 hours. Inhibition of growth was measured by XTT assay and a dose-response curve was 
plotted to determine the IC20 (concentration at 20% growth inhibition) of HLI373 in each cell 
line. Error bars represent the mean ± SEM of 3 separate experiments.  
Nalm-6 wild-type cells were treated with increasing concentrations of TOP2 poison 
alone or in combination with 2.7 µM HLI373 (see Figure 6.12 – Figure 6.15). The 
IC50 of mAMSA was significantly reduced in the presence of HLI373 (p=0.0135), 
while HDM2 inhibition did not affect the IC50 of any other TOP2 poison tested (Table 
5). The potentiation of mAMSA by HLI373 was also observed in Nalm-6TOP2A+/- cells 
(p=0.0002), but was abolished in Nalm-6TOP2B-/- cells (p=0.3262). This suggests that 
TOP2B is required for the HLI373-mediated potentiation of mAMSA in Nalm-6 cells. 
While HDM2 inhibition did not significantly affect the IC50 of mitoxantrone or 
etoposide in wild type cells, the growth inhibitory effects of mitoxantrone and 
etoposide were significantly increased by HLI373 treatment in Nalm-6TOP2A+/- cells  
(p=0.0009 and p=0.038), with Pf50 values of 1.69 and 1.34, respectively (Table 5, 
see also Figure 6.12 – Figure 6.15). Mitoxantrone and etoposide were also 
significantly potentiated by HLI373 in Nalm-6TOP2B-/- cells (Pf50 = 1.95 and 1.48, 
respectively), suggesting that TOP2B is not involved in the potentiation of 
mitoxantrone and etoposide with HLI373. However, this also shows that HDM2 
inhibition increases mitoxantrone and etoposide sensitivity in cells expressing lower 
levels of TOP2, which is associated with TOP2 poison resistance (Ogiso et al., 2000; 
Congdon et al., 2008a). Therefore, HDM2 inhibitors may be clinically useful in 
combination with TOP2 poisons to reduce TOP2 poison resistance. 
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Figure 6.12. Effect of HDM2 inhibition on the growth inhibitory effect of mitoxantrone 
in Nalm-6 cell lines. Nalm-6 wild-type (WT), Nalm-6TOP2A+/- and Nalm-6TOP2B-/- cells were 
treated with increasing concentrations of mitoxantrone alone or in combination with 2.7 µM 
HLI373 for 120 hours, and growth inhibition was measured by XTT assay. The IC50 
(concentration at 50% growth inhibition) of mitoxantrone alone or in combination with HLI373 
was determined by plotting dose-response curves. Error bars represent the mean ± SEM of 
at least 3 separate experiments.  
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Figure 6.13. Effect of HDM2 inhibition on the growth inhibitory effect of etoposide (VP-
16) in Nalm-6 cell lines. Nalm-6 wild-type (WT), Nalm-6TOP2A+/- and Nalm-6TOP2B-/- cells were 
treated with increasing concentrations of etoposide (VP-16) alone or in combination with 2.7 
µM HLI373 for 120 hours, and growth inhibition was measured by XTT assay. The IC50 
(concentration at 50% growth inhibition) of etoposide alone or in combination with HLI373 
was determined by plotting dose-response curves. Error bars represent the mean ± SEM of 
at least 3 separate experiments.  
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Figure 6.14. Effect of HDM2 inhibition on the growth inhibitory effect of mAMSA in 
Nalm-6 cell lines. Nalm-6 wild-type (WT), Nalm-6TOP2A+/- and Nalm-6TOP2B-/- cells were 
treated with increasing concentrations of mAMSA alone or in combination with 2.7 µM 
HLI373 for 120 hours, and growth inhibition was measured by XTT assay. The IC50 
(concentration at 50% growth inhibition) of mAMSA alone or in combination with HLI373 was 
determined by plotting dose-response curves. Error bars represent the mean ± SEM of at 
least 3 separate experiments.  
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Figure 6.15. Effect of HDM2 inhibition on the growth inhibitory effect of doxorubicin in 
Nalm-6 cell lines. Nalm-6 wild-type (WT), Nalm-6TOP2A+/- and Nalm-6TOP2B-/- cells were 
treated with increasing concentrations of doxorubicin alone or in combination with 2.7 µM 
HLI373 for 120 hours, and growth inhibition was measured by XTT assay. The IC50 
(concentration at 50% growth inhibition) of doxorubicin alone or in combination with HLI373 
was determined by plotting dose-response curves. Error bars represent the mean ± SEM of 
at least 3 separate experiments.  
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Nalm-6 WT Nalm-6TOP2A+/- Nalm-6TOP2B-/- 
Pf50 SEM Pf50 SEM Pf50 SEM 
Mitoxantrone n=6 1.20 0.17 1.69 0.11 1.95 0.14 
mAMSA n=3 1.52 0.08 1.33 0.02 1.18 0.14 
VP-16 n=6 1.09 0.04 1.34 0.06 1.48 0.15 
Doxorubicin n=3 1.21 0.10 1.06 0.04 1.02 0.07 
Table 5. Potentiation factor (Pf50) values of TOP2 poisons in combination with HLI373 
in Nalm-6 cell lines. Potentiation factors were calculated by dividing the IC50 of TOP2 
poison alone by the IC50 of TOP2 poison in combination with HLI373. Pf50 values represent 
the mean Pf50 from at least three biological replicates.  
6.2 Effect of MLN7243 on the overall genotoxicity of etoposide 
UAE inhibition prevents the processing of etoposide-induced TOP2-DNA complexes 
to DSBs (Chapter 3). It was therefore hypothesised that UAE inhibition would reduce 
the likelihood of oncogenic chromosome translocations which arise due to mis-repair 
of protein-free DSBs following treatment with a TOP2 poison. As a surrogate for 
specific chromosome translocations which occur at a very low frequency, the 
micronucleus assay was used to test the effect of UAE inhibitor MLN7243 on overall 
etoposide genotoxicity.  
The following experiments were designed according to the OECD guidelines for the 
testing of potentially genotoxic chemicals. For example, cells were incubated with 
test substance for 48 hours to ensure that all cells have completed at least one 
round of mitosis. Another important consideration is the cytotoxicity of etoposide 
alone and in combination with MLN7243, as false positive results can arise due to 
secondary cytotoxic effects (Galloway, 2000). Therefore, cells were treated with a 
sub-lethal concentration of etoposide and MLN7243 which corresponds to the IC20 
as determined previously by XTT assay. In addition, apoptotic and necrotic cells 
were identified through incubation of cells with 2 µg/mL ethidium monoazide bromide 
(EMA). EMA is a cell-impermeable nucleic acid dye which labels the DNA of cells 
with damaged membranes. EMA-stained cells were detected by fluorescence 
microscopy and excluded from the analysis. 
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K562 cells were treated with 120 nM etoposide (VP-16) alone or in combination with 
47 nM MLN7243 for 48 hours. Cells were also incubated with 20 µM or 50 µM methyl 
methanesulfonate (MMS), a known clastogen, as a positive control. According to the 
OECD guidelines, it is important to demonstrate that all cells have completed at least 
one round of cell division, and to monitor the cytotoxicity of drug treatments. Thus, 
cells were counted before and after drug treatment, and cell counts were used to 
calculate the Relative Increase in Cell Count (RICC). RICC is expressed as a 
percentage of cell growth in treated cells compared to untreated cells (Equation 2). 
Equation 2 
𝑅𝐼𝐶𝐶 =
(𝐼𝑛𝑐𝑟𝑒𝑎𝑠𝑒 𝑖𝑛 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑢𝑙𝑡𝑢𝑟𝑒𝑠(𝑓𝑖𝑛𝑖𝑠ℎ − 𝑠𝑡𝑎𝑟𝑡𝑖𝑛𝑔))
(𝐼𝑛𝑐𝑟𝑒𝑎𝑠𝑒 𝑖𝑛 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 (𝑓𝑖𝑛𝑖𝑠ℎ − 𝑠𝑡𝑎𝑟𝑡𝑖𝑛𝑔))
× 100 
As expected, MMS reduced the RICC in a dose-dependent manner, which was 
reduced to 51% following exposure to 20 µM MMS and 31% following 50 µM MMS 
(Figure 6.16). Consistently, treatment of cells with 120 nM etoposide also reduced 
the RICC by approximately 50%. MLN7243 alone reduced cell viability by 54%, while 
co-treatment with both etoposide and MLN7243 further reduced the RICC to 26%. 
According to the OECD guidelines, compounds are considered cytotoxic when the 
RICC is reduced to less than 40%. Therefore, due to the cytotoxicity of etoposide in 
combination with MLN7243 the following micronuclei data should be interpreted with 
caution. In contrast, no significant changes in cell viability were detected by trypan 
blue exclusion (Figure 6.16). 
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Figure 6.16. Cell viability of cells treated with etoposide alone or in combination with 
MLN7243. K562 cells were treated with 120 nM etoposide (VP-16) alone or in combination 
with 47 nM MLN7243 (or 20 µM and 50 µM MMS as a positive control) for 48 hours. Cell 
viability was measured by Relative Increase in Cell Count (RICC) and trypan blue exclusion. 
Error bars represent the mean ± SEM of 3 separate experiments. Statistical comparisons 
were made by unpaired t-test (n=3).  
Cells were incubated with EMA prior to fixing on microscope slides. Micronuclei were 
detected by staining of cells with Hoechst DNA stain, and quantified by manual 
counting of at least 2000 cells per condition. The induction of micronuclei was 
expressed by percentage of cells containing micronuclei (% micronuclei, Equation 3), 
which was then used to determine the fold change in % micronuclei as shown in 
Equation 4. 
Equation 3 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑐𝑒𝑙𝑙𝑠 𝑤𝑖𝑡ℎ 𝑚𝑖𝑐𝑟𝑜𝑛𝑢𝑐𝑙𝑒𝑖
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑
× 100 = % 𝑚𝑖𝑐𝑟𝑜𝑛𝑢𝑐𝑙𝑒𝑖 
Equation 4 
𝐷𝑟𝑢𝑔 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 (𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑚𝑖𝑐𝑟𝑜𝑛𝑢𝑐𝑙𝑒𝑖 %)
𝑈𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 (𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑚𝑖𝑐𝑟𝑜𝑛𝑢𝑐𝑙𝑒𝑖 %)
= 𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 
As expected, the number of cells containing micronuclei were significantly increased 
in the presence of 50 µM MMS (p=0.0047), though were not significantly affected 
following exposure to 20 µM MMS (Figure 6.17). In addition, 3% of etoposide-treated 
cells contained micronuclei compared to 0.6% of untreated cells (p= 0.0138), while 
MLN7243 alone did not significantly induce micronuclei (p= 0.1208). According to the 
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OECD guidelines, a substance is classified as genotoxic when the % micronuclei is 
increased by a 2-fold change over untreated control. Etoposide induced an 
approximately 23-fold increase in micronuclei levels compared to untreated control 
(Figure 6.17). Micronuclei were induced by 10-fold when etoposide-treated cells 
were also co-incubated with MLN7243, although this was not significantly different to 
etoposide alone. Furthermore, MLN7243 did not significantly affect levels of 
etoposide-induced micronuclei when measured by percentage of cells containing 
micronuclei (% micronuclei, p=0.1850). Therefore contrary to the hypothesised 
effect, UAE inhibition does not significantly affect etoposide genotoxicity, as 
measured by micronucleus assay. However, it is important to note that these 
experiments did not meet strict OECD conditions due to the high cytotoxicity of 
etoposide in combination with MLN7243. Therefore, some micronuclei induced in 
these conditions may be due to secondary cytotoxic effects, thereby skewing the 
interpretation of results. 
 
Figure 6.17. Effect of MLN7243 on etoposide-induced micronucleus formation. K562 
cells were treated with 120 nM etoposide (VP-16) alone or in combination with 47 nM 
MLN7243 (or 20 µM and 50 µM MMS as a positive control) for 48 hours. After staining of 
cells with EMA to identify apoptotic cells, cells were fixed in paraformaldehyde and DNA was 
stained with Hoechst 33258. Micronuclei were counted manually and expressed as % 
micronucleated cells and fold change in micronuclei induction (compared to the 50 µM MMS 
control). Statistical comparisons were made by unpaired t-test (n=3).  
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6.3 Discussion 
The ubiquitin-proteasome system is involved in the regulation of many cellular 
processes and is implicated in various diseases. This has stimulated a widespread 
clinical interest in the development of specific inhibitors targeting multiple steps in the 
ubiquitin-proteasome pathway, especially following the regulatory body approval of 
the proteasome inhibitor bortezomib (Velcade). In the current chapter, inhibition of 
UAE activity significantly increased the growth-inhibitory effects of four clinically used 
TOP2 poisons. Like proteasome inhibition, UAE inhibition leads to the upregulation 
of key proteins involved in cell cycle arrest and apoptosis, including the tumour 
suppressor p53. Indeed, the potentiation of TOP2 poisons with MLN7243 was 
greater in the wild type p53 Nalm-6 cell line than in p53-null K562 cells, suggesting 
that increased growth inhibition may be partly due to p53 upregulation. However, 
UAE inhibition also reduces the processing and repair of TOP2-DNA complexes 
(Chapter 3), and the potentiation of TOP2 poisons with MLN7243 was reduced in 
Nalm-6TOP2B-/- cells compared to wild type cells. This suggests that TOP2B is 
involved in the potentiation of TOP2 poisons by MLN7243 due to reduced repair of 
TOP2B-DNA complexes. 
While proteasome inhibitors are surprisingly well tolerated in patients, the 
proteasome is involved in the regulation of many proteins, and a potentially superior 
approach may be the inhibition of specific ubiquitinating enzymes. There are over 
600 E3 ubiquitin ligases in human cells, which mediate the proteasomal degradation 
of specific substrates. While the identification of relevant E3 ubiquitin ligases for a 
particular target is challenging, multiple E3 enzymes have been shown to regulate 
the proteasomal degradation of TOP2A, including the ECV ligase, Fbw7 and Hdm2 
(Nayak et al., 2007; Yun et al., 2009; Chen et al., 2011). Specifically, BMI1/RING1A 
is involved in the ubiquitination and proteasomal degradation of TOP2A-DNA 
complexes following teniposide treatment (Alchanati et al., 2009), and inhibition of 
BMI1/RING1A slows the processing of TOP2-DNA complexes to DSBs (Chapter 3). 
In the current study, inhibition of BMI1/RING1A also increased the growth-inhibitory 
effects of three TOP2 poisons, including mitoxantrone, etoposide, and mAMSA. 
Similarly, HDM2 inhibition increased the growth-inhibitory effects of mAMSA in Nalm-
6 wild type cells, and sensitised Nalm-6TOP2A+/- and Nalm-6TOP2B-/- cells to 
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mitoxantrone and etoposide. Therefore, the efficacy of TOP2 poisons can be 
increased through inhibition of specific E3 ubiquitin ligases. 
However, PRT4165 may potentiate TOP2 poisons in ways other than through 
reduced processing of TOP2A covalent complexes. Importantly, PRT4165 also 
inhibits BMI1/RING1B (Ismail et al., 2013), which functions as part of the polycomb 
repressive complex (PRC1) to mediate the ubiquitination of histones during the DNA 
damage response (Facchino et al., 2010; Ismail et al., 2010; Ginjala et al., 2011; Pan 
et al., 2011). Consequently, PRT4165 inhibits ubiquitin signalling at DSBs which is 
ultimately required for DNA repair (Ismail et al., 2013). Therefore, the potentiation of 
TOP2 poisons with PRT4165 may be at least partly due to inhibition of repair of the 
TOP2-mediated DSB. 
Similarly, HDM2 is involved in the ubiquitin-dependent degradation of essential 
tumour suppressor proteins such as p53 and the retinoblastoma (Rb) protein (Sdek 
et al., 2005; Uchida et al., 2005; Miwa et al., 2006). Therefore, the upregulation of 
these proteins upon HDM2 inhibition may also account for increased cell cycle arrest 
and inhibition of growth in Nalm-6 cell lines. However, the reduced etoposide 
sensitivity of cells overexpressing Mdm2 is independent of p53 (Nayak et al., 2007; 
Senturk et al., 2017). Furthermore, the Mdm2 inhibitor PXN822 increases the 
sensitivity of murine PDAC cells to etoposide regardless of p53 status (Conradt et 
al., 2013). Nayak et al. suggest that HDM2 mediates the export of TOP2A from the 
nucleus, as previously described for p53. Therefore, HDM2 inhibition may increase 
the efficacy of TOP2 poisons by increasing the levels of TOP2A in the nucleus. 
Although effective anticancer agents, TOP2 poisons are also associated with the 
development of secondary leukaemias, which are thought to arise following the 
aberrant NHEJ repair of the enzyme-induced DSB. In addition to increasing drug 
cytotoxicity, inhibition of the ubiquitin-proteasome system may reduce TOP2 poison 
genotoxicity by preventing the processing of TOP2-DNA complexes to protein-free 
DSBs. The micronucleus assay is routinely used as a measure of overall 
genotoxicity, and was used here to investigate the effect of UAE inhibition on the 
genotoxicity of etoposide. Using this approach, micronuclei induction was 
successfully detected following treatment of cells with two known genotoxic 
compounds (MMS and etoposide). Levels of etoposide-induced micronuclei were not 
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significantly affected by the co-treatment of cells with MLN7243, suggesting that 
inhibition of ubiquitination does not dramatically affect TOP2 poison genotoxicity. 
However, the number of cells containing micronuclei varied significantly between 
individual experiments, as indicated by the large standard error. Therefore, this 
method may not be suitable for detecting small changes between different 
conditions. In addition, micronuclei were counted manually and are therefore subject 
to investigator bias and human error. Because of these technical limitations, the 
effect of UAE inhibition on the genotoxicity of TOP2 poisons warrants further 
investigation. 
In summary, the growth inhibitory effects of TOP2 poisons can be increased upon 
co-treatment of cells with small molecule inhibitors of the ubiquitin-proteasome 
system. Given the clinical availability of proteasome inhibitors and the ongoing 
investigation of MLN7243 in phase I clinical trials, combination therapies with UPS 
inhibitors may present an easily translatable approach to the improvement of therapy 
with TOP2 poisons.  
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Chapter 7 Discussion 
The processing of drug-stabilised TOP2-DNA complexes is a major step in the repair 
of TOP2 poison-mediated DNA damage. The removal of covalently bound TOP2 
from DNA liberates the otherwise concealed DSB, which is then repaired 
predominantly by NHEJ. Multiple pathways have been shown to remove TOP2 
complexes from DNA, but the appearance of etoposide-induced DSBs is largely 
proteasome-dependent (see Chapter 3, Figure 3.15A). Despite this, the regulation of 
the proteasomal processing pathway is poorly understood. In particular, conflicting 
studies have reported both ubiquitin-dependent and ubiquitin-independent pathways 
of TOP2B-DNA complex processing following inactivation of UAE1 (the primary 
ubiquitin activating enzyme) in temperature-sensitive ts85 cells (Mao et al., 2001; 
Ban et al., 2013), while the proteasome-dependent processing of TOP2A-DNA 
complexes was shown to involve the E3 ubiquitin ligase, BMI1/RING1A (Alchanati et 
al., 2009). A major aim of this project was therefore to clarify the ubiquitin-
dependence of TOP2A- and TOP2B- DNA complex processing following etoposide 
treatment. This was investigated primarily through targeting of both UAE in human 
cells, namely UAE1 and UBA6, by small molecule inhibition and siRNA knockdown. 
The effect of UAE inhibition on the processing of drug-stabilised TOP2-DNA 
complexes was assessed by the direct measurement of TOP2-DNA complexes 
using the TARDIS assay, and through the appearance of etoposide-induced DSBs 
via the ɣH2AX assay. This work showed that ubiquitination is partly required for the 
removal of both TOP2A- and TOP2B- DNA complexes, in a manner epistatic to the 
proteasomal processing pathway. Like proteasomal inhibition, inhibition of UAE (by 
both small molecule inhibition and siRNA knockdown) greatly reduced the 
appearance of etoposide-induced DSBs, thereby demonstrating a previously 
underappreciated role for ubiquitination in the repair of TOP2 poison-mediated DNA 
damage. 
The ubiquitin-dependent processing of TOP2-DNA complexes was also evident 
when cells were treated with the BMI1/RING1A E3 ligase inhibitor, PRT4165. 
BMI1/RING1A is an E3 ubiquitin ligase associated with the polycomb repressive 
complex, which is also implicated in the degradation of TOP2A- (but not TOP2B-) 
DNA complexes (Alchanati et al., 2009). However, inhibition of BMI1/RING1A slowed 
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the removal of both TOP2A- and TOP2B- DNA complexes following etoposide 
exposure, further supporting a ubiquitin-dependent processing pathway which is 
common to both TOP2 isoforms. While it is possible that other E3 ubiquitin ligases 
can also mediate the ubiquitin-dependent processing of TOP2-DNA complexes, 
PRT4165 completely abolished the etoposide-induced ɣH2AX response, suggesting 
that BMI1/RING1A is a major component of the ubiquitin-dependent processing 
pathway. Given that the BMI1/RING1A-dependent processing of TOP2B-DNA 
complexes was not reported by Alchanati et al. following siRNA-mediated 
knockdown of BMI1 in HeLa cells, it is important to consider that the effect of 
PRT4165 on TOP2B-DNA complex processing could be due to off-target inhibitor 
effects. This could be tested by repeating the above experiments following siRNA 
knockdown of BMI1/RING1A. 
Role of transcription in TOP2-DNA complex processing 
Multiple publications demonstrate a transcription-dependent mechanism of TOP2 
complex processing which is implicated as part of the proteasome-dependent 
pathway. While initially described for TOP2B-DNA complexes (Mao et al., 2001; Xiao 
et al., 2003; Zhang et al., 2006), transcription is also involved in the processing of 
TOP2A-DNA complexes (Fan et al., 2008; Tammaro et al., 2013). Surprisingly, 
studies using the TARDIS assay could detect transcription-dependent removal of 
TOP2A-DNA complexes, but not TOP2B-DNA complexes (Chapter 3, Figure 3.23). 
This corresponded to the reduced appearance of etoposide-induced DSBs in 
transcription-inhibited cells following 4 hours etoposide exposure (Figure 3.24). This 
supports a transcription-dependent mechanism of TOP2-DNA complex processing, 
although it is not possible to conclude whether this mechanism is part of the 
proteasome- (and ubiquitin-) dependent pathway, as suggested by others. This could 
be addressed by repeating the TARDIS assay with DRB alone or in combination with 
MG132 or MLN7243. Interestingly, inhibition of transcription reduced levels of 
etoposide-induced ubiquitinated TOP2-DNA complexes, suggesting that transcription 
could be involved in the regulation of the ubiquitin-dependent pathway. For example, 
collision of RNAPII with TOP2-DNA complexes could provide the DNA damage 
signal required for the ubiquitination of TOP2 complexes, and subsequent 
degradation of TOP2 by the proteasome. 
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TOP2A ubiquitination 
Given the epistatic effect of proteasome and UAE inhibition on the removal of TOP2-
DNA complexes, it was hypothesised that TOP2 is ubiquitinated in response to 
poisoning by etoposide, leading to its ubiquitin-dependent proteasomal degradation. 
In support of this, BMI1/RING1A has been shown to directly bind and ubiquitinate 
TOP2A in vitro, and in cells following teniposide exposure (Alchanati et al., 2009). 
Furthermore, the ubiquitination of TOP2A has been demonstrated in response to 
other stimuli such as glucose starvation and HDAC inhibition, which leads to 
proteasomal degradation (Yun et al., 2009; Chen et al., 2011). Another aim of the 
current project was therefore to investigate the ubiquitination of TOP2A and TOP2B 
in the presence and absence of etoposide following pulldown of ubiquitinated 
proteins with TUBEs or by immunoprecipitation. 
Mass spectrometry analysis has identified numerous ubiquitination sites within 
TOP2A and TOP2B in the absence of TOP2 poison (Kim et al., 2011) and 
consistently, ubiquitinated TOP2 was detected in both untreated and etoposide-
treated cells. Surprisingly, the polyubiquitination of TOP2A (previously reported by 
Alchanati et al. following teniposide exposure) was not observed in etoposide-treated 
cells. Instead, TOP2A was detected as a discrete band following western blot 
analysis both before and after etoposide treatment, likely corresponding to 
monoubiquitination. While the polyubiquitination of TOP2A reported by Alchanati et 
al. could be a teniposide-specific effect, K48- and K63-linked ubiquitin chains were 
detected on etoposide-induced TOP2-DNA complexes using the TARDIS assay, 
albeit at low levels. Therefore, it is possible that etoposide-induced polyubiquitination 
of TOP2A is below the level of detection, and may require the overexpression of 
ubiquitin or ubiquitinating proteins.  
Alternatively, the ubiquitin-dependent proteasomal processing of TOP2-DNA 
complexes may not involve the canonical polyubiquitination of TOP2. Instead, TOP2 
monoubiquitination could lead to the removal of complexes through the recruitment 
of other repair proteins to TOP2-DNA complexes. For example, TDP2 contains a 
ubiquitin binding domain which is required for the repair of TOP2-DNA complexes 
(Rao et al., 2016). However, unlike UAE, inhibition of TDP2 does not affect the 
removal of TOP2 complexes or the appearance of etoposide-induced DSBs in the 
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presence of functional proteasomes (Gómez-Herreros et al., 2013; Schellenberg et 
al., 2017) (see also Chapter 3, Figure 3.30). Therefore the potential role of ubiquitin 
in the regulation of TDP2-mediated repair is distinct from the ubiquitin-dependent 
pathway described here. Interestingly, SUMOylation of TOP2 has been implicated in 
the removal of TOP2-DNA complexes by TDP2 upon proteasomal inhibition 
(Schellenberg et al., 2017), although this pathway was not observed in the current 
study following TDP2 knockdown in K562 cells (Chapter 3, Figure 3.28). The 
requirement for SUMO in the processing of TOP2-DNA complexes was not 
investigated here, but could be tested using commercially available SUMO inhibitors 
such as the recently described SAE inhibitor, ML-792 (He et al., 2017b). 
It was not possible to conclude how levels of ubiquitinated TOP2A change following 
etoposide treatment, as this was affected by other variables including the efficiency 
of TOP2 extraction from DNA, and the gel running system used. Thus, further 
optimisation is required to more confidently conclude how levels of Ub-TOP2A 
change (if at all) after etoposide treatment. It is also possible that the perceived 
decrease in levels of Ub-TOP2A in etoposide-treated cells is due to the proteasomal 
degradation of ubiquitinated TOP2A. Indeed, proteasome-dependent degradation 
may be detectable in the pool of ubiquitinated TOP2A following ubiquitin pulldown or 
IP, but not following standard western blotting or immunofluorescence of total 
TOP2A protein (Chapter 3, Figure 3.10 and 3.12). While this could normally be 
circumvented by co-treatment of cells with a proteasome inhibitor, studies using the 
TARDIS assay showed that TOP2 is deubiquitinated in response to proteasome 
inhibition. This is itself a novel finding which is consistent with TOP2 as a highly 
abundant monoubiquitinated protein which is deubiquitinated upon proteotoxic 
stress, as previously described for histone H2A and other proteins (Dantuma et al., 
2006; Kim et al., 2011; Udeshi et al., 2012). 
TOP2B ubiquitination 
Less is known regarding the ubiquitination of TOP2B, although polyubiquitination of 
TOP2B has been demonstrated following treatment of granule cells with the TOP2 
catalytic inhibitor, ICRF-193 (Isik et al., 2003). In contrast, Ban et al. were unable to 
detect TOP2B following immunoprecipitation of ubiquitin in cells overexpressing a 
HA-tagged ubiquitin construct (Ban et al., 2013). Consistently, ubiquitination of 
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TOP2B was not detected in the current study following immunoprecipitation of 
ubiquitinated proteins, although this could be accounted for by a number of technical 
issues. For example, the efficiency of ubiquitin pulldown was poor in these 
experiments, suggesting that a large proportion of ubiquitinated proteins were lost in 
the supernatant. Therefore, future experiments with TUBEs should involve 
optimisation of pulldown conditions. Furthermore, TOP2 levels were reduced in the 
whole cell lysate of etoposide-treated cells compared to untreated cells, suggesting 
that not all TOP2-DNA complexes were extracted for analysis by western blotting. 
Therefore, the extraction of TOP2 complexes should be optimised in future studies. 
While sonication did not appear to increase the extraction of TOP2 complexes from 
DNA (Appendix Table 3), other nucleases are available with superior efficiency to 
DNase I, such as benzonase (Turbonuclease), which should be used in future 
experiments. The inability to detect Ub-TOP2B could also be due to low endogenous 
protein levels if only a small proportion of TOP2B is ubiquitinated. Therefore, these 
assays could be performed in cells overexpressing a tagged TOP2B construct, which 
would enable both enrichment of TOP2B protein and efficient isolation by affinity 
purification.  
Due to the complications and discrepancies described above, TOP2 ubiquitination 
should be investigated using another approach. For example, multiple ubiquitination 
sites have been identified within TOP2B by mass spectrometry (Kim et al., 2011), 
which could be used to investigate TOP2B ubiquitination in the presence and 
absence of etoposide. This could be used to detect changes or the enrichment of 
ubiquitination at specific lysine residues following etoposide treatment, which cannot 
be achieved by western blotting techniques. Indeed, trapping of TOP2 on DNA may 
expose otherwise inaccessible ubiquitination sites, as previously shown for the 
PIASγ-dependent SUMOylation of TOP2A at Lys662 (Ryu et al., 2010; Wendorff et 
al., 2012). 
Processing of TOP2-DNA complexes by VCP/p97 
A major finding of the current study was the identification of VCP/p97 as another 
ubiquitin-dependent protein involved in the processing of TOP2-DNA complexes. 
Like inhibition of the proteasome or UAE, inhibition of VCP/p97 significantly reduced 
the processing of TOP2A- and TOP2B- DNA complexes and reduced the 
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appearance of etoposide-induced DSBs. The role of VCP/p97 was epistatic with that 
of the proteasomal pathway, consistent with the increasingly established role of 
VCP/p97 in the ubiquitin-proteasome system. It is therefore proposed that VCP/p97 
facilitates the proteasomal degradation of TOP2-DNA complexes by unfolding and 
extracting covalently bound TOP2 from chromatin, as previously described for other 
chromatin-associated protein complexes like Ku80 and RNAPII. As a ubiquitin-
dependent AAA ATPase, this finding further supports a ubiquitin- and proteasome- 
dependent pathway of TOP2-DNA complex processing. 
Important evidence of this model is derived from immunoprecipitation experiments, 
which showed an interaction between VCP/p97 and TOP2. Interestingly, VCP/p97 
interacts with TOP2 even in the absence of etoposide, which could indicate an 
endogenous role for VCP/p97 in the regulation of TOP2 complexes. For example, 
VCP/p97 could help resolve trapped TOP2-DNA complexes which arise during 
normal DNA metabolism. Surprisingly, this interaction was reduced in the presence 
of etoposide, which could be due to proteasomal degradation of TOP2 or insufficient 
extraction of TOP2-DNA complexes from chromatin. Extraction was improved upon 
preparation of lysates with benzonase, but no interaction between TOP2A and 
VCP/p97 was observed in the same experiment. Indeed, the interaction detected 
between VCP/p97 and both TOP2A and TOP2B was highly variable, and requires 
further confirmation with other experimental approaches. This is not necessarily 
surprising, as interactions between VCP/p97 and its substrates are reported to be 
transient and difficult to detect by IP. Instead, other studies have utilised a ‘substrate-
trapping’ mutant of VCP/p97 containing a mutation in the D2 ATPase domain which 
increases the stability of the VCP/p97-substrate interaction (van den Boom et al., 
2016). Therefore, further work could involve the transfection of cells with the EQ-p97 
mutant followed by IP. Future work could also include the investigation of protein 
interactions using mass spectrometry-coupled techniques. For example, Rapid 
Immunoprecipitation Mass spectrometry of Endogenous proteins (RIME) involves the 
isolation of chromatin-associated proteins by chromatin immunoprecipitation (ChIP), 
followed by the identification of interacting proteins by LC-MS/MS (Mohammed et al., 
2016). This would be a highly informative approach which could be used to test the 
interaction of etoposide-induced TOP2-DNA complexes with VCP/p97, as well as 
other proteins potentially involved in repair such as E3 ubiquitin ligases. 
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VCP/p97 binds poly- and mono- ubiquitinated proteins both directly via the N 
terminal domain, and indirectly through ubiquitin adaptor proteins like p47 and Ufd1-
Npl4 (Park et al., 2005; Pye et al., 2007). Therefore, monoubiquitination of TOP2 
may lead to the recruitment of VCP/p97 to TOP2-DNA complexes. However, in one 
study VCP/p97 was required only for the degradation of polyubiquitinated 
dihydrofolate reductase (DHFR) protein and not monoubiquitinated DHFR (Song et 
al., 2015). The role of ubiquitin in the VCP/p97-dependent processing of TOP2-DNA 
complexes was further investigated in the current study following siRNA knockdown 
of Ufd1 and Npl4. Ufd1-Npl4 is involved in the degradation of other chromatin-
associated protein complexes such as Ku70/80 and RNAPII (Verma et al., 2011; van 
den Boom et al., 2016; He et al., 2017a). However, unlike siRNA knockdown of 
VCP/p97, depletion of Ufd1-Npl4 did not affect the appearance of etoposide-induced 
DSBs, suggesting that Ufd1-Npl4 is not required for the VCP/p97-dependent removal 
of TOP2-DNA complexes. Instead, VCP/p97 may be recruited directly to 
ubiquitinated TOP2 complexes via the VCP/p97 N terminal domain, or indirectly via 
other ubiquitin adaptor proteins such as FAF1. The role of other ubiquitin adaptor 
proteins in the processing of TOP2-DNA complexes should be investigated in future 
studies. 
It is uncertain whether VCP/p97 can completely remove covalently bound TOP2 from 
DNA. Instead, VCP/p97 may facilitate TOP2 proteolysis by unfolding TOP2 as it 
remains covalently attached to the DNA. This would result in an unstructured protein 
adduct which could then be degraded by proteasomes on chromatin. Inhibition of 
ubiquitinating enzymes, proteasomes and VCP/p97 all prevent the processing of 
TOP2-DNA complexes to DSBs, as indicated by both small molecule inhibition and 
siRNA knockdown. While this implicates a role for ubiquitin and VCP/p97 in the 
proteasomal pathway of TOP2-DNA complex processing, it is important to note that 
perturbation of the ubiquitin-proteasome system with all of these inhibitors is 
reported to deplete nuclear ubiquitin (Xu et al., 2004; Dantuma et al., 2006; 
Heidelberger et al., 2018). It is therefore plausible that inhibition of VCP/p97 or the 
proteasome simply inhibits a ubiquitin-dependent pathway of TOP2-DNA complex 
processing which is independent of the proteasomal pathway. 
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Effect of ubiquitin-proteasome system inhibitors on the response to TOP2 
poisons 
TOP2 poison therapy can be improved through a better understanding of how TOP2 
poison-induced DNA damage is repaired. This knowledge can be exploited to 
increase the anticancer effects of TOP2 poisons. For example, DNA-PK is required 
for the repair of TOP2 poison-induced DSBs, and inhibition of DNA-PK increases the 
cytotoxicity of TOP2 poisons (Willmore et al., 2004). Of particular interest is the 
development of small molecule inhibitors of the ubiquitin-proteasome system 
following the regulatory approval of the proteasome inhibitors bortezomib and 
carfilzomib. In the current study, inhibition of UAE and specific E3 ubiquitin ligases 
significantly increased the growth-inhibitory effects of various clinically relevant 
TOP2 poisons. While these effects may be attributed to multiple consequences of 
ubiquitin inhibition, this nonetheless demonstrates that the cytotoxicity of TOP2 
poisons can be increased by targeting the ubiquitin-proteasome system. It is 
important to consider that ubiquitination regulates many cellular processes, through 
both proteasome-dependent and non-proteolytic mechanisms. Therefore, while the 
UAE inhibitor MLN7243 is in phase I clinical trials, UAE inhibition may be less 
favourable than proteasome inhibitors due to a greater potential for unwanted toxic 
effects. Furthermore, the development of specific E3 ubiquitin ligase inhibitors is 
challenging as many E3s (such as the RING or U-box E3s ligase family) lack intrinsic 
catalytic activity (Landre et al., 2014). While the effect of VCP/p97 inhibition on the 
growth inhibitory effects of TOP2 poisons was not investigated in this study, 
VCP/p97 was identified as another druggable component of the ubiquitin-
proteasome system which is involved in the repair of TOP2 poison-induced DNA 
damage. Notably, the VCP/p97 inhibitor CB-5083 is also in phase I clinical trials. 
Micronucleus assays show that the cytotoxicity of TOP2 poisons is increased by 
UAE inhibition without increasing overall TOP2 poison genotoxicity, which is 
associated with the development of t-AML. It is hypothesised that the likelihood of 
leukaemogenic chromosomal translocations is reduced upon inhibition of the 
ubiquitin- and proteasome- dependent processing pathway by preventing the 
liberation of protein-free DSBs. This could be investigated further by measuring the 
frequency of specific etoposide-induced chromosome translocations in cells treated 
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with and without UAE or proteasome inhibitors, for example by DNA-FISH 
(Fluorescence In-Situ Hybridisation). 
Proposed model 
This work (summarised in Table 6) indicates a new model of TOP2-DNA complex 
processing by the proteasome, and is illustrated in Figure 7.1. This is a ubiquitin- and 
VCP/p97- dependent mechanism common to both TOP2 isoforms, whereby 
BMI1/RING1A-dependent monoubiquitination of TOP2 (or ubiquitination of another 
protein involved in repair) may lead to the recruitment of VCP/p97 to stalled TOP2-
DNA complexes. VCP/p97 then facilitates the proteasomal degradation of TOP2 
adducts by unfolding the covalently bound TOP2 protein, which can then be 
translocated into the narrow core of proteasomes present on chromatin. This 
liberates protein-free DSBs (attached to short phosphotyrosyl peptides), which are 
further processed to ligatable ends for NHEJ repair by TDP2. 
In conclusion, this work clarifies a requirement for ubiquitination in the proteasomal 
processing of drug-stabilised TOP2A- and TOP2B- DNA complexes. A previously 
unreported and additional layer of complexity is the involvement of VCP/p97 in the 
processing of complexes to DSBs. VCP/p97 is known to facilitate the proteasomal 
degradation of proteins through protein unfolding and extraction from cellular 
components such as chromatin. It is therefore proposed that VCP/p97 is recruited to 
ubiquitinated TOP2-DNA complexes, leading to the unfolding of TOP2 and TOP2 
proteolysis. 
  
206 
 
 
Figure 7.1. Proposed model of TOP2-DNA complex processing by VCP/p97 and the 
proteasome.  Collision of elongating polymerases with stabilised TOP2-DNA complexes 
leads to the ubiquitination of TOP2 (or another protein involved in repair) by BMI1/RING1A. 
This leads to the recruitment of VCP/p97 to the damage site and the subsequent unfolding of 
TOP2 adducts on DNA. Proteasomes present on chromatin (including for example, those 
recruited to stalled RNA polymerases) degrade the bulk of the unfolded TOP2 protein, and 
liberate protein-free DSBs covalently attached to short phosphotyrosyl peptides. Final end-
polishing by TDP2 produces ligatable ends for NHEJ repair. Alternatively, aberrant repair 
leads to the generation of leukaemogenic chromosome translocations which are associated 
with the development of therapy-related acute myeloid leukaemia (t-AML).
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Table 6. Overview of results. 
 TOP2 TARDIS ɣH2AX assay Ubiquitin TARDIS XTT assay 
VP-16 + 
Proteasome 
inhibitor (MG132) 
Levels of remaining TOP2A- 
and TOP2B-DNA complexes 
are significantly higher after 
VP-16 removal. 
 
Consistent with the role of 
the proteasome in the 
degradation of TOP2-DNA 
covalent complexes. 
Levels of VP-16-
induced DSBs are 
significantly reduced (in 
K562 cells and Nalm-6 
cells). 
 
Consistent with 
published literature and 
the notion that the 
degradation of TOP2 
adducts is required for 
the liberation of protein-
free DSBs. 
Levels of ubiquitinated 
TOP2-DNA complexes 
is reduced. 
 
Combination 
experiments with PR-
619 indicate that TOP2 
complexes are actively 
deubiquitinated upon 
proteasome inhibition. 
XTT data published by 
Lee et al. (2016) shows 
that proteasome 
inhibition significantly 
reduces the IC50 of 
clinically relevant TOP2 
poisons (in K562 cells 
and Nalm-6 cells). 
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VP-16 + UAE 
inhibitor 
(MLN7243) 
Levels of remaining TOP2A- 
and TOP2B-DNA complexes 
are significantly higher after 
VP-16 removal, in a manner 
that is epistatic with the 
proteasome. 
 
Indicates that the 
proteasomal processing of 
TOP2A- and TOP2B-DNA 
complexes is ubiquitin-
dependent. 
Levels of VP-16-
induced DSBs are 
significantly reduced (in 
K562 cells and Nalm-6 
cells). 
 
Therefore the 
appearance of VP-16-
induced DSBs is partly 
ubiquitin-dependent. 
Levels of ubiquitinated 
TOP2-DNA complexes 
are completely reduced 
to background levels. 
 
Therefore MLN7243 is 
a potent UAE inhibitor. 
The IC50 of all TOP2 
poisons tested were 
reduced in Nalm-6 
cells. Potentiation was 
reduced in TOP2B 
knockout cells, 
indicating that 
potentiation by 
MLN7243 is partly 
TOP2-dependent. 
However, potentiation 
was absent or 
noticeably reduced in 
K562 cells lacking 
functional p53. 
 
UAE inhibition is a 
viable strategy for the 
potentiation of clinically 
relevant TOP2 poisons, 
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but likely mediated by 
both TOP2-dependent 
and -independent 
mechanisms. 
VP-16 + 
BMI1/RING1A 
inhibitor 
(PRT4165) 
Levels of remaining TOP2A- 
and TOP2B-DNA complexes 
are significantly higher after 
VP-16 removal. 
 
Indicates that the E3 
ubiquitin ligase 
BMI1/RING1A is involved in 
the processing of TOP2A- 
and TOP2B-DNA 
complexes. 
Levels of VP-16-
induced DSBs are 
significantly reduced to 
background levels. 
 
Indicates that 
BMI1/RING1A is the 
major E3 ligase 
involved in the 
ubiquitin-dependent 
processing of TOP2-
DNA complexes. 
Levels of ubiquitinated 
TOP2-DNA complexes 
are reduced, but not 
completely abolished. 
 
BMI1/RING1A is 
involved in the 
ubiquitination of TOP2. 
However, other E3 
ligases can also 
ubiquitinate TOP2 (for 
example, Fbw7, ECV, 
APC/Cdh1), which may 
occur before or after 
The IC50 of all TOP2 
poisons (with the 
exception of 
doxorubicin) was 
reduced in all Nalm-6 
cell lines, regardless of 
TOP2 levels. However, 
potentiation of mAMSA 
by PRT4165 is TOP2A-
dependent. 
 
The potentiation of 
TOP2 poisons by 
PRT4165 is likely 
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TOP2 is trapped on 
DNA. 
mediated by TOP2-
dependent 
and -independent 
mechanisms (e.g. 
inhibition of histone 
H2A Lys119 
ubiquitination or off-
target effects). 
VP-16 + 
Transcription 
inhibitor (DRB) 
Levels of remaining TOP2A- 
(but not TOP2B) DNA 
complexes are significantly 
higher after VP-16 removal. 
 
Indicates that the processing 
of TOP2A-DNA complexes is 
partly transcription-
dependent, consistent with 
other studies. 
Levels of VP-16-
induced DSBs are 
significantly reduced 
following 4 hours drug 
exposure. 
 
Indicates a 
transcription-dependent 
mechanism of TOP2-
DNA complex 
Levels of ubiquitinated 
TOP2-DNA complexes 
are significantly 
reduced. 
 
Suggests that 
transcription could be 
involved in the 
ubiquitination of TOP2 
(e.g. ubiquitination of 
TOP2 complexes after 
Not investigated in the 
current study. 
211 
 
processing to protein-
free DSBs. 
collision with the 
transcription 
machinery). 
VP-16 + VCP/p97 
inhibitor (NMS-
873) 
Levels of remaining TOP2A- 
and TOP2B-DNA complexes 
are significantly increased. 
 
Suggests VCP/p97 is 
involved in the processing of 
TOP2-DNA complexes, 
epistatic with the 
proteasomal pathway. 
Levels of VP-16-
induced DSBs are 
significantly reduced in 
K562 cells. 
 
Consistent with the 
notion that VCP/p97 is 
required for the removal 
of TOP2 complexes 
from DNA and the 
subsequent 
appearance of protein-
free DSBs. 
 
Levels of ubiquitinated 
TOP2-DNA complexes 
are slightly but 
significantly increased. 
 
This could suggest that 
VCP/p97 targets 
ubiquitinated TOP2, or 
may simply be a 
consequence of 
increased TOP2 
complex formation 
(independent of 
ubiquitination status). 
Not investigated in the 
current study (future 
work). 
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Appendices 
 
Figure 1. Using the TARDIS assay to measure levels of TOP2A- and TOP2B- DNA complexes in 
response to the irreversible TOP2 poison clerocidin.K562 cells were treated with the indicated 
concentration of clerocidin for 2 hours, followed by 2 hours incubation in drug-free medium. Levels of 
TOP2A- and TOP2B- DNA complexes were measured immediately following 2 hours continuous 
exposure to clerocidin (0 hours after drug removal) and 2 hours after clerocidin removal. Histograms 
show raw median values from a single experiment.  
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Figure 2. The appearance of etoposide-induced ɣH2AX foci is reduced in Nalm-6 cell lines 
following co-treatment with the proteasome inhibitor, MG132. Nalm-6 wild type (WT, left panel) or 
Nalm-6TOP2B-/- cells (right panel) were treated with 10 µM etoposide (VP-16) alone or in combination 
with 10 µM MG132 for 0, 1 or 2 hours. Levels of histone H2AX phosphorylation were measured by 
ɣH2AX assay. Values represent the mean of median integrated fluorescence ± SEM from at least 
three replicate experiments, and are normalised to an additional 1 hour 10 µM VP-16 positive control. 
Drug treatments were performed by RS, and immunofluorescence/microscopy/data analysis by 
Charlotte Sanders. 
 
Figure 3. The appearance of mitoxantrone-induced ɣH2AX foci is reduced in Nalm-6 cell lines 
following co-treatment with the proteasome inhibitor, MG132. Nalm-6 wild type (WT, left panel) or 
Nalm-6TOP2B-/- cells (right panel) were treated with 1 µM mitoxantrone (MTX) alone or in combination 
with 10 µM MG132 for 0, 1 or 2 hours. Levels of histone H2AX phosphorylation were measured by 
ɣH2AX assay. Values represent the mean of median integrated fluorescence ± SEM from at least 
three replicate experiments, and are normalised to an additional 1 hour 1 µM MTX positive control. 
Drug treatments were performed by RS, and immunofluorescence/microscopy/data analysis by 
Charlotte Sanders.  
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Figure 4. The appearance of etoposide-induced ɣH2AX foci is reduced in Nalm-6 cell lines 
following co-treatment with the UAE inhibitor, MLN7243. Nalm-6 wild type (WT, left panel) or 
Nalm-6TOP2B-/- cells (right panel) were treated with 10 µM etoposide (VP-16) alone or in combination 
with 10 µM MLN7243 for 0, 1 or 2 hours. Levels of histone H2AX phosphorylation were measured by 
ɣH2AX assay. Values represent the mean of median integrated fluorescence ± SEM from at least 
three replicate experiments, and are normalised to an additional 1 hour 10 µM VP-16 positive control. 
Drug treatments were performed by RS, and immunofluorescence/microscopy/data analysis by 
Charlotte Sanders. 
 
Figure 5. The appearance of mitoxantrone-induced ɣH2AX foci is reduced in Nalm-6 cell lines 
following co-treatment with the UAE inhibitor, MLN7243. Nalm-6 wild type (WT, left panel) or 
Nalm-6TOP2B-/- cells (right panel) were treated with 1 µM mitoxantrone (MTX) alone or in combination 
with 10 µM MLN7243 for 0, 1 or 2 hours. Levels of histone H2AX phosphorylation were measured by 
ɣH2AX assay. Values represent the mean of median integrated fluorescence ± SEM from at least 
three replicate experiments, and are normalised to an additional 1 hour 1 µM MTX positive control. 
Drug treatments were performed by RS, and immunofluorescence/microscopy/data analysis by 
Charlotte Sanders. 
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Figure 6. Expression of ZATT (ZNF451) in K562 cells, shown by western blot. K562 cell lysate 
was prepared as described in Chapter 2, section 2.6.1. Levels of ZATT protein was analysed by SDS-
PAGE followed by western blotting. 
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Table 1. Investigating the TOP2 poison-induced proteasomal degradation of TOP2 by western blotting 
Experiment 
Biological replicates (n 
drug treatments) 
Technical replicates (n 
western blots) 
Result 
TOP2A 
TOP2B 
100 µM VP-16 +/- 50 µM 
MG132 (Figure 3.10) 
1 of 1 (treated 
14/05/2015) 
1 of 5 (22/05/2015) N/A, actin failed N/A, actin failed 
2 of 5 (28/05/2015) 
Protein quantification by 
Bradford assay repeated 
to improve loading 
TOP2A levels decreased 
in VP-16 treated cells 
compared to DMSO 
control. Decrease is 
proteasome dependent. 
No TOP2B signal – 
antibody issue? 
 
3 of 5 (04/06/2015) TOP2A levels decreased 
in VP-16 treated cells 
compared to DMSO 
control. Decrease is 
proteasome dependent. 
Poor TOP2B signal 
after stripping blot – has 
stripping removed 
protein? 
4 of 5 (10/05/2015) 2 
identical gels for TOP2A 
and TOP2B to avoid 
stripping) 
TOP2A levels decreased 
in VP-16 treated cells 
compared to DMSO 
TOP2B detected in 
some lanes and not 
others (even DMSO 
control) despite even 
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control. Decrease is 
proteasome dependent. 
loading. Antibody 
issue? 
5 of 5 (10/05/2015) TOP2A levels are not 
affected by etoposide 
treatment. 
TOP2B appears reduced 
in etoposide-treated cells 
compared to untreated 
control 
TOP2B levels are 
slightly decreased 
compared to untreated 
control. 
100 µM VM-26 +/- 50 µM 
MG132 (data not shown) 
1 of 2 (treated 
27/05/2015) 
1 of 1 (08/06/2015) TOP2A levels decreased 
in VP-16 treated cells 
compared to DMSO 
control. Decrease is 
proteasome dependent. 
TOP2B antibody failed 
2 of 2 (treated 
14/05/2015) 
1 of 1 (10/06/2015) TOP2A levels decreased 
in VP-16 treated cells 
compared to DMSO 
control. Decrease is 
proteasome dependent. 
No TOP2B signal 
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100 µM VM-26 +/- 50 µM 
PRT4165 (drug treatment 
and WCE by R. Swan, 
blots by Alessandro 
Mozzarelli, data not 
shown) 
1 of 1 (treated 
10/07/2015) 
22/07/2015 N/A (Not probed) Uneven loading, bands 
missing 
TOP2B levels unaffected 
by VM-26 treatment 
23/07/2015 TOP2A levels unaffected 
by VM-26 treatment 
No TOP2B signal 
250 µM VP-16 +/- 50 µM 
MG132 (data not shown) 
1 of 1 (treated 
28/07/2015) 
31/07/2015 TOP2A levels unaffected 
by VP-16 treatment 
N/A (not probed) 
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Table 2. Investigating the ubiquitination of TOP2 using GST-TUBEs 
Experiment Conditions Result Problems Optimisation for future 
experiments 
#1 (16/04/2016) 1 x 106 cells per condition, 
RIPA buffer + DNase I, 
incubation with 1.8 µM 
GST-TUBE2 for 1 hour at 
4°C 
Successful ubiquitin 
pulldown 
No TOP2A or TOP2B 
detected in input, though 
some detected on beads. 
Protein concentration too 
low? 
 Could include 
GST-TUBE1 in 
lysis buffer to 
protect proteins 
from non-specific 
proteolysis and 
DUBs 
#2 (19/04/2016) 1 x 106 cells per condition, 
RIPA buffer + DNase I, 
incubation with 1.8 µM 
GST-TUBE2 for 1 hour at 
4°C. GST-TUBE1 
included in lysis buffer. 
Ub-TOP2A detected after 
GST-TUBE1 pulldown 
TOP2A not detected in  
input 
 
#3 (3/08/16) (Figure 4.15) 1 x 106 cells per condition, 
RIPA buffer + DNase I, 
incubation with 1.8 µM 
GST-TUBE1 for 1 hour at 
Ub-TOP2A detected in input 
and after GST-TUBE 
pulldown 
Ubiquitin conjugates 
detected in input but not 
on beads 
 DNase I is not 
sufficient for 
complete 
extraction of 
covalently-linked 
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4°C. GST-TUBE1 
included in lysis buffer. 
Poor pulldown efficiency – 
ubiquitin conjugates lost in 
supernatant 
Less TOP2A in lysate of 
etoposide-treated cells 
compared to untreated 
control, suggesting 
incomplete extraction of 
TOP2 complexes from 
DNA 
TOP2-DNA 
complexes. Future 
studies should 
include an 
alternative 
nuclease such as 
benzonase 
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Table 3. Investigating the ubiquitination of TOP2 using MultiDsk2 
Experiment Conditions Result Problems Optimisation for future 
experiments 
#1 (23/02/2016) 2 x 106 cells per condition, 
RIPA buffer + DNase I, 
incubation with 0.2 µM 
MultiDsk2 for 4 hours at 
4°C 
Ubiquitin conjugates 
depleted in supernatant 
(pulldown successful) 
Too much protein loaded, 
film overexposed and 
unable to strip blot 
~55-60 kDa bands 
corresponding to GST 
when probing with TOP2 
antibodies, as 4566 and 
4555 are raised to GST 
fusion proteins 
 Repeat with serial 
dilutions of 
sample, less cells 
 Blots ran in 
duplicate to avoid 
stripping 
 Develop blots 
using the LiCor C-
DiGit blot scanner 
to avoid saturation 
 Other TOP2 
antibodies to be 
used where 
possible 
#2 (1/03/2016) 1 x 106 cells per condition, 
RIPA buffer + DNase I, 
incubation with 0.2 µM 
Highly efficient pulldown 
of K48-linked ubiquitin 
conjugates (none 
detected in supernatant, 
Multiple bands present 
when probing for TOP2A 
(4566), including a ~50 
 Higher 
concentration of 
protease inhibitors 
to avoid 
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MultiDsk2 for 4 hours at 
4°C 
even with prolonged 
exposure on film). An 
efficient pulldown may be 
achieved with lower 
concentration of 
MultiDsk2. 
kDa GST band and an 
unknown band ~90 kDa 
degradation of 
sample 
 All wash steps 
performed in 
cooled centrifuge 
and samples 
handled in cold 
room or on ice at 
all times 
 Test lower 
concentration of 
MultiDsk2 to 
preserve reagent 
#3 (10/03/2016) 1 x 106 cells per condition, 
RIPA buffer + DNase I, 
incubation with 0.1 µM 
MultiDsk2 for 4 hours at 
4°C 
 Ubiquitin pulldown less 
efficient (a significant 
amount of ubiquitin 
conjugates remains in 
supernatant) 
No TOP2 protein detected 
(even in input) suggesting 
antibody failure (including 
4566 and 30400) 
 0.2 µM MultiDsk2 
required for 
efficient ubiquitin 
pulldown 
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#4 (31/03/2016) 1 x 106 cells per condition, 
RIPA buffer + DNase I, 
incubation with 0.2 µM 
MultiDsk2 for 4 hours at 
4°C 
 Ubiquitin pulldown 
unsuccessful even with 
0.2 µM MultiDsk2 
No TOP2 protein detected 
 RIPA buffer may 
not be appropriate 
to study protein-
protein 
interactions. 
Repeat with TENT 
buffer as per 
Anindya et al 2007 
(mild lysis buffer 
requires sonication 
to disrupt the 
nucleus) 
#5 (8/06/2017) Figure 
4.16 
1 x 106 cells per condition, 
TENT buffer + sonication 
[2 rounds (15 seconds, 5 
cycles, 20% power)], 
followed by incubation 
with 0.2 µM MultiDsk2 at 
4°C overnight (as per 
Anindya et al 2007) 
Full length TOP2 protein 
detect in input and 
enriched by MultiDsk2 
Insufficient ubiquitin 
pulldown 
Gloopy sample difficult to 
load, suggests sonication 
is insufficient to 
adequately break up DNA 
 More rounds of 
sonication 
required to break 
up DNA 
#6 (15/06/2017) 1 x 106 cells per condition, 
TENT buffer + sonication 
 No ubiquitin conjugates 
detected on beads 
 Use new batch of 
GSH beads – old 
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[5 rounds (15 seconds, 5 
cycles, 20% power)],, 
followed by incubation 
with 0.2 µM MultiDsk2 at 
4°C overnight 
(though some Ub-TOP2A 
present) 
Poor ubiquitin pulldown 
beads are expired 
and may not bind 
GST if oxidised 
#7 (23/06/2017) 1 x 106 cells per condition, 
TENT buffer + sonication 
[5 rounds (15 seconds, 5 
cycles, 20% power)],, 
followed by incubation 
with 0.2 µM MultiDsk2 at 
4°C overnight 
Pulldown efficiency 
improved 
Gloopy samples difficult to 
load 
 Extraction 
conditions to be 
optimised in future 
experiments 
(include nuclease 
like DNase I or 
benzonase) 
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